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Fifteen million people have a stroke each year.  The majority survive due to 
improvements in medical care, although most experience ongoing physical, cognitive and 
psychological difficulties.  Preliminary data suggest that stem cell (SC) therapy may improve 
stroke survivor outcomes but, in the absence of large-scale clinical trials, the overall 
effectiveness and medical and psychological risks remain unclear.  Moreover, SC therapies 
administered throughout the acute, sub-acute and chronic phases of stroke are assumed to 
work differently due to differences in blood-brain-barrier permeability, however, the optimal 
treatments for each phase remain unknown due to current technological limitations.   
Interest in the experimental SC treatments offered by private clinics throughout Asia, 
South America and Russia – known as ‘stem cell tourism’ – is increasing among some patient 
groups, although, whether this is true for stroke survivors is unknown.  Additionally, whether 
patients with particular biopsychosocial and attitudinal characteristics are more likely to 
consider experimental SC treatments is undetermined.  Patient educational resources have 
been developed to warn patients with neurodegenerative conditions about the risks associated 
with ‘stem cell tourism’, however, their content, format and design may impact upon their 
effectiveness with stroke survivors, due to differences in the physical, cognitive and 
psychological sequelae.   
Four studies explored these issues.  Two meta-analyses examined the safety and 
efficacy of SC therapies.  Study 1 examined 11 SC therapies (Nstudies-=-28) administered in 
the hyper-acute, acute, and sub-acute phases of stroke (≤-90 days).  Serious adverse events 
were observed following five therapies; improved neurological, functional and/or radiological 
outcomes were noted following six therapies.  Study 2 analysed 17 SC therapies (Nstudies-=-
23) administered in the chronic phase of stroke (>-90 days).  Safety concerns were identified 
for three therapies; four reported improved neurological and/or functional outcomes.  Across 
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both meta-analyses, few studies tracked the SCs post-implantation, employed sham treatment 
control groups, performed psychological screening or evaluated participants’ psychological 
wellbeing pre-/post-treatment.   
Next, a cross-sectional survey of 183 Australian stroke survivors was conducted to 
assess patient attitudes toward experimental SC treatments (Study 3).  Twenty-five percent 
were considering ‘stem cell tourism’.  Individuals with positive SC attitudes, longer post-
stroke intervals, poorer physical functioning, and greater perceived caregiver burden were 
most likely to be considering treatment.  Lastly, a randomised controlled trial (Study 4) was 
conducted to evaluate whether an online International Society for Stem Cell Research booklet 
or Stem Cell Network video deterred stroke survivors’ (N-=-112) from considering 
experimental SC treatments.  Forty-five percent of participants were considering SC 
treatments at study commencement; significantly fewer were still considering SC treatments 
after reading the booklet.  However, after 30 days, neither intervention was found to have 
altered participants’ attitudes. 
Overall, the findings suggest that whilst a small number of SC therapies may improve 
stroke outcomes, further large-scale, placebo-controlled clinical trials are required to clarify 
the medical and psychological risks.  The level of interest in ‘stem cell tourism’ identified 
among patients with specific biopsychosocial and attitudinal characteristics suggests a 
potential role for clinicians to initiate discussions with higher-risk groups.  The need for 
stroke-specific SC education resources, in conjunction with more proactive dissemination, is 
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Chapter 1: Stroke 
1.1 Overview  
Stroke is the second leading cause of death and the third leading cause of disability 
worldwide (Feigin, Norrving, & Mensah, 2017; Thrift et al., 2017).  Of the 15 million people 
who experience a stroke each year, only 70% survive and, of those, only one in ten fully 
recover (Feigin et al., 2017; Jung, 2017; Mozaffarian et al. 2016).  In global terms, this 
equates to approximately 33 million people who are currently living with stroke-related 
physical, functional, and/or cognitive disabilities (Hankey, 2017).  Psychological problems, 
such as depression and anxiety are also common and affect one third of all stroke survivors 
(Cumming, Blomstrand, Skoog, & Linden, 2016; Mitchell et al., 2017).  These consequences 
contribute to the significant economic and psychosocial burden of stroke.  
The current chapter examines the biopsychosocial aspects of stroke, commencing 
with a discussion of the medical symptoms, epidemiology, and incidence and prevalence 
rates.  The two major subtypes of stroke (i.e. ischaemic and haemorrhagic) are outlined and 
differences in the diagnosis, classification, and outcomes of each are described.  Following 
this, the economic burden of stroke is highlighted and major risk factors for stroke are 
introduced.  Lastly, a summary of the current recommended multidisciplinary treatments 
throughout the hyper-acute (≤ 24 hours post-stroke), acute (< 30 days post-stroke), sub-acute 
(< 90 days post-stroke), and chronic [> 90 days post-stroke]) phases is provided, with a focus 
on the role of clinical psychology at each stage.   
1.2 Definition and General Characteristics of Stroke 
A stroke, or cerebrovascular accident (CVA), occurs when cerebral blood supply is 
interrupted due to an obstructed (i.e. ischaemic stroke) or ruptured (i.e. haemorrhagic stroke) 
blood vessel (Sacco et al., 2013).  Initial symptoms vary according to the type and location of 
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the stroke, but most commonly include: headaches/migraines, dizziness, loss of balance or 
coordination (ataxia), unilateral limb weakness (hemiparesis), paralysis (hemiplegia), facial 
droop, vision loss or double vision (diplopia), language and communication problems 
(aphasia, dysarthria), and swallowing difficulties (dysphagia) (Hankey & Blacker, 2015).  
Patients may also experience atypical symptoms including confusion, delirium, memory loss 
(amnesia), breathing difficulties (stridor), involuntary limb movement (Choi, 2016; Edlow & 
Selim, 2011), and a lack of insight into the nature and extent of their symptoms (anosognosia) 
(Byrd, Jablonski, & Vance, 2018).  To be formally diagnosed as a stroke, the primary 
symptoms must persist for longer than 24 hours or result in death.  The cause of the 
symptoms must be also visible on neuroimaging or at autopsy (Sacco et al., 2013). 
1.3 Subtypes of Stroke 
Ischaemic stroke is the first major subtype and accounts for approximately 85% of all 
CVAs (Mozaffarian et al., 2016).  An ischaemic stroke occurs when a blood clot forms in an 
artery that supplies blood to the brain (thrombotic stroke) (Adams & Biller, 2015), or forms 
elsewhere in the body (e.g. the heart) before travelling through the blood stream and lodging 
in the brain (embolic stroke) (Hankey, 2017).  Ischaemic strokes most commonly occur in the 
middle cerebral artery (MCA), which supplies blood to the lateral aspects of the frontal, 
temporal and parietal lobes; the anterior cerebral artery (ACA), which supplies blood to the 
medial portions of the frontal and parietal lobes; and the posterior cerebral artery (PCA), 
which supplies blood to the midbrain, thalamus, and temporal and occipital lobes (Kim, 
2016).  A small number of ischaemic strokes are also caused by cerebral small-vessel disease; 
a pathological condition that results in damage to the small (lacunar) blood vessels in the 
brain (Hankey, 2017; Shi & Wardlaw, 2016).   
Haemorrhagic stroke is the second major subtype and accounts for the remaining 15% 
of CVAs (Mozaffarian et al., 2016).  A stroke that results from bleeding within the brain is 
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referred to as an intracerebral haemorrhage (ICH).  This type of stroke most commonly 
occurs following the rupturing of blood vessels that are tangled (arteriovenous 
malformations) or damaged from chronic high blood pressure (hypertension) (Keep, Hua, & 
Xi, 2012).  ICHs may result in increased intracranial pressure and cerebral herniation, which 
may be fatal (An, Kim, & Yoon, 2017).  The areas of the brain that are no longer receiving 
blood may also die, with secondary damage occurring throughout the areas around the 
haemorrhage due to the release of toxins present within the blood (An, Kim, & Yoon, 2017).   
In contrast, a bleed that occurs within the tissue located between the brain and the 
skull (meninges) is referred to as a subarachnoid haemorrhage (SAH) (Miller, 2017).  SAHs 
are commonly caused following the balloon-like swelling of weakened/damaged blood 
vessels (‘berry’ aneurysms) that subsequently rupture, or as a result of arteriovenous 
malformations that begin leaking blood into the subarachnoid space (Miller, 2017).  Similar 
to ICHs, patients who experience a SAH may die as a result of the increased intracranial 
pressure (Kakami & Garg, 2016).  Brain damage is common throughout the areas of the brain 
that are no longer receiving blood (Kakami & Garg, 2016), and/or within areas that were 
previously occupied only by cerebral spinal fluid (Miller, 2017). 
1.4 Diagnosis 
Ischaemic strokes may be provisionally diagnosed using the Face Arm and Speech 
Test (FAST) (Robinson, Reid, Haunton, Wilson, & Naylor, 2013) or tools such as the 
Recognition of Stroke in the Emergency Room (ROSIER) score (Nor et al., 2005).  Where a 
stroke is suspected, neuroimaging is typically performed to confirm the diagnosis.  
Computerised Tomography (CT) scans are generally performed first, in order to identify 
whether a blockage or bleed has occurred within the brain (Malhotra & Liebeskind, 2017).  
However, as CT scans are less effective at identifying small or recent blockages, follow-up 
magnetic resonance imaging (MRI) scans may be conducted.  Diffusion-Weighted MRIs are 
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the most effective method of detecting new ischaemic strokes and differentiating between 
strokes and other conditions with similar symptoms (e.g., seizures, tumours, encephalitis, 
multiple sclerosis, migraines) (Vilela & Rowley, 2017).  More advanced MRI techniques, 
such as functional MRI, diffusion tensor imaging, magnetic resonance perfusion, magnetic 
resonance spectroscopy, and volumetric imaging, are also being developed to provide more 
detailed images of the brain (Almeida, Castellano, Vicentini & Min, 2018).  
For haemorrhagic strokes, CT scans are highly effective at identifying recent 
intracranial and subarachnoid bleeds (Malhotra & Liebeskind, 2017), although MRI scans 
provide more detailed information about the aetiology and pathophysiological consequences 
of the stroke (Kakami & Garg, 2016).  Digital Subtraction Cerebral Angiography, which 
involves the injection of contrast dye into the carotid artery via catheter, may also be used to 
determine the cause for an ICH or SAH.  However, its use is limited, because it increases the 
risk of ischaemic stroke due to the potential for dislodging fatty plaques at the point of the 
catheter insertion (Malhotra & Liebeskind, 2017).  
1.5 Classification 
Once diagnosed, ischaemic strokes are classified according to the primary cause 
(aetiology) of the blockage, in order to inform treatment planning and to formulate the short- 
and long-term prognoses for a patient (Adams & Biller, 2015).  A range of methods are used 
to classify ischaemic strokes; common examples include the Causative Classification System 
(CCS) (Arsave et al., 2010), the Atherosclerosis-Small vessel disease-Cardiac pathology-
Other causes (ASCO) phenotyping system (Amarenco et al., 2013), and the Trial of Org 
10172 in Acute Stroke Treatment (TOAST) classification system (Adams & Biller, 2015).  
While minor differences exist in the terminology used, each system broadly classifies the 
aetiology of an ischaemic stroke as: large artery atherosclerosis, small artery occlusion, 
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cardioembolism, other demonstrated cause, or undetermined (cryptogenic) (Adams & Biller, 
2015; Amarenco et al., 2013; Arsave et al., 2010). 
Haemorrhagic strokes are classified based on the location of the bleed.  The majority 
of ICHs occur close to the surface of the brain (supratentorial) or within the deeper structures 
surrounding the cerebral ventricles (deep ICH) (Kakami & Garg, 2016).  The severity of an 
ICH is then assessed based on the severity of the bleed and the associated mortality risk, 
which are determined from the ICH volume (mL) and affected locations, the person’s age (≥ 
or < 80 years), and level of responsiveness (Kakami & Garg, 2016).  When classifying a 
SAH, CT scans are used to calculate a Fisher Grading Scale score, which estimates the 
mortality risk based on the size (thin/thick) and location (one/both ventricles) of the 
haemorrhage (Miller, 2017).  Additional information regarding the severity of a SAH is based 
on the alertness and orientation of the patient (ranging from mild confusion to comatose), or 
the presence of neurological deficits, neck stiffness (nuchal rigidity) and/or headache (Miller, 
2017). 
1.6 Outcomes 
Approximately 90% of ischaemic stroke patients from developed countries survive, 
although the outcomes experienced depend on the location of the blockage (Mittal & Goel, 
2017).  Ischaemic strokes within the anterior circulation system (i.e. ACA, MCA) disrupt 
blood flow to the frontal, temporal and parietal lobes (Chandra, Li, Stone, Geng, & Ding, 
2017), resulting in motor and sensory deficits, swallowing problems, language impairments, 
cognitive dysfunction, and impaired vision (Walcott et al., 2014).  Depression is also 
common, particularly during the acute (24 hours to < 30 days post-stroke) and sub-acute 
phases (30 to 90 days post-stroke), when neuro-vegetative symptoms, such as, aboulia, 
anhedonia, akinetic mutism, insomnia, and agitation are most prevalent (Brust & Chamorro, 
2016).  PCA infarcts disrupt blood flow throughout the occipital lobe, inferomedial temporal 
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lobe and upper brainstem, causing hemiparesis, ataxia, oculomotor deficits, and sensory 
disturbances (Kim, 2016).  The thalamus and limbic system may also be damaged, resulting 
in memory loss and increased emotional dysregulation (e.g. sadness, anger, fear, agitation, 
aggression) (Kim, 2016).  Lacunar strokes cause damage to small arteries throughout the 
outer cortex, the cerebellum, and the deep encephalic areas (e.g. caudate nucleus, internal 
capsule, globus pallidus) (Norrving, 2016).  Most lacunar infarcts fail to produce significant 
acute symptoms, although, over time the cumulative effects may cause cognitive decline 
(Vascular Neurocognitive Disorder), in addition to neuro-behavioural symptoms, such as, 
confusion, agitation and aggression (Makin, Turpin, Dennis, & Wardlaw, 2013).   
Unlike ischaemic strokes, 30% to 40% of people who have a haemorrhagic stroke die 
within the first week (An, Kim, & Yoon, 2017).  As ICHs predominantly occur throughout 
the cerebrum and cerebellum (Kase, Shoamanesh, Greenberg, & Caplan, 2016), sensorimotor 
and oculomotor deficits are common (An et al., 2017).  Cognitive dysfunction, including 
aphasia, are also common following an ICH (An et al., 2017), as are symptoms of depression 
and anxiety, particularly among younger ICH survivors with poor health-related quality of 
life (e.g. severe pain, poor quality sleep, social isolation, unemployment) (Koivunen, Harno, 
Tatlisumak, & Putaala, 2015).  The outcomes associated with SAH are highly variable and 
depend on the cause (e.g. aneurysm, trauma) and area of the haemorrhage.  Nonetheless, 
unilateral limb weakness and visual problems are common (Suarez & Bershad, 2016), as are 
memory, attention, communication, concentration and problem solving deficits (Petridis et 
al., 2017).  Depression and anxiety are also common following SAH, particularly among 
those with severe physical and functional disabilities (Petridis et al., 2017; Von Vogelsang, 






Each year around 15 million people experience a new or recurrent stroke, which 
equates to an annual global incidence rate of 260 per 100,000 (Thrift et al., 2017).  However, 
there is significant variability between countries.  For instance, the 1-year incidence rate in 
the United States of America is slightly less than the global average of 243 per 100,000 
(Mozaffarian et al. 2016).  In Europe, the 1-year incidence rate ranges from 150 per 100,000 
in the United Kingdom, France and Italy, and up to 300 per 100,000 throughout Eastern 
Europe and Russia (Béjot, Bailly, Durier, & Giroud, 2016).  Similar variability is seen 
throughout Asia.  China, India, South Korea and Malaysia have the lowest rates of stroke (70 
to 220 per 100,000), while Japan, Taiwan, Pakistan, and Mongolia have the highest rates (250 
to 420 per 100,000) (Venketasubramanian, Yoon, Pandian, & Navarro, 2017).  The 1-year 
incidence rate of stroke in Australia (230 per 100,000) is also lower than the global average, 
but nonetheless remains a significant problem, with approximately 56,000 people diagnosed 
each year (Stroke Foundation, 2017).   
Prevalence  
Of the 15 million people who have strokes each year, approximately 30% die (Feigin 
et al., 2017).  Of the 70% of people who survive, only 10% fully recover (i.e. have no 
residual symptoms) (Thrift et al., 2017).  The remaining 60% of stroke survivors experience 
ongoing physical, functional and/or cognitive disabilities, in addition to psychological 
problems (Feigin et al., 2017; Hackett, Köhler, O’Brien, & Mead, 2014; Jung, 2017; Thrift et 
al., 2017).  In global terms, this equates to an estimated 33 million people currently living 
with ongoing stroke-related disabilities (12-month prevalence rate: 50 per 100,000) (Feigin et 
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al., 2017); a number that increases by approximately 5 million people each year (Hankey, 
2017).   
The majority of stroke-related deaths occur in low-and-middle-income countries 
(71%) where specialised stroke treatments are less accessible (Feigin et al., 2017).  Indeed, 
the mortality rate in countries throughout Southeast Asia and Eastern Europe is more than 
twice that of the United States of America, the United Kingdom and Australia (105 versus 60 
per 100,000) (Feigin et al., 2017).  However, as a result of having lower mortality rates, high-
income countries have significantly more people living with stroke-related disabilities (12-
month prevalence rates 1.5% to 2.6% versus < 1%) (Béjot et al., 2016; Mozaffarian et al. 
2016; Rajsic et al., 2019).  Despite the difference in prevalence rates, the number of healthy 
years lost due to stroke-related death or disability still remains significantly higher throughout 
developing countries (disability-adjusted life years: 1820 versus 980 per 100,000).  This 
difference has been attributed to the fact that strokes occur earlier in life throughout 
developing countries (Feigin et al., 2017; Venketasubramanian et al., 2017).   
Economic Cost 
The current economic burden associated with stroke is estimated to be over US$73 
billion per annum in the United States of America (Mozaffarian et al., 2016), €38 billion per 
annum throughout the European Union (Rajsic et al., 2019), and AUD$5 billion in Australia 
(Stroke Foundation, 2017).  Concerningly, the economic burden experienced throughout 
these countries is expected to more than double by the year 2050 due to their ageing 
populations (Béjot et al., 2016; Rajsic et al., 2019; Stroke Foundation, 2017), at which time 
estimates suggest the cost may exceed US$1.5 trillion in the United States alone (Rajsic et al. 
2019).  The economic burden associated with treatment-related costs is greatest within the 
first five years after a stroke (Xu et al., 2018), during which time patients who have had more 
severe strokes, are older, and have more medical (e.g. diabetes, arthritis) and/or psychological 
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(e.g. depression) comorbidities are the most expensive to care for (Chinthammit, Coull, 
Nimworapan, & Bhattacharjee, 2017). 
Risk Factors 
Large-scale studies have identified a core group of risk factors that account for 90% 
of all strokes.  These risk factors can be classified as modifiable - meaning that individuals 
can take measures to change them, or non-modifiable - indicating that they cannot be 
changed.  In terms of modifiable risk factors, a history of hypertension (blood pressure > 
160/90 mm Hg) is associated with the highest risk of ischaemic and haemorrhagic stroke, 
followed by current cigarette smoking, excessive alcohol consumption (> 30 drinks per 
month), obesity, poor diet, and prolonged stress (Feigin et al., 2016; O’Donnell et al., 2016).  
Individuals with coronary heart disease, diabetes mellitus, hypercholesteremia and carotid 
stenosis are also at increased risk of ischaemic stroke (Feigin et al., 2016; O’Donnell et al., 
2016), as are people with major depressive disorder - due to its detrimental effect on 
neuroendocrine and immunological functioning (Lightbody et al., 2017).  Lastly, while 
anticoagulant medications reduce the risk of ischaemic stroke, they increase the risk of 
haemorrhagic stroke due to their ‘blood-thinning’ properties (Batta, Kalra, & Khirasaria, 
2019).  
In terms of non-modifiable factors, older age increases the risk for ischaemic and 
haemorrhagic strokes, mainly due to the narrowing (atherosclerosis) and hardening 
(arteriosclerosis) of human arteries that occurs over time (Feigin et al., 2016; O’Donnell et 
al., 2016).  Indeed, 90% of all CVAs occur in people over the age of 50 (Feigin et al., 2016).  
Women are also at a higher overall risk of stroke due to their longer life expectancy (Gibson 
& Attwood, 2016).  Compared with men, women are also older, on average, at the time of 
their stroke (70 vs 66 years of age), which increases their disability and mortality risk 
(Gibson & Attwood, 2016).  In terms of ethnicity, studies from the United States of America 
10 
 
suggest that people of Hispanic and African-American backgrounds are at increased risk of 
stroke, even after controlling for the effects of modifiable risk factors, such as hypertension, 
smoking and diabetes (Gardois, Booth, Goyder, & Ryan, 2014).  Similarly, studies from 
Australia have found that Aboriginal people are more than twice as likely to have a stroke 
compared to non-Indigenous Australians and are also 1.4 times more likely to die as a result 
(Stroke Foundation, 2017).  In addition, individuals with a family history of cerebrovascular 
disease are known to be at increased risk of stroke, which suggests that specific genes may 
also play a role (Anttila et al., 2018; Hankey, 2017).   
1.8 Stroke Treatments and Rehabilitation 
Medical Treatments 
In the hyper-acute phase (< 24 hours) following an ischaemic stroke there are two 
approved emergency treatments, both of which are designed to break down/remove blockages 
from occluded blood vessels.  The first, thrombolysis, involves the intravenous administration 
of tissue plasminogen activating medication to break down and disperse small-to-medium 
sized blood clots (Powers et al., 2019).  Thrombolysis is most effective within the first 4.5 
hours following a stroke and, historically, was not administered beyond this time due to the 
increased risk of ICH (Emberson et al., 2014; Powers et al., 2019).  However, evidence from 
a recent clinical trial suggests that thrombolysis may be effective up to 9 hours after a stroke, 
when patients are identified via neuroimaging as having a large portion of salvageable brain 
tissue (Ma et al., 2019).  Despite these advances, thrombolysis remains less effective at 
dispersing large-artery (e.g. carotid artery, MCA, basilar artery) occlusions (Evans, White, 
Cowley, & Werring, 2017), and is medically contraindicated where patients: are older than 80 
years of age, had a seizure at stroke onset, have a history of/current haemorrhagic stroke, had 
head trauma or neurosurgery in the past 3 months, have a low platelet count, and/or take anti-
coagulant medications (Hankey, 2017).  Therefore, despite the effectiveness of thrombolysis 
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for small-to-medium sized ischaemic strokes, restrictions regarding its use mean that only 1% 
to 3% of all stroke patients currently receive this treatment (Emberson et al., 2014; Hankey, 
2017). 
Mechanical thrombectomy is the second of the approved emergency treatments for 
ischaemic stroke and involves the removal of the clot using a retractable mechanical device 
inserted via an artery (Evans et al., 2017).  Thrombectomy is highly effective for large-vessel 
occlusions and, until recently, was only performed within 6 hours of a stroke due to the risk 
of ICH (Evans et al., 2017).  However, the results of a recent trial suggest that patients with 
focal damage (i.e. small ischaemic cores) may benefit from having the procedure up to 24 
hours post-stroke (Nogueira et al., 2018).  Patients receiving thrombectomy in conjunction 
with thrombolysis also experience better functional outcomes than patients who receive just 
one treatment, therefore both treatments may be provided where indicated (Zhao & Willing, 
2018).      
Unfortunately, there are fewer hyper-acute treatments for haemorrhagic stroke and 
30% to 40% of patients die within the first week (An et al., 2017).  For large ICHs, an open 
craniotomy may be performed to remove the haematoma, minimise cerebral swelling and 
reduce intracranial pressure (Dastur & Yu, 2017).  However, beyond reducing mortality, the 
clinical benefits of this procedure remain contentious, with 1 in 2 patients experiencing 
significant, ongoing physical disabilities as a result (An et al., 2017; Dastur and Yu, 2017).  
Therefore, non-surgical methods to reduce the size of the haematoma, including lowering 
blood pressure and providing blood clotting medications, are currently being examined 
(Dastur & Yu, 2017; Law, Salman, Bath, Steiner, & Sprigg, 2018).  For SAH, surgery to clip 
a ruptured aneurysm, thereby stopping the haemorrhage, is commonly performed (Miller, 




Multi-Disciplinary Rehabilitation   
Where available, medically stable patients typically commence low-intensity physical 
rehabilitation five to 10 days post-stroke, including assisted walking and hand/arm training to 
improve mobility, restrengthen weakened limbs and improve fine motor skills (Dobkin & 
Dorsch, 2013; Jung, 2017).  The benefits of commencing more intensive physiotherapy prior 
to this time have been examined, however, doing so was found to increase the risk of 
mortality (Bernhardt et al., 2015).  In contrast, commencing speech therapy in the two weeks 
after a stroke has been found to benefit patients with severe communication (aphasia) and/or 
swallowing (dysphagia) difficulties (Coleman et al., 2017; Nouwens et al., 2017).   
Clinical psychologists may also begin working with patients throughout the acute 
phase; a period where mood and adjustment disorders are present in 15% to 20% of patients 
(Mitchell et al., 2017).  The initial interactions generally focus on validating any distress or 
frustration felt by the patient and affirming the therapist’s supportive role throughout the 
rehabilitation process (Ownsworth, 2014).  Following this, personalised information or 
‘psychoeducation’ regarding the cause of the stroke and its expected sequelae, may be 
provided to the patient and family in order to reduce any feelings of worry and uncertainty 
(Hildebrand, 2015; Ownsworth, 2014).  To assist with the communication of this information, 
memory aids such as written summaries and printed resources, may be used (Ni et al., 2018).   
Following this, clinical psychologists may work with patients to identify short-term, 
achievable steps (e.g. walking with support for 5 minutes) that are aligned with their broader 
rehabilitation goals (e.g. regaining full mobility), as a means of boosting confidence and 
maintaining motivation throughout the rehabilitation process (Frost et al., 2018).  A 
‘strengths-based approach’ is generally utilised to achieve this, where the main focus is on 
providing positive feedback about the patient’s current abilities, often combined with 
‘errorless-learning’ tasks (Hildebrand, 2015).  Where challenging/responsive behaviours are 
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present (e.g. physical and verbal aggression), clinical psychologists may work with staff and 
family members to implement behaviour management strategies with the goal of teaching 
patients more adaptive methods of coping with distress and frustration (Fisher, Bellon, Lawn, 
& Lennon, 2018).   
The majority of stroke survivors enter the sub-acute phase (30 to 90 days post-stroke) 
with a myriad of ongoing disabilities (Mozaffarian et al., 2016).  Intensive rehabilitation is 
not always available (Enderby et al., 2017), despite the sub-acute phase being recognised as 
the optimal time for undergoing rehabilitation (Cassidy & Cramer, 2017; Langhammer et al., 
2015).  During this time, the central nervous system begins to reallocate and reorganise 
neurons within the injured parts of the brain to recover motor functioning (Cassidy & 
Cramer, 2017).  Furthermore, the benefits associated with sub-acute rehabilitation are 
enhanced by a range of natural endogenous repair processes that occur at this time 
(‘spontaneous recovery’), due to the increased blood flow and reduced inflammation 
throughout the stroke-affected parts of the brain (Cassidy & Cramer, 2017; Jung, 2017).   
In terms of specific physical rehabilitation techniques in the sub-acute phase, task-
oriented, repetitive training approaches are commonly used to improve mobility and 
restrengthen weakened limbs, including treadmill walking, constraint-induced movement 
therapy, and robotic-assisted gait or arm training (Jung, 2017).  Multimodal sensory 
stimulation may also be employed for the same purposes, using mirror therapy, action 
observation, motor imagery and virtual reality training (Jung, 2017).  A variety of non-
invasive cortical stimulation methods, such as repetitive transcranial magnetic stimulation 
and transcranial direct current stimulation, are also being investigated as ways of further 
augmenting physical and functional recovery, by altering the rate of neuronal firing 
throughout specific areas of the brain (Kang, Summers, & Cauraugh, 2016; Zhao & Willing, 
2018).   
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Where multidisciplinary teams are present, other allied-health professionals may 
contribute to the rehabilitation process.  For example, occupational therapists may commence 
work with patients to improve their level of independence, by teaching the necessary skills 
involved in performing self-care, leisure, and other ‘activities of daily living’ (Schiavi, Costi, 
Pellegrini, Formisano, Borghi, & Fugazzaro, 2018).  Where modifications are required to the 
patient’s home (e.g. grab bars, steps or ramps), occupational therapists may recommend and 
arrange the required changes (Fukumoto, Watanabe, Yasufuku, Furudate, & Momosaki, 
2019).  Speech therapists may also commence or continue to work with patients to treat 
communication deficits (aphasia, dysarthria) and swallowing problems (dysphagia) (Clarke & 
Foster, 2015), while social workers may help patients and their caregivers to prepare for the 
transition back into the community by helping to address any unmet needs (e.g. financial 
assistance, support groups) (Hughes, Woodward, Fritz, & Reeves, 2018).   
The role of clinical psychology often continues throughout the sub-acute 
rehabilitation phase; a period where the number of patients exhibiting depressive symptoms 
increases to 40%, due to the increased level of insight gained by patients into the nature and 
severity of their disabilities (Dar et al., 2017; Mitchell et al., 2017).  Notably, patients with 
damage throughout the frontal-subcortical-limbic networks may also experience ‘Vascular 
Depression’, a condition that presents with more prevalent neuro-vegetative symptoms 
(Aizenstein et al., 2016).  Equally as problematic is anxiety, which is estimated to occur in up 
to one quarter of patients in the sub-acute period (Rafsten, Danielsson, & Sunnerhagen, 
2018).  Anxiety is typically due to increased worry about aspects of their recovery, including 
the risk of further strokes, and whether they will be able to return home, live independently, 
and return to work (Campbell-Burton et al., 2013; Rafsten et al., 2018). 
Identifying and treating patients with depression and/or anxiety throughout the sub-
acute phase is of critical importance because the presence of these affective symptoms can 
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lead to an increased risk of various medical complications, including death (Dar et al., 2017).  
Patients with low motivation, fatigue, and anxiety about falling, are also less likely to engage 
in physical rehabilitation, which directly impacts on their long-term functional recovery (Dar 
et al., 2017; Rafsten et al., 2018).  Where symptoms are identified, anti-depressant 
medications, specifically, selective serotonin reuptake inhibitors (SSRIs), are commonly 
prescribed (Damsbo, Kraglund, Buttenschøn, Johnsen, Andersen, & Mortensen, 2019; Mead 
et al., 2013).  However, in some situations, medications may not be appropriate due to side-
effects, including headache, dizziness, tremor, fatigue, and insomnia (Deng et al., 2018).    
Psychotherapeutic interventions, including cognitive behavioural therapy (CBT) and 
acceptance and commitment therapy (ACT), may also be provided by clinical psychologists 
in place of, or in addition to, taking medications (Graham, Gillanders, Stuart, & Gouick, 
2015; Kneebone, 2016; Majumdar & Morris, 2019).  There is now strong evidence in support 
of these treatment modalities for reducing depression and anxiety (Hildebrand, 2015; Wang 
et al., 2018), particularly when adapted or modified in line with the patient’s specific 
cognitive or communication deficits (Kneebone, 2016).  Initial data also support the use of 
complementary treatments for depression and anxiety, including relaxation therapy (Golding, 
Fife-Schaw, & Kneebone, 2018) and music therapy (Clements-Cortes & Haire, 2019).   
Neuropsychological assessments may also be conducted during the sub-acute phase 
where concerns exist regarding the decision-making capacity of patients (Jokinen et al., 
2015).  These cognitive assessments also provide important information regarding the 
strengths and weaknesses of the patient, which may need to be considered when planning 
rehabilitation programs (Nakling et al., 2017).  Increasingly, neuropsychologists are also 
being asked to provide cognitive interventions for attention, memory and executive 
functioning deficits (Loetscher, Potter, Wong, & das Nair, 2019; Sigmundsdottir, Longley, & 
Tate, 2016).  There is preliminary support for the use of repeated activation and stimulation 
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tasks (e.g. repetitive drills, memory exercises) to improve attention and memory, in addition 
to interventions in the areas of problem solving, organisation and planning and organisational 
skills to improve executive functioning (De Luca, Calabrò, & Bramanti, 2018; Hill, House, 
Knapp, Wardhaugh, Bamford, & Vail, 2019). 
Only 10% of stroke survivors achieve full physical, functional and cognitive recovery 
following sub-acute rehabilitation (Jung, 2017).  For the remaining 90% percent, the rate of 
recovery begins to slow around the 90-day mark (i.e. the start of the chronic phase), and 
plateaus at the six-month mark (Bernhardt et al., 2017; Cassidy & Cramer, 2017).  Some 
patients continue high-intensity rehabilitation post-discharge in an attempt to further enhance 
functional improvement (e.g., walk faster/for longer distances, improved fine motor skills) 
(Lee et al., 2015).  However, most stroke survivors are discharged into the community at this 
time and the treatment focus switches from inpatient rehabilitation to adapting the home 
environment (e.g., installing ramps, grab rails, lifters) (Jung, 2017).   
Unsurprisingly, clinical psychologists play an important role in supporting stroke 
survivors as they transition home from the rehabilitation environment.  Indeed, the transition 
process is recognised as a period where symptoms of depression and anxiety may increase 
acutely (Chun et al., 2018; Mitchell et al., 2017).  There are a myriad of reasons for this 
exacerbation of symptoms, including ongoing fears of further strokes or falls, increased 
insight into their overall loss of independence, concerns about burdening caregivers, financial 
difficulties, and social isolation (Cunningham, Blomstrand, Skoog, & Linden, 2016; Mitchell 
et al., 2017; Wright, Wu, Chun, & Mead, 2017).  Although anti-depressant medications may 
again be prescribed, pharmacological approaches are not always effective (Damsbo et al., 
2019) and the risk of unwanted side effects remains (Deng et al., 2018).   
Psychotherapeutic interventions may aagain be used as an alternative to, or in 
conjunction with medication, to reduce the emotional distress experienced by patients 
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throughout the chronic phase of stoke (Mead et al., 2013; Wang et al., 2018).  Specifically, 
research suggests that CBT is effective at helping patients change unhelpful thought 
processes which, in turn, impact their mood and/or quality of life, by challenging negative or 
unrealistic thoughts or by testing the accuracy of the thoughts through behavioural 
experiments (Kneebone & Jeffries, 2013; Kneebone, 2016; Wang et al., 2018).  In addition, 
behavioural activation, whereby stroke survivors are encouraged and supported to resume 
participation in pleasurable activities (e.g. socialising, moderate exercise, old/new hobbies) 
(Ekers et al., 2014; Lee, Heffron, & Mirza, 2019), is commonly used to reduce depression by 
increasing levels of the neurotransmitter serotonin (Lee, Heffron, Mirza, 2019; Thomas, 
Walker, Macniven, Haworth, & Lincoln, 2013).   
Clinical psychologists may also provide psychoeducation to patients and caregivers to 
promote awareness of, and potential solutions for, the range of longer-term medical (e.g. 
fatigue, chronic pain), functional (e.g. reduced independence, social withdrawal), cognitive 
(e.g. dementia) and emotional (e.g. loss of identity) challenges that may occur throughout the 
chronic phase (Hong et al., 2017).  Although these educational programs may not always 
directly involve the patient, research suggests that they are critical to stroke survivor 
wellbeing, due to the fact that increased caregiver burden is associated with worse physical 
(e.g. mortality, illness), psychological (e.g. depression, anxiety), and social (e.g. isolation) 
outcomes for the patient (Haley, Roth, Hovater, & Clay, 2015; Wan-Fei et al., 2017).   
1.9 Summary 
Stroke remains as one of the leading causes of death and disability worldwide 
(Mozzafarian et al., 2016).  Existing emergency stroke treatments are effective at saving lives 
and may reduce the severity of the associated disabilities (Hankey, 2017).  However, the 
majority of patients do not receive the recommended treatments, due to medical 
contraindications and/or a lack of availability (Powers et al., 2019).  Consequently, many 
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stroke survivors commence sub-acute rehabilitation with significant physical, functional, 
cognitive and psychological problems (Feigin et al., 2017; Mitchell et al., 2017; Thrift et al., 
2017).  An intensive period of sub-acute multidisciplinary rehabilitation may further improve 
the outcomes of stroke survivors (Enderby et al., 2017; Hankey, 2017).  Although, this type 
of rehabilitation is not widely available (Jung, 2017).  New and innovative treatments that 
improve the physical, cognitive and psychological outcomes of stroke survivors are therefore 
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Chapter 2:  Stem Cell Therapies for Stroke 
2.1 Overview 
A variety of novel treatments that involve the injection of SCs into the brain 
(intracranial), spinal cord (intrathecal), vein (intravenous), artery (intra-arterial), and/or skin 
(subcutaneous) of patients, are currently being developed in order to overcome the current 
limitations associated with existing stroke treatments and rehabilitation practices (Savitz, 
2018).  Although much of this research is still in its early stages, experimental SC treatments 
are now being offered by private clinics throughout Asia, South America and Eastern Europe 
(Cohen & Simana, 2018).  Moreover, increasing numbers of patients are travelling overseas 
for the express purpose of receiving these risky and expensive treatments, a trend that is 
causing concern among government health agencies, clinicians and patient advocacy groups.  
This chapter provides a detailed overview of SC therapy for stroke, including the 
main sources and types of SCs, primary methods of transplanting SCs, and hypothesised risks 
and benefits associated with each approach.  Following this, current SC research guidelines, 
which were formulated to expedite the translational research process, are summarised and 
critiqued from a psychological perspective.  Lastly, the practise of ‘stem cell tourism’ is 
discussed, including the associated medical and financial risks, and available interventions to 
dissuade patients from having these risky and experimental treatments.   
2.2 Overview of SC Therapies 
Definitions 
SCs are cells that have the ability to produce copies of themselves and to reproduce or 
‘differentiate’ into other cells (Giri, Alexander, Agrawal, & Saraf, 2019).  ‘SC therapy’ or 
‘cell therapy’ refers to the injection of SCs, SC derivatives (e.g. progeny cells obtained from 
SCs) and/or other cellular materials (e.g. granulocyte-colony stimulating factor [G-CSF], 
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exosomes) for the purposes of preventing or treating a medical condition (Dolati et al., 2019; 
Savitz, 2018).  These terms are distinct from ‘SC treatment’ which is used more broadly in 
reference to non-evidence based experimental SC injections (Srivastava et al., 2016).   
SC Sources 
SCs are categorised according to their source.  SCs harvested from the patient are 
referred to as autologous.  SCs harvested from another human, including an embryo or fetus, 
are referred to as allogeneic.  Finally, SCs harvested from a different species/animal are 
referred to as xenogeneic (Kenmuir & Wechsler, 2017; Zafar, Goswami, & Kumar, 2018).  
The distinctions between autologous, allogeneic and xenogeneic cells are important, from a 
treatment perspective, because SCs derived from foreign sources (i.e. allogeneic, xenogeneic) 
may be rejected by the recipient's immune system in the absence of immunosuppressant 
drugs (Boltze et al., 2015). 
SC Types  
SCs are categorised based upon whether they were derived from embryonic or post-
natal adult cells, and the number of cell lines/lineages they can reproduce, referred to as their 
‘differentiation potential’ (Mummery, Van de Stolpe, Roelen, & Clevers, 2014).  Embryonic 
SCs only occur in the early stages following the fertilization of the ovum, during which time 
the zygote divides via the process of mitosis to form a blastocyst-stage embryo (Mummery et 
al., 2014).  SCs that form following the initial splitting of the zygote (blastomeres) are 
totipotent and have the ability to reproduce into all embryonic and adult cells (Rossant & 
Tam, 2017).   
Following this, totipotent SCs differentiate to form the blastocyst-stage embryo, at 
which time the SCs become pluripotent, meaning they can differentiate into the cell lineages 
required to form a human body (Trounsen & DeWitt, 2016).  Human pluripotent SCs are 
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generally sourced from donated unused in-vitro fertilisation embryos (embryonic SCs) and, 
once obtained, can be replicated to create an ongoing line of ‘daughter cells’ (Romito & 
Cobellis, 2016).  However, as a result of recent scientific breakthroughs, human pluripotent 
SCs, known as induced pluripotent SCs, can now also be made in labs by genetically 
reprogramming skin cells (Marei et al., 2018; Shi, Inoue, Wu, & Yamanaka, 2017).   
Embryonic SCs are of significant interest to stroke researchers as they are thought to 
be a potential means of regrowing/replacing damaged brain tissue (e.g. neurons, 
oligodendrocytes, astrocytes), and if administered during the acute stage of stroke, may also 
support naturally occurring/endogenous repair processes through the release of anti-
inflammatory cytokines and growth factors (Marei et al 2018; Zhao & Willing, 2018).  
However, there are significant risks associated with the use of totipotent and pluripotent cells, 
given that they may differentiate into tumours (Marei et al., 2018).  Strong ethical concerns 
also remain regarding the harvesting and subsequent use of embryonic SCs, which was a key 
driver behind the research undertaken to create induced pluripotent SCs (Volarevic et al., 
2018).   
SCs obtained from post-natal human tissue are referred to as adult SCs (Visvadar & 
Clevers, 2016).  Adult SCs are multipotent and, as such, only have the potential to 
differentiate into cells within the human body, including organs (e.g., heart, liver), tissue 
(e.g., bone, cartilage, fat), and blood (Giri et al., 2019).  Multipotent SCs are harvestable from 
fat/adipose, dental and skin tissue (Dolati et al., 2019; Gancheva et al., 2019; Ojeh, Pastar, 
Tomic-Canic, & Stojadinovic, 2015; Ullah, Subbarao, & Rho, 2015).  However, bone 
marrow is the most common source and provides both bone marrow mesenchymal SCs, a 
non-hematopoietic SC with the potential to differentiate into organs and tissue (Dolati et al., 
2019), and bone marrow mononuclear cells, a collection of non-hematopoietic and 
hematopoietic cells (e.g. endothelial progenitor cells, CD34+ cells) with the potential to 
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differentiate into blood cells, organs and tissue (Boulais & Frenette, 2015; Gancheva et al., 
2019).  In addition, bone marrow mesenchymal and mononuclear cells are also thought to 
release trophic factors that provide neuroprotection and support naturally occurring 
(endogenous) repair processes in the brain following a stroke (Giri et al., 2019).   
Umbilical cord blood, placental tissue and umbilical tissue (e.g. Wharton’s jelly) are 
also a source of multipotent mesenchymal SCs and are of interest to stroke researchers given 
that they have the potential to repair tissue throughout artery walls (Li et al., 2016).  SCs 
obtained from aborted human fetuses are also multipotent and form progenitor cells, which 
subsequently differentiate into the organs or tissue from which they were obtained 
(Mummery, Van de Stolpe, Roelen, & Clevers, 2014).  Neural SCs, which are located within 
the dentate gyrus and subventricular zone of the human brain, are one such example and are 
of significant interest in the field of stroke because they have the potential to differentiate into 
brain tissue (Fuentealba et al., 2015).  Notable examples of neural SCs that have been 
previously harvested then expanded to create an ongoing source for stroke research include 
the CTX (Kalladka et al., 2016) and LBS (Kondziolka et al., 2000) neural SC lines.   
Broader ‘Cell Therapies’    
In addition to the injection of SCs and their derivatives, a small number of related 
cellular materials are also under investigation as potential ‘cell therapies’ for stroke.  G-CSF, 
a naturally occurring hematopoietic growth factor used to treat white blood cell depletion 
(neutropenia) (Dale et al., 2015), is also thought to inhibit inflammation and promote 
regrowth of damaged brain tissue when administered during the early stages following a 
stroke (Cramer, 2018; Solaroglu, Digicaylioglu, Evren Keles, & Zhang, 2015).  The synthetic 
equivalent of G-CSF, Filgrastim, has also been investigated as a possible adjunct to specific 
SC therapies (‘combination SC therapies’) and preclinical data suggest it may create a more 
receptive microenvironment for implanted SCs through the expression of pro-inflammatory 
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cytokines (Sarmah et al., 2018).  Importantly, as G-CSF is naturally occurring, it does not 
require immunosuppressant drugs to be administered (Solaroglu et al., 2015).  Instead, it 
passes through the intact blood-brain-barrier (i.e. the capillary wall that protects the brain 
from pathogens in the blood) and, as a result, is suitable for use throughout the acute, sub-
acute and chronic stroke phases (England et al., 2016). 
Exosomes, which are extracellular vesicles released by cells throughout the body to 
carry and transfer biomolecules, such as proteins, lipids and nucleic acids between cells, are 
also being investigated as a potential additional type of cell therapy for stroke (Chen & 
Chopp, 2018).  Animal studies suggest that exosomes may mediate the effectiveness of 
transplanted mesenchymal SCs following a stroke by facilitating the transfer of beneficial 
biomolecules between the brain and its surroundings (Zhang, Buller, & Chopp, 2019).  The 
stand-alone benefits of exosomes produced by mesenchymal SCs and injected into the 
bloodstream of rodents post-stroke have also been examined.  The results suggest that 
exosomes are able to pass through an intact blood-brain-barrier, after which they promote 
neuronal regeneration, stimulate endogenous repair processes and reduce inflammation 
(Zhang et al., 2019).  Although, preliminary clinical research has begun in the field of brain 
cancer, studies examining the benefits of exosomal therapy in stroke have yet to be conducted 
(Chen & Chopp, 2018; Zhang et al., 2019).            
Methods of SC Transplantation 
 In addition to the broad range of SCs under consideration as treatments for stroke, a 
variety of transplantation methods have been examined, including intravenous, intra-arterial, 
intracranial, intrathecal and subcutaneous injections.  The optimal transplantation methods 
remain unclear at present (Rodríguez-Frutos et al., 2016) and are hypothesised to differ based 
on: the type of stroke (ischaemic, haemorrhagic), phase of treatment (hyper-/acute, sub-acute, 
or chronic) (Bhatia, Gupta, Khurana, Sharma, & Khandelwal, 2018; Guzman et al., 2018; 
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Savitz et al., 2019), the permeability of the blood-brain-barrier (Daneman & Prat, 2015), the 
type of the SCs being administered, their expected mechanisms of action (e.g., replacement 
of damaged tissue, release of growth factors) (Rodríguez-Frutos et al., 2016), and the 
outcomes that are being measured (e.g. neurological, functional, radiological) (Wechsler, 
Bates, Stroemer, Andrews-Zwilling, & Aizman, 2018).   
The least invasive transplantation methods (i.e. intravenous, intra-arterial, 
subcutaneous) have been examined predominantly throughout the hyper-acute and acute 
stages of stroke, a period of time when patients are at increased risk of treatment-related side 
effects (Boltze et al., 2015).  Moreover, the blood-brain-barrier is more permeable throughout 
the early stages after a stroke, which allows SCs injected into the bloodstream to reach the 
brain (Daneman & Prat, 2015).  Intravenous injections are one of the most common methods 
and are generally made into a vein of the forearm (Mays & Savitz, 2018).  It was hoped that 
SCs administered in this way would migrate throughout the bloodstream toward the stroke-
affected areas of the brain (Bhatia, Gupta, Khurana, Sharma, & Khandelwal, 2018; Savitz et 
al., 2019); however, most appear to divert to the other major organs (e.g., lungs, liver, spleen) 
where they are at risk of causing blood clots (Boltze et al., 2015; Rosado-de Castro et al., 
2013).  Although most SCs do not reach the brain, research suggests that intravenously 
administered cells may still exert neuroprotective effects indirectly, via the peripheral 
immune system (Mays & Savitz, 2018).      
Intra-arterial SC injections are also relatively non-invasive and are most commonly 
injected into the MCA via femoral or carotid artery catheterisation (Guzman, Janowski, & 
Walczak, 2018).  Intra-arterial delivery is thought to result in a larger number of cells 
reaching the brain, compared to intravenous injections, as the SCs bypass the major organs 
(Guzman et al., 2018).  However, there is an increased risk of recurrent stroke due to either 
the SCs causing a blockage or as a result of arterial fat/plaque becoming dislodged in the 
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process and lodging in the brain (Boltze et al., 2015).  Once located in the brain, the SCs may 
release trophic factors that aid endogenous repair processes and/or begin to replace lost 
neural connections (Rodríguez-Frutos et al., 2016). 
Subcutaneous injections are the least invasive transplantation method and are 
generally made via the abdomen into the cutis (i.e. the skin layer directly below the dermis 
and epidermis) (Rodríguez-Frutos et al., 2016).  G-CSF/Filgrastim is most commonly 
administered using this method, as it is thought to provide its neuroprotective effects via a 
range of paracrine mechanisms (i.e. bystander effects), rather than by directly restoring brain 
tissue (Gorthi, Prasad-Pathak, Dhull, & Nair, 2018; Solaroglu et al., 2015).  In addition, given 
that G-CSF factor is able to bypass an intact blood-brain-barrier (Huang et al., 2017), 
subcutaneous injections are being investigated throughout all stroke phases (Gorth et al., 
2018; Huang et al., 2017).   
 Two additional, but more invasive transplantation methods are also being examined, 
predominantly as a treatment throughout the chronic phase of stroke, at which time the blood-
brain-barrier is no longer permeable (Daneman & Prat, 2015).  Intracranial administration, 
which involves the stereotactic injection of SCs in-or-around the damaged areas of the brain 
via burr holes, is the first method (Steinberg et al., 2018).  Despite being the most invasive 
form of SC transplantation (Boltze et al., 2015; Marei et al., 2018), intracranial injections are 
of particular interest because the cells can be directly implanted with a high degree of 
accuracy into the stroke-damaged areas of the brain (Neal et al., 2018; Savitz, 2018).  
Embryonic and neural SCs have been used most often in the hope that the SCs will regenerate 
and restore damaged areas (Kalladka et al., 2016; Wechsler et al., 2018).  However, given 
that embryonic SCs have an increased risk of tumour formation (Boltze et al., 2015), 
intracranial neural SC and mesenchymal SC injections are thought to be potentially safer 
treatment options (Steinberg et al., 2018).   
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Intrathecal delivery, whereby SCs are injected into the spinal canal via lumbar 
puncture, is the last major method of transplantation.  This method is again of significant 
interest in the field of stroke because the implanted cells are understood to reach the brain via 
the cerebral-spinal fluid, rather than intracranial injections (Zakerinia et al. 2018).  Although 
primarily used in the chronic phase of stroke, intrathecal SC injections have been tested 
previously throughout the acute and sub-acute phases (Xue et al., 2014).  Intraventricular 
injections are understood to work in a similar way to intrathecal injections (Rodríguez-Frutos 
et al., 2016); however, given the SCs are neurosurgically implanted directly into cerebral-
spinal fluid within the subarachnoid space, it is considered to be more invasive (Al Fauzi, 
Suroto, Bajamal, & Machfoed, 2016).  Embryonic SCs have again been used primarily for 
intrathecal and intraventricular injections given their potential to restore brain tissue 
(Borlongan, 2019).  Their use is, however, associated with an increased risk of spinal and/or 
brain tumours (Marei et al., 2018).  
2.3 Published Guidelines for SC Research 
Given that SC research in the field of stroke is in the early stages, a range of 
recommended guidelines have been published to help expedite the translational research 
(bench-to-bedside) process.  For preclinical research, this includes the Stroke Therapy 
Academic Industry Roundtable (STAIR) (STAIR collaborators, 1999; Albers et al., 2011; 
Fisher, 2003; Fisher, Hanley, Howard, Jauch, & Warach, 2007; Saver, Albers, Dunn, 
Johnston, & Fisher, 2009) and ‘Stem Cell Therapies as an Emerging Paradigm in Stroke’ 
(STEPS) guidelines (Boltze et al., 2019; Savitz et al., 2011; Wechsler et al. 2009).  These 
guidelines suggest: (1) undertaking randomised, observer-blinded studies with multiple 
species, (2) documenting inclusion/exclusion criteria, (3) performing statistical power 
analyses, (4) investigating different administration routes, dosages and lengths of time post-
stroke, (5) measuring multiple outcomes throughout each phase of stroke, (6) establishing 
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efficacy across multiple laboratories, (7) disclosing all conflicts of interest, (8) examining all 
stroke sub-types, (9) considering the age and medical comorbidities (e.g. diabetes, 
hypertension) of the recipients, and (10) reporting and sharing all data (positive, neutral, 
negative).   
A further version of the STEPS document (Savitz et al., 2014) and the related ‘Rigor 
Guidelines’ (Lapchak, Zhang, Noble-Haeusslein, 2013) provide specific recommendations 
for clinical research.  In addition to recommending that all data are published and any 
conflicts of interest are disclosed, these guidelines also advocate for: (1) the inclusion of 
sham treatment conditions to control for placebo effects, (2) justifying the type of SC, 
transplantation method and dosage based upon preclinical research, (3) screening for and 
documenting relevant medical comorbidities, (4) assessing pre-treatment functioning on two 
or more occasions to attain a stable neurological baseline, (5) performing neuroimaging of the 
stroke lesion/infarct size pre-and-post treatment, (6) labelling and tracking SCs to identify the 
mechanisms of action, (7) examining domain-specific outcomes, (8) providing physical 
rehabilitation in addition to the SC treatment, and (9) reporting serious adverse events beyond 
12 months.  The majority of the recommendations are intended for current clinical trials, 
although some recommendations, such as the labelling and tracking SCs post-implantation, 
remain aspirational due to current technological limitations (Mangin & Kubis, 2019).  
However, despite their apparent utility, the overall level of adherence by SC researchers has 
yet to be evaluated, therefore it is unclear whether particular aspects of research are being 
overlooked.    
Further Psychological Considerations  
Current SC clinical research guidelines were developed to help expedite the 
translational research process and, as such, are primarily focussed on confirming the medical 
safety and neurological, functional, and radiological efficacy of SC treatments for stroke 
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(Mangin & Kubis, 2019; Savitz et al., 2014).  Unfortunately, the guidelines place much less 
emphasis on a range of potentially important psychological factors that may also influence 
both SC treatment outcomes and patient wellbeing.  For instance, while it is recommended 
that all relevant medical comorbidities (e.g. diabetes, hypertension) are identified prior to SC 
treatment (Lapchak et al., 2013; Savitz et al., 2014), the routine assessment of depression and 
anxiety is not advocated for, despite patients with mood symptoms being at increased risk of 
treatment-related complications (e.g. mortality, infections, increased pain) and poorer long-
term functional outcomes (Chun et al., 2018; Dar et al., 2017; Rafsten, Danielsson, & 
Sunnerhagen, 2018).   
Furthermore, pre-operative anxiety, which is estimated to occur in up to 90% of 
patients who undergo invasive medical procedures, also places patients are greater risk of 
serious treatment-related complications and poorer treatment outcomes (Aust et al., 2018; 
Kumar, Dubey, & Ranjan, 2019; Majumdar et al., 2019; Strøm et al., 2018).  Therefore, given 
the invasive nature of some SC therapy procedures, it is possible that pre-operative anxiety 
may also impact upon the safety and efficacy of those particular treatments.  Moreover, 
patients who experience adverse treatment outcomes, including a perceived lack of 
effectiveness, are also at risk of longer-term depression and anxiety (Abu-Ruz, Alaloul, & Al-
Dweik, 2018; Ghoneim & O’Hara, 2016), whereas patients who experience positive 
treatment outcomes generally experience an improvement in their mood (Mancuso et al., 
2018; Switzer, Debru, Church, Mitchell, & Gill, 2016).  These risks are again noteworthy in 
the current context, given that participants in the majority of SC trials are providing consent 
to receive treatments with largely unquantified risks and benefits.    
Similarly, screening for the presence of a neurocognitive disorder (mild or major) is 
not explicitly stated in the available SC guidelines (Lapchak et al., 2013; Savitz et al., 2014).  
This is potentially problematic given that cognitive deficits are common following a stroke 
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and may impact upon the overall functioning of the patient (Hankey, 2017).  In addition, SC 
therapies may also improve cognitive outcomes following a stroke, however, this is not 
examinable in the absence of pre-treatment screening and neuropsychological assessment 
(Giri et al., 2019).    
2.4 Experimental SC Treatments and ‘Stem Cell Tourism’ 
SC therapies that involve the injection of foreign cells (i.e. allogeneic, xenogeneic) to 
treat stroke and its related symptoms have yet to be approved for use in the United States of 
America, United Kingdom or Australia, due to ongoing concerns about the safety and 
effectiveness of these treatments (Sipp et al., 2018).  However, autologous SC treatments, 
which involve the injection of the patient’s own cells, are permitted under current regulations 
for stroke, stroke-related symptoms (e.g. chronic pain), and for certain neurological 
conditions, such as multiple sclerosis, Parkinson’s disease, spinal cord injury and traumatic 
brain injury (Berger et al., 2016; McLean, Stewart, & Kerridge, 2015; Munsie et al., 2017; 
Turner, & Knoepfler, 2016).  Autologous SC treatments are thought to be medically safer 
than the use of foreign SCs, due to a lower risk of immune rejection and tumour formation 
(Boltze et al., 2015), although recipients still face financial risks due to the significant 
expenses incurred when receiving these unproven treatments (Berger et al., 2016; Munsie et 
al., 2017).          
In addition to the SC treatments offered by domestic clinics throughout the United 
States of America, United Kingdom and Australia, private clinics throughout Asia, South 
America and parts of Europe also offer experimental SC treatments that utilise both 
multipotent autologous and pluripotent foreign cell types (Cohen & Simana, 2018).  The 
treatments provided by these clinics are largely unregulated and, as a result, the clinics are 
not required to disclose the source of their SCs or to provide empirical data to support the 
safety or efficacy of their treatments (Bauer Elsallab, & Abou-El-Enein, 2018; Srivastava et 
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al., 2016).  In addition, the manufacturing processes used by these private clinics may lack 
the sophistication required to ensure high quality SCs, and in some cases, lack the capabilities 
to routinely test donor SCs for hepatitis or the Human Immunodeficiency Virus (Cohen & 
Simana, 2018; Mummery et al., 2014).  In addition to these significant medical risks (Bauer 
et al., 2018), patients who undergo experimental SC treatments are at high risk of financial 
exploitation, with some patients reportedly paying up to US$100,000 to receive these non-
evidence-based treatments (Sipp et al., 2017).    
While little is currently known about the number of patients receiving autologous 
treatments in their home countries, travelling overseas for experimental SC injections, a 
practise known as ‘stem cell tourism’, is thought to have become increasingly popular over 
the past decade, particularly among patients with spinal cord injuries, multiple sclerosis, 
Parkinson’s disease and amyotrophic lateral sclerosis (Rachul, 2011; Rai, Yuhasz, Julian, 
Salerno, & Imitola, 2019; Tanner, Petersen, & Munsie, 2017).  Despite this concerning trend, 
only a small number of studies have examined the reasons why patients do so.  A qualitative 
analysis of online blog posts from American, Canadian, Australian and Brazilian patients 
who had sought out SC injections for a range of neurological conditions (N = 32), found that 
dissatisfaction with the effectiveness of mainstream treatments, coupled with frustration 
regarding the perceived length of time taken for new treatments to become available in their 
home countries, were the main reasons for them having done so (Rachul, 2011).  A 
subsequent Australian study, which interviewed 16 patients with a similar range of 
conditions, further identified that the notion of ‘hope’ along with a sense of having ‘nothing 
to lose’ as being strong motivating factors for them having travelled overseas to undergo 
experimental SC treatments (Petersen, Seear, & Munsie, 2014).  
Preliminary research suggests that interest in ‘stem cell tourism’ may also be 
increasing among the stroke cohort (Cohen & Simana, 2018).  This is extremely concerning, 
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given that there are published reports of stroke survivors experiencing brain tumours 
(Amariglio et al., 2009; Nakamura et al., 2016), spinal cord lesions, seizures and serious 
infections (Berkowitz et al., 2016; Hurst et al., 2013; Kawarai et al., 2011) following 
experimental SC treatments from clinics in Asia and Russia.  The factors that specifically 
motivate stroke survivors to travel overseas for unproven SC treatments have yet to be 
identified.  Although, a single South Korean study found that male stroke survivors who had 
more severe ongoing physical disabilities and positive expectations regarding the risks and 
benefits associated with SC treatments were more likely to consider them (Kim et al., 2013). 
Theoretical Frameworks That May Further Predict Interest in ‘Stem Cell Tourism’ 
A number of pre-existing theoretical frameworks may help to shed light on which 
patients are most likely to seek out experimental SC treatments.  One such framework is the 
biopsychosocial model (Bolton, 2019).  According to this model, which forms the basis for 
the World Health Organisation’s International Classification of Functioning (Stucki, 2016), a 
patient’s overall level of disability is not only based on biological factors (i.e. the medical 
model), but rather a complex interaction between biological, psychological and social factors 
(Wade & Halligan, 2017).  When applied to stroke, the biopsychosocial model suggests that 
physical and functional disabilities, in addition to health-related quality of life (e.g. severity 
of pain, quality of sleep, presence of communication deficits), mental health, cognitive 
functioning, and social support should all be considered when measuring a patient’s level of 
incapacity (Zhang et al., 2018).  When considered in conjuction with previous research, 
which found that patients with severe ongoing physical disabilities were more likely to be 
considering experimental SC treatments (Kim et al., 2013), it appears possible that the 
biopsychosocial model may offer additional insight into which stroke survivors’ are at 
greatest risk of participating in ‘stem cell tourism’.  However, despite its potential utility, it 
has yet to be applied in this context.    
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In addition to the biopsychosocial model, psychological research suggests that the 
attitudes and beliefs of a patient regarding a treatment or intervention may strongly influence 
whether they will consider undergoing it or not.  This view, which is primarily associated 
with the Theory of Planned Behaviour model (Ajzen, 1991), proposes that a person’s beliefs 
regarding the benefits of a particular intervention, the ease with which they believe they can 
access the intervention, and the broader perceived societal norms regarding the intervention, 
all influence the individual's intentions and subsequent actions (Ajzen, 1991).  When applied 
to ‘stem cell tourism’, the Theory of Planned Behaviour posits that patients who perceive SC 
injections to be very safe, highly effective, easily accessible, financially affordable, and who 
feel that their family/friends support this treament, are more likely to consider and seek out 
these treatments (Sheeran et al., 2016).  Preliminary evidence exists in support of the Theory 
of Planned Behaviour when assessing participation in other forms of ‘medical tourism’ (Seow 
et al., 2017; Sheeran et al., 2016), however, its utility has yet to be evaluated in the context of 
‘stem cell tourism’.   
Interventions to Deter Patients from ‘Stem Cell Tourism’   
In recognition of the increasing level of interest in ‘stem cell tourism’ among various 
patient groups, and the significant risks associated with these unregulated treatments, a 
number of governments have implemented laws that prohibit experimental SC clinics from 
operating (Sipp & Okano, 2018).  A prime example of this occurred in Germany in 2011, 
when the X-Cell Centre - one of Europe’s largest SC clinics at the time - was shut down 
following the death of a boy following intracranial SC injections for autism (Bauer et al., 
2018).  The United States of America has also begun to review SC treatment practices, which 
has lead to a number of clinics closing, due to increased regulatory scrutiny regarding safety, 
efficacy, and treatment costs (Sipp, 2018; Sipp & Okano, 2018).  Australia appears to have 
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been slower to act, however, and continues to have one of the highest percentage of SC 
clinics, per capita, in the world (Berger et al., 2016; Munsie et al., 2017). 
In addition to regulatory changes, a plethora of patient education resources (e.g. 
written resources/handbooks, online videos, presentation slides, cartoons/comics) have been 
developed by SC research organisations, scientists and patient advocacy groups to dissuade 
patients from receiving unproven SC treatments, either in their home countries or abroad 
(Weiss, Turner, Levine, & Ikonomou, 2018).  Although the type and level of detail varies 
considerably between these resources, most focus on the medical and financial risks 
associated with ‘stem cell tourism’ for neurological disorders, including multiple sclerosis, 
cerebral palsy, spinal cord injury, amyotrophic lateral sclerosis and Parkinson’s disease, as 
opposed to stroke (Master, Robertson, Frederick, Rachul, & Caulfield, 2014).   
A preliminary review of available SC educational resources designed for patients with 
neurodegenerative disorders highlighted strong concerns about the likely effectiveness of 
patient education as a stand-alone strategy against ‘stem cell tourism’ (Master et al., 2014).  
However, the extent to which patient education interventions effectively dissuade patients, 
including stroke survivors, from having experimental SC treatments has yet to be formally 
evaluated.  This is particularly noteworthy in the current context because stroke survivors 
may require resources that have been developed with their specific disabilities, risk profiles, 
and psychological and cognitive comorbidities in mind for them to be effective (Du, Ma, & 
Li, 2016).    
2.5 Summary  
 SCs, SC derivatives and cellular materials are being examined as potential treatments 
for stroke given they have the potential to restore and regenerate damaged brain tissue (Giri 
et al., 2019).  A wide variety of SC sources, types and transplantation methods are being 
investigated; however, the safest and most efficacious SC therapies have yet to be determined 
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for each phase of stroke (Boltze et al., 2015; Giri et al., 2019; Kenmuir & Wechsler, 2017).  
Despite the availability of SC research guidelines to assist in the translational process 
(Lapchak et al., 2013; Savitz et al., 2014), their medical focus has lead to a number of 
important psychological considerations having been overlooked (Giri et al., 2019; Kenmuir & 
Wechsler, 2017).  Very little is also currently known about the level of interest in ‘stem cell 
tourism’ among stroke survivors, and the reasons why patients may be considering these 
unregulated, experimental treatments is unclear.  A number of biopsychosocial factors, 
including physical independence, health-related quality of life, cognition, depression, anxiety, 
social support, perceived caregiver burden, may provide important insights into this, but have 
yet to be examined.  The Theory of Planned Behaviour (Ajzen, 1991) also suggests attitudinal 
factors may also influence whether stroke survivors will consider experimental SC 
treatments, however its utility has yet to be evaluated in this context.  In the interim, SC 
research organisations and advocacy groups have created patient education booklets and 
videos warning patients about the medical and financial risks associated with ‘stem cell 
tourism’ (Weiss et al., 2018).  However, whether existing patient education resources, which 
were primarily designed for patients with neurological disorders, are an effective means of 
dissuading stroke survivors from having risky treatments remains unknown.   
2.6 Aims of the Current Research  
As highlighted in this review, significant gaps remain in the treatment of stroke due to 
the inaccessibility and/or limitations associated with existing emergency interventions, 
varying availability of multidisciplinary rehabilitation, and a lack of safe and effective long-
term restorative treatments (Emberson et al., 2014; Enderby et al., 2017; Jung, 2017).  
Moreover, while preliminary research suggests that SC therapies may improve the physical, 
functional and radiological outcomes of stroke survivors, the medical and psychochological 
risks, optimal SC types, administration methods, and dosages for each phase of stroke remain 
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unclear (Giri et al., 2019; Marei et al., 2018).  Research also suggests that increasing numbers 
of patients with neurological conditions are travelling abroad to private SC clinics (Cohen & 
Simana, 2018).  However, the number of stroke survivors that may be considering 
undergoing experimental SC treatments, and the reasons for doing so are undetermined.  
Patient education resources aimed at deterring patients with a range of conditions from 
participating in ‘stem cell tourism’ are available online, although the effectiveness of the 
existing resources for stroke survivors has yet to be examined.  
The four studies that follow were designed to: (1) review and evaluate clinical 
research examining the safety and efficacy of SC therapy for stroke; (2) identify the extent to 
which psychological factors have been considered by existing SC researchers, (3) provide an 
estimate of the number of stroke survivors who are considering having experimental SC 
treatments; (4) clarify some of the biopsychosocial and attitudinal factors that increase the 
likelihood that stroke survivors will consider having experimental SC treatments; and (5) 
examine whether existing patient education resources deter stroke survivors from ‘stem cell 
tourism’. 
Objective 1 was examined through a systematic review and meta-analysis of 
published safety and efficacy data pertaining to use of SC therapy for stroke.  Data were 
analysed according to whether the SC therapies were administered in the acute and sub-acute 
(Study 1; Chapter 3) or chronic (Study 2; Chapter 4) phases.  The number of treatment-
related serious adverse events was used to evaluate the safety of individual treatments.  
Efficacy was assessed across neurological, functional and radiological outcomes.  The 
reporting quality of the included studies was also assessed using published reporting 
guidelines (e.g. Consolidated Standards of Reporting Trials [CONSORT]) (Moher et al., 
2010) and recommended SC research guidelines (e.g., STEPS [Savitz et al., 2011; Savitz et 
al., 2014; Wechsler et al. 2009]). Studies 1 and 2 additionally examined the degree to which 
44 
 
psychological factors have been considered within the existing SC research literature 
(objective 2).  
Objectives 3 and 4 were addressed by conducting a cross-sectional survey of stroke 
survivors regarding their beliefs and attitudes about experimental SC treatments (Study 3; 
Chapter 5).  In addition to their beliefs and attitudes, participants provided demographic 
information, completed questionnaires detailing their current level of biopsychosocial 
functioning, and specified whether or not they were considering experimental SC treatments 
at the time of the survey (objective 3).  From these data, a number of biopsychosocial (i.e. 
biological/medical, cognitive, and psychological) (Bolton, 2019) and attitudinal factors 
(based on the Theory of Planned Behaviour [Ajzen, 1991]) that increased the likelihood that a 
stroke survivor may consider experimental SC treatments were identified (objective 4).  As 
part of the survey, participants also nominated their preferred SC types, administration 
methods, and treatment outcomes, which were then compared with the current focus of SC 
researchers to highlight inconsistencies that may be used to inform future research.  
Lastly, the effectiveness of two patient education interventions for deterring stoke 
survivors from considering ‘stem cell tourism’ (objective 5) was examined in a small-scale, 
parallel-group RCT (Study 4; Chapter 6).  Participants indicated whether they were 
considering ‘stem cell tourism’ prior to, immediately following, and 30-days after reading a 
booklet (intervention 1) or watching an online video (intervention 2).  A wait-list control 
group (intervention 3) was included to provide further clarity about the effectiveness of the 
interventions over time.  The proportion of stroke survivors who were considering ‘stem cell 
tourism’ at each time interval was compared to identify within-group changes and between-
group differences.  The attitudes of the groups toward SC treatments were also assessed at 
each point to measure the effect of the interventions on particular areas (e.g. safety, efficacy, 
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Chapter 3: Study 1 
Safety and Efficacy of Cell Therapies administered in the Acute and Sub-
Acute Stages after Stroke: A Meta-Analysis. 
 
This chapter consists of a published paper, however copyright restrictions prevent the 
reproduction of this paper in its published form. The details of this publication are:  
Unsworth, D. J., Mathias, J. L., & Dorstyn, D. S. (2016). Safety and efficacy of cell therapies 
administered in the acute and sub-acute stages after stroke: A meta-analysis. 
Regenerative Medicine, 11, 725-741. doi: 10.2217/rme-2016-0063 
 
Please note:   
- Tables and Figures are formatted in line with the Journal’s requirements.  
- Australian/British English spelling was used.   
- The term ‘cell therapies’ is used in place of ‘SC therapies’, in line with the accepted 
vernacular, to describe treatments involving SCs, SC by-products, and SC-related 
materials.  
- The lack of knowledge and research about the psychological variables had to be 




 This study provides a comprehensive overview of existing data pertaining to the 
safety and efficacy of SC therapy throughout the hyper-acute/acute and sub-acute stages of 
stroke (objective 1).  A secondary aim was to identify the degree to which psychological 
factors had been considered in the published literature (objective 2). In doing so, this review 
extends upon the small number of previous reviews that focussed on specific study designs 
(e.g. RCTs, single-arm studies) and SC types (e.g. mesenchymal SCs) and combined data 
from patients with different types of stroke (i.e. ischaemic, haemorrhagic) and phases of 
recovery (e.g. acute, chronic) (Boncoraglio, Bersano, Candelise, & Reynolds, 2010; Cao & 
Li, 2015; Fan et al., 2015; Jeong et al., 2014; Lalu et al., 2012; Wang et al., 2016).   
The current study analysed data solely from the hyper-/acute and sub-acute phases, 
and stratified SC therapies based upon the delivery route and SC type.  The safety of the 
individual SC therapies was determined, based upon reported serious adverse events.  
Efficacy was assessed by comparing the neurological, functional, and/or radiological 
outcomes of: (1) patient groups who had received either SC therapy or standard care; and (2) 
the pre-/post-treatment outcomes of individual SC therapy treatment groups.  The latter pre–
/post-treatment changes were also compared with standard-care control group data from the 
included RCTs, to determine whether the observed changes exceeded those of current 
treatment practices.  Data regarding the stroke type, region, and length of time post-stroke 
were also collated to characterise the treatment samples. Whether patients were screened for 
mood disoders prior to treatment, and whether mood was evaluated throughout the trials, was 
additionally noted.     
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Aims: To evaluate the safety and efficacy of cell therapies administered acutely/sub-acutely 
after stroke.  Methods: Five databases were searched for studies examining the 
safety/efficacy of cell therapies administered ≤ 90 days post-stroke.  Reporting quality and 
adherence to research guidelines were evaluated.  Safety and efficacy were assessed using 
risk ratios/pooled incidence rates and Hedges’ g, respectively.  Results: 11 therapies (Nstudies= 
28) were trialled: reporting quality was high, but adherence to guidelines low.  Serious 
adverse events were observed following five treatments; six improved outcomes.  There was 
a trend toward larger treatment effects in non-blinded studies, younger participants, and 
higher dosages.  Conclusion: Although a number of therapies appear effective, many studies 






Stroke is a leading cause of death and disability worldwide (Mozaffarian et al., 2015), 
with medical and functional outcomes being highly dependent on the treatments that are 
received in the first 90 days (Antonios & Sillman, 2013).  Intravenous thrombolysis is the 
main treatment for acute ischaemic stroke but is used in less than 10% of cases due to the 
narrow recommended treatment window and potential for adverse effects (Reeves et al., 
2005).  For acute haemorrhagic stroke, surgery is typically performed to evacuate the 
hematoma and reduce intracranial pressure, although the impact is usually modest (NINDS, 
2005).  Beyond this, treatment has been limited to physical rehabilitation and the 
pharmacological management of psychological co-morbidities (e.g., depression, anxiety) 
(Belagaje & Butler, 2013).  Given the restricted range and efficacy of existing treatments, 
combined with the significant medical and economic burden associated with stroke 
(Mozaffarian et al., 2015), cell therapies are increasingly being investigated as an alternative. 
A variety of cell therapies have been trialed to promote structural and functional 
restoration after stroke, utilising a range of cell types (e.g., stem cells [SCs], mononuclear 
cells, growth factors), delivery routes (e.g., brain, spinal cord, vein, artery, abdomen) and cell 
sources (e.g., human, animal).  Treatments involving cells derived from human tissue (e.g., 
bone marrow) and synthetic growth factors (e.g., G-CSF/Filgrastim) are the most common, 
and are typically injected via intravascular or subcutaneous routes where they are believed to 
stimulate neural repair through the release of trophic, growth and/or neuroprotective factors 
(Kitago & Marshall, 2015).  Although less common, cells derived from embryonic or fetal 
matter (e.g., neural SCs [NSCs]) are usually administered via the intracranial or intrathecal 
route, after which they are thought to differentiate into specific brain cells, such as neurons 
and astrocytes (Liu et al., 2014).  While cells are normally sourced from the patient 
(autologous) to prevent rejection, cells from other individuals (allogeneic) and animals 
(xenogeneic) are also being investigated in stroke patients (Boltze et al., 2015). 
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Cell therapies used in the acute/sub-acute phases of stroke are of particular interest 
because there are a number of changes that are specific to this period, including increased 
inflammatory markers and greater blood–brain barrier permeability, which have the potential 
to attract the injected cells to the injury site (Cramer, 2008; Detante et al., 2014).  In addition, 
cells or growth factors administered in the early stages after a stroke (< 24 hours) may reduce 
secondary damage (e.g., necrosis, apoptosis) by releasing neuroprotective factors, which 
modify the inflammatory response (Savitz, 2015). However, patients are also at a higher risk 
of serious complications throughout this period (e.g., intracranial hemorrhaging, recurrent 
stroke) and, consequently, invasive cell therapies (e.g., intracerebral injections) may not be 
appropriate.  Seizures, tumors and pulmonary emboli have also been observed following the 
injection of cells (Boltze et al., 2015), suggesting that some cell types, delivery methods and 
sources may be preferable to others.  Given these potential benefits and risks, it is important 
to determine the safest and most effective form of cell therapy for acute/sub-acute stroke.   
Early meta-analyses have focused on the efficacy of cell therapies for ischaemic 
stroke (Boncoraglio et al., 2010; Yuan, Zeng, & Wu, 2007) but were inconclusive, possibly 
due to the small number of randomised controlled trials (RCTs) and the fact that acute and 
chronic data were combined. A subsequent meta-analysis (Jeong et al., 2014) compared the 
pre- and post-outcomes of cell therapy recipients who were recruited into single-arm/cohort 
studies but, without controls, was unable to determine whether the observed improvements 
resulted from the cell therapy, spontaneous recovery and/or placebo effects, and whether they 
exceeded those seen as a consequence of standard care.  Ischaemic and haemorrhagic strokes 
were also combined, therefore any differential efficacy for these stroke types remains unclear.  
Other meta-analyses have examined bone marrow mesenchymal SCs (BM-MSCs) (Cao & Li, 
2015) or intravascular mesenchymal SC therapies (pediatric and adult) (Lalu et al., 2012) 
following ischaemic stroke, but they did not examine safety or efficacy relative to other 
treatments.  Moreover, the impact of a number of clinical (patient age, treatment phase, 
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dosage) and methodological (randomisation) variables on efficacy remains uncertain, and an 
objective evaluation of the study reporting quality has yet to be undertaken.  Thus, the 
optimal cell therapy for adult stroke patients in the acute/sub-acute phase remains unclear.   
The current study therefore examined the safety and efficacy of cell therapies – 
broadly defined as SCs, cell-related materials and growth factors (Savitz, 2015) – 
administered within 90 days of ischaemic or haemorrhagic stroke.  RCTs/non-RCTs and 
cohort/case–control studies were all included, and reporting quality assessed using the 
Consolidated Standards of Reporting Trials (CONSORT) (Moher et al., 2010) and 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines 
(Von Elm et al., 2008). All studies were additionally evaluated in terms of the Stem Cells as 
an Emerging Paradigm in Stroke (STEPS I–III) and RIGOR (Lapchak, Zhang, & Noble-
Haeusslein, 2013; Reynolds, 2009; Savitz et al., 2011; Savitz et al., 2014) guidelines for cell 
therapy research.  Therapies were stratified by cell type and delivery route: safety was 
assessed in terms of treatment-related serious adverse events (SAEs) and efficacy was 
assessed across neurological, functional and/or radiological outcomes.  Control data from the 
RCTs were additionally used to determine whether the treatment effects reported by cell 
therapy recipients in the cohort/case–control studies exceeded the changes seen in non-
treatment controls over an equivalent interval.  Lastly, subgroup analyses examined whether 
efficacy differed according to patient age (< 60 vs ≥ 60 years), stroke type (ischaemic vs 
haemorrhagic), treatment phase (hyper-acute vs acute/sub-acute), dosage (< 108 vs ≥ 108 
cells) or study blinding (none vs single or double).  
3.5 Methodology 
 This study followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (Moher, Liberati, Tetzlaff, & Altmann, 2009). 
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Search Strategy and Inclusion Criteria 
A comprehensive search of the PubMed, Embase, Web of Science, Cochrane and 
PsycINFO databases was completed (January 1960–April 2016) to identify research that 
administered cell therapies within 90 days of stroke onset (see Supplementary Appendix A 
for searches).  Citation searches were additionally performed via Scopus and the reference 
lists of eligible studies and relevant reviews checked for references. 
To be included, studies had to have assessed the neurological (e.g., National Institute 
of Health Stroke Scale [NIHSS]), functional (e.g., Barthel Index), radiological 
(e.g., MRI) and/or safety outcomes of adults (≥ 18 years) who had sustained an ischaemic or 
haemorrhagic stroke within 90 days of receiving cell therapy, and provided data that enabled 
the calculation of effect sizes (means and SDs, t- statistics, χ2, exact p-values).  Published 
studies that used randomised, non-randomised and observational (cohort/case–control) 
designs were all included, but case studies were excluded.  Publications were not restricted to 
English. Study eligibility was assessed by the first author (DJ Unsworth) in consultation with 
the second author (JL Mathias). 
The literature search identified 3940 articles (see flowchart, Supplementary Appendix 
B for details). Initial screening of the titles and abstracts reduced the number to 85, after 
which full-text versions were reviewed: two papers required information/data to be extracted 
by a fluent Mandarin Chinese speaker to enable inclusion (Chen et al., 2015; Meng et al., 
2009).  Thirty articles met the inclusion criteria; however, closer examination of the 
participant data revealed that nine had used overlapping samples, reducing the number to 25 
independent studies (see Supplementary Appendix C for summary details).  Of these, two 
examined multiple treatments in separate samples (Meng et al., 2009; Rosado-de-Castro et 
al., 2013), which were thereafter treated as five additional independent studies.  Effectively, 
data from 28 independent studies were included in this meta-analysis (see Supplementary 
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Appendix C for details), including two for which graphical data were converted to numerical 
data (Moriya et al., 2013; Savitz et al., 2011) using GetData Digitizer software, Version 2 
(Federov, 2013). 
Data Extraction 
Key background (sample size, age, gender, country), stroke (type, region) and 
treatment (delivery route, cell type/source/dosage, assessment point) data were extracted from 
each study by the first author (DJ Unsworth), as were outcome data. The corresponding 
authors were contacted if additional information was required. Data were analysed using the 
Comprehensive Meta-Analysis Software, Version 3 (CMA; 2014, Biostat, Inc., NJ, USA) and 
forest plots were generated using Meta Data Viewer (National Institutes of Health, 2015). 
Assessment of Reporting Quality and Adherence to Research Guidelines 
The 25-item CONSORT (Moher et al., 2010) and 22-item STROBE (Von Elm et al., 
2008) guidelines were used to assess the reporting quality of the randomised and non-
randomised/observational studies, respectively.  A 13-item checklist (Supplementary 
Appendix D) was additionally constructed from the STEPS I–III (Reynolds, 2009; Savitz et 
al., 2011; Savitz et al., 2014) and RIGOR (Lapchak et al., 2013) guidelines to evaluate 
adherence to current recommendations for cell therapy research (e.g., placebo/sham 
treatments, assessment of co-morbidities, cell labeling/tracking).  
For every study, information relating to each item was assessed as: ‘Present’ (2 
points), ‘Present with Limitations’ (1 point), ‘Not Present’ (0 points) or ‘Not Applicable’ 
(n/a). Two scores were calculated: first, an overall quality score for each study, expressed as a 
percentage ([study score ÷ no. of applicable items] × 100) with scores < 50%/50%–75%/> 
75% reflecting low/medium/high quality (Viswanathan et al., 2012) and second, the 
percentage of studies receiving scores of 2, 1 and 0 for each item (Viswanathan et al., 2012). 
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Effect size, Heterogeneity and Publication Bias analyses 
Hedges’ g, which takes into account the greater variance associated with small 
samples (Hedges, 1982), was calculated using a random-effects model (DerSimonian & 
Laird, 1986).  The first set of analyses compared the post-treatment outcomes of cell therapy 
and standard-care stroke groups (‘Post-treatment vs Control’) using data obtained from the 
RCTs and non-RCTs (note: the cell therapy groups also received standard care; this 
comparison therefore controls for improvements due to normal recovery and rehabilitation).  
The second set of analyses compared the pre- and post-treatment outcomes of a single 
treatment group (‘Pre-/post-treatment’) using data extracted from all three study designs 
(RCTs, non-RCTs and cohort studies) in order to maximise the available data (note: not all 
RCTs/non-RCTs provided pre- and post-treatment data, consequently some could not be 
included here).  Lastly, the latter pre–post changes were compared with those seen in a 
standard-care stroke control group over an equivalent interval (‘Pre-/post-treatment vs 
Control’) in order to determine whether they exceeded what would be expected to occur as a 
result of normal recovery and physical rehabilitation.  Data for the standard-care stroke group 
were sourced from six of the eligible RCTs (Ncontrols = 196; see Supplementary Appendix E 
for details) because they were thought to provide better quality data (Moher et al., 2010; Von 
Elm et al., 2008).  Controls from non-RCTs were not suitable because they were often 
ineligible for cell therapy. 
Cell therapies were stratified by delivery route, cell type and study design (Post-
treatment vs Control, Pre-vs post-treatment) to enable comparisons between the individual 
treatments.  Combined therapies were also included in order to assess whether they provided 
any additional benefits over and above those seen when used as mono-therapies (dela Peña & 
Borlongan, 2015).  Risk ratios (RR) and pooled incidence rates (%) – including 95% CIs – 
were calculated to estimate the risks associated with each cell therapy. However, because the 
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definition of SAEs differed between studies, only instances of: death, cancer/tumor and major 
neurological (new stroke, seizure)/cardiac/renal disorders – which were common to all 
studies – were recorded. Moreover, SAEs were only included in the pooled incidence rates 
when they were ‘possibly’ or ‘likely’ to be related to treatment. 
Mean effect sizes (Hedges’ g) were calculated to assess changes in the neurological, 
functional, radiological and ‘overall’ (combined neurological, functional and radiological) 
outcomes for each treatment.  The upper/lower bounds of g were estimated using 95% CIs 
and forest plots were used to assess statistical power, based on the width of the intervals 
(Boyles, Harris, Rooney, & Thayer, 2011; Valentine, Pigott, & Rothstein, 2010).  A 
significant (p < 0.05) positive g indicates that cell therapy recipients experienced better 
outcomes than controls (Post-treatment vs Control and Pre-/post-treatment vs Control 
analyses) or improved pre- to post-treatment (Pre-/post-treatment analyses), with g = 0.2, 0.5, 
0.8, 2.0 and 4.0 equating to small, medium, large, very large and extremely large treatment 
effects, respectively (Cohen, 1988; Hopkins, Marshall, Batterham, & Hanin, 2009).  Fail-safe 
N statistics (Nfs) assessed the risk of publication bias by indicating the number of 
unpublished studies with small/non-significant effects required to reduce a finding to a small 
effect (g = 0.2) (Lipsey & Wilson, 2001).  An Nfs greater than the number of studies 
examining a specific treatment (Nstudies) was the criteria used to indicate a low risk of 
publication bias. 
Unfortunately, we were not able to conduct heterogeneity analyses to determine 
whether the effect sizes for studies that examined the same therapy varied significantly 
(Nstudies for individual treatments too small) (Higgins, Thompson, Deeks, & Altman, 2003).  
Instead, a random-effects model was used to calculate the effect sizes in order to take into 
account clinical and methodological variability between the studies (Hopkins et al., 2009).  In 
addition, Q-statistics and the I2 index were calculated to measure the level of heterogeneity in 
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the treatment effects reported by studies included in: (1) the Post-Treatment vs Control and 
(2) the Pre-/post-treatment analyses.  A significant Q indicates that treatment effects differed 
between studies, and I2 index values < 50%, 50–75% and > 75% suggest low, medium and 
high levels of heterogeneity, respectively (Higgins et al., 2003).  Subgroup analyses (with 
Bonferroni corrections [p < 0.01]) then examined potential source/s of heterogeneity (Xu, 
Platt, Luo, Wei, & Fraser, 2008) in order to determine whether the treatment effects differed 
according to: participants’ age (< 60 vs ≥ 60 years), the type of stroke (ischaemic vs 
haemorrhagic), the cell dosage (< 108 vs ≥ 108 cells), stroke phase (hyper-acute/acute [≤ 30 
days] vs sub-acute [> 30–90 days]) and study blinding (none vs single/double). 
3.6 Results 
Study Characteristics 
Details of the participants (age, sex, stroke type/region), cell therapies (time between 
stroke onset and therapy, type of cell therapy), outcomes assessed (safety, neurological, 
functional, radiological), study designs (RCT, non-RCT, observational) and countries of 
origin are summarised in Table 3-1.  The Post-treatment vs Control analyses were based on 
18 studies of 1273 participants (Ntreatment = 675; Ncontrols = 598).  Participants were typically 
middle-aged (mean age: 61.8 years) and had suffered ischaemic middle cerebral artery 
(MCA) strokes (45%).  On average, cell therapies were administered in the acute phase 
(mean = 8.1 days post-stroke) with intravenous injections of G-CSF being most common 
(Nparticipants = 193).  Seven mono- and two combined therapies were examined (see Table 3-1).  
All studies examined safety and most examined efficacy (94%), predominantly focusing on 
neurological and functional outcomes.  Eleven studies were RCTs (Phase I or II) and most 




Table 3-1.   Descriptive and Categorical Data for the Study Participants 
 Post-treatment vs Control Pre-/post-treatment 
 Nstudies Nparticipants M SD Nstudies Nparticipants M SD 
Total Studies & Participants:  18 1273 71 78.9 22 535 24 33.8 
Treatment Group: 18 675 37 40 22 535 24 33.8 
Age (years): 18 1273 61.8 10.6 22 535 62.3 11.6 
Sex:         
Male 15 700 (55%)   -   - 19 316 (59%)   -   - 
Female  573 (45%)    219 (41%)   
Stroke type:         
Ischemic 18 917 (72%)   22 530 (99%)   
Haemorrhagic  353 (28%)   -   -  5 (1%)   -   - 
Stroke Region:         
Mixed / Not specified 11 347 (27%)   -   - 11 179 (33%)   -   - 
MCA 8 575 (45%)   -   - 12 346 (65%)   -   - 
ICH 3 346 (27%)   -   - 1 1 (<1%)   -   - 
ACA 1 5 (1%)   -   - 2 9 (1.7%)   -   - 
Onset to Therapy (days): 18 675 8.1 8.9 22 535 10.8 15.1 
Cell Therapies:          
SubCut / G-CSF 7 136   -   - 6 122   -   - 
IV / G-CSF 2 193   -   - 3 211   -   - 
IV / BM-MNC 2 72   -   - 5 98   -   - 
IV / BM-MSC 2 46   -   - 3 58   -  - 
IV + SubCut / BM-MSC + G-CSF 1 30      -   - - -   -  - 
IC + IT / BM-MSC 1 110   -   - - -   -   - 
IC / BM-MNC 1 60   -   - - -   -   - 
IT / NSC 1 20   -   - - -   -   - 
IA / BM-MNC 1 10   -   - 3 37   -   - 
IA / BM-CD34+  - -   -   - 1 5   -   - 
IA / UC-MSC  - -   -   - 1 4   -   - 
Outcomes Assessed:         
Safety 18 1273   -   - 22 535   
Neurological 17 1130   -   - 19 374   -   - 
Functional 14 798   -   - 12 149   -   - 
Radiological 6 488   -   - 6 96   -   - 
 Nstudies Phase / Study type Nstudies Phase / Study type 
RCT 
11 I/II x 1  
IIb x 2 
II x 2 
n.s. x 4 
IIa x 2 8 I/II x 1 
IIb x 2  
II x 1  
n.s. x 3 
IIa x 1 
Non-RCT 7 I/II x 1  I/IIa x 1 n.s. x 5 10 I x 5  
n.s. x 2 
I/II x 2 I/IIa x 1 
Observational   4    Cohort x 4 
 Nstudies Study Origin Nstudies Study Origin 
Asia 12 China x 8  
South Korea x 1 
India x 2 
 
Japan x 1 12 China x 5  
Japan x 3 
India x 3  
South Korea x 1 
Europe 6 U.K. x 2  
Russia x 1 
Germany x 1 
Europe x 1 
Spain x 1 6 U.K. x 2 
Spain x 1 
Germany x 2  
Europe x 1 
Other   4 Brazil x 3  U.S.A. x 1 
ACA = anterior circulation artery; BM-CD34+ = bone marrow CD34+ cells; BM-MNC = bone marrow mononuclear cells; BM-
MSC = bone marrow mesenchymal stem cells; G-CSF = granulocyte-colony stimulating factor; IA = intra-arterial; IC = 
intracerebral; ICH = intracerebral haemorrhage; IT = intrathecal; IV = intravenous; M = mean;  MCA = middle cerebral artery; 
n.s. = not specified; NSC = neural stem cells; Nparticipants = number of participants assessed; Nstudies = number of studies; 




As seen in Table 3-1, the Pre-/post-treatment analyses were based on 22 studies of 
535 participants (which included 11 studies/323 participants from the preceding Post-
treatment vs Control analysis. The average age was 62.3 years, 59% were male and most 
suffered ischaemic MCA strokes (65%). Cell therapies were administered, on average, 10.8 
days post-stroke (acute phase) and, of the seven treatments trialed (all mono-therapies), 
intravenous injections of G-CSF were again most common (Nparticipants = 211). Safety was 
again examined by all studies and most assessed neurological outcomes (86%), with fewer 
considering functional (55%) and radiological (27%) outcomes. Most of the data originated 
from non-RCTs (Phase I or II), largely undertaken in Asia.  
For the Pre-/post-treatment vs Control analysis, standard-care control data (Nparticipants 
= 196; see Supplementary Appendix E for details) were additionally sourced from six RCTs 
that reassessed a non-treatment group after a comparable interval in order to determine 
whether the Pre-/post-treatment effects experienced by cell therapy recipients exceeded what 
would be expected as a consequence of normal recovery. The average age of the standard-
care control group was 65.9 years, 58% were male and 88% had ischaemic strokes. Standard 
care commenced, on average, 2.3 days post-stroke. 
Reporting Quality 
The reporting quality of all 25 studies was assessed.  Eleven RCTs were evaluated 
using the CONSORT reporting guidelines (Moher et al., 2010): the mean score was 79% 
(range: 40–97%), with nine (82%) equating to high quality reports (scored > 75%). Individual 
item data are summarised in Figure 3-1A, where it can be seen that the research objectives 
(item 2b: 100%), eligibility criteria (item 4a: 100%), baseline demographics (item 15: 91%), 
effectiveness (item 17a: 100%), risks (item 19: 100%) and funding sources (item 25: 82%) 
were all frequently reported.  By contrast, sample size calculations (item 7a: 36%), 
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randomisation methods (items 9–10: 45-55%) and limitations/biases (item 20: 55%) were 
provided less consistently. 
In total, 14 non-RCT/prospective cohort studies were evaluated using the STROBE 
guidelines (Von Elm et al., 2008), with a mean score of 79% (range: 62–93%) and the 
majority (86%) equating to high-quality reports.  As Figure 3-1(b) shows, studies consistently 
provided information about their research objectives (item 3: 100%), study design (item 4: 
100%), eligibility criteria (item 6a: 86%), baseline demographics (item 14a: 93%), missing 
data (item 14b: 100%), key findings (item 8: 100%), generalisability (item 21: 93%) and 
funding sources (item 22: 79%), but frequently omitted measurement information (item 8a: 





        Figure 3-1(a)        Figure 3-1(b) 
Figure 3-1.      Reporting quality assessment: (a) CONSORT evaluation of RCT study designs (Nstudies = 11) and (b) STROBE evaluation of 
non-RCTs and cohort study designs (Nstudies = 14). 
Nstudies = number of studies; RCT = randomised controlled trial.   
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Adherence to Research Guidelines 
All 25 studies were additionally evaluated against 13-key recommendations for cell-
therapy research provided in the STEPS I–III (Reynolds, 2009; Savitz et al., 2011; Savitz et 
al., 2014) and RIGOR (Lapchak et al., 2013) guidelines. The average score was 43% (range: 
19–77%), indicating relatively low adherence to the guidelines. As shown in Figure 3-2, very 
few studies used placebo/sham treatments (item 1: 20%), assessed psychological (item 4: 4%) 
or cognitive (item 5: 8%) comorbidities prior to inclusion, established stable neurological 
baselines (item 6: 8%) or labeled and tracked the cells (item 8: 8%). A higher number 
reported using physical rehabilitation with the cell therapy (item 9: 48%) and reported SAEs 
beyond 1 year (item 11: 32%), and most used neuroimaging to detect changes in the 
lesion/infarct size (item 7: 84%), reported significant and non-significant findings (item 12: 





Figure 3-2.     Percentage of studies (Nstudies = 25) meeting the STEPS (I-III) and   





Safety and Efficacy of Cell Therapies 
The safety and efficacy data for cell therapies administered in the hyper-acute, acute 
and sub-acute phases of stroke are summarised in Figure 3-3, with the Post-treatment versus 
Control and Pre-/post-treatment analyses grouped separately. For each of these analyses, the 
cell therapies are ordered (highest to lowest) according to their overall treatment effect, with 
individual therapies also being numbered (1 to 16, left-most column) to enable easy reference 
to specific findings. Study and participant details (age, stroke type/region, therapy/assessment 
timing), and safety and efficacy data are summarised for each treatment.  Forest plots display 
the mean overall effect size and 95% CIs for each treatment.  Mean differences in scores for 
the underlying measures (e.g., NIHSS) were additionally calculated when treatment effects 
were significant in order to provide clinically useful information (Cooper, 2008).  Additional 
study information (e.g., number of injections and cells) is provided in Supplementary 





Notes:  ** p < .001 * p < .05   The overall effect for standard care is shown by a dashed line on the forest plots for Treatments 10-16.  †: Nstudies and Nparticipants differs, refer to Appendix F for 
further details. 
 
ACS = anterior circulation stroke; BM-CD34+ = bone marrow CD34+ cells; BM-MNC = bone marrow mononuclear cells; BM –MSC = bone marrow mesenchymal stem cells; CI =  
confidence interval; Func = functional; g = Hedges’ g effect size; G-CSF = granulocyte-colony stimulating factor; Hem = haemorrhagic; hrs = hours; IA = intra-arterial; IC = intracerebral;  
ICH = intracranial haemorrhage; Isch = ischaemic; IT = intrathecal; IV = intravenous; M = mean; MCA = middle cerebral artery; Neuro = neurological; Nparticipants = number of participants; 
NSC = neural stem cells; Nstudies = number of studies; p = p-value; Radio = radiological; Ref = reference; SubCut = subcutaneous; T/ment = treatment; UC-MSC = umbilical  
cord mesenchymal stem cells.  
Figure 3-3.    Safety and efficacy of cell therapy for hyper-acute, acute and sub-acute stroke, separated by 






As seen in Figure 3-3, the risk of experiencing an SAE varied considerably between 
the treatment and control groups (treatments 1–9; RR range: 0.7–5.0). Although none of the 
nine treatments resulted in a significantly higher risk of SAEs, some had very wide 
confidence intervals (treatments 1, 2, 4, 6, 9), indicating that these RR estimates were very 
imprecise and should be interpreted cautiously. Moreover, the risk of experiencing a SAE 
following intravenous BM-MNCs (treatment 7) approached significance (p = 0.07), based on 
14 SAEs (n = 8 deaths; n = 6 seizures/strokes) in the treatment group, compared with 12 
SAEs (n = 5 deaths; n = 7 seizures/strokes) in the control group (Prasad et al., 2014).  
The pooled incidence rates for treatments 10–16 (Figure 3-3) indicate that SAEs were 
experienced by: 14% of patients who received intravenous BM-MSCs (treatment 10: n = 8 
out of 58), 11% who received intravenous BM-MNCs (treatment 14: n = 11 out of 89), 11% 
who received intra-arterial BM-MNCs (treatment 16: n = 4 out of 37), 1% who received 
subcutaneous G-CSF (treatment 11: n = 2 out of 156) and 1% who received intravenous G-
CSF (treatment 12: n = 3 out of 211). Of these SAEs, seizures and recurrent strokes were 
most common. No SAEs were reported following intra-arterial BM-CD34+ or UC-MSC 
injections (treatments 13 and 15). However, the CIs for each treatment were again found to 
be wide, which suggest these statistics lack precision and warrant caution. 
Post-treatment versus Control Groups 
When the treatment and control groups were compared (Figure 3-3: treatments 1–9), 
patients undergoing cell therapy experienced significantly better overall outcomes after 
treatment with: (1) intrathecal NSCs (treatment 1: resulting from very large improvements in 
neurological and radiological outcomes); (2) combined intravenous BM-MSC and 
subcutaneous G-CSF injections (treatment 2: resulting from very large improvements in 
neurological and functional outcomes); (3) intravenous BM-MSCs (treatment 3: resulting 
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from large improvements in functional outcomes); (4) intracerebral BM-MNCs (treatment 4: 
resulting from medium improvements in neurological and functional outcomes); (5) 
subcutaneous G-CSF (treatment 5: no significant effects for individual outcome areas); and 
(6) combined intracerebral and intrathecal BM-MSCs (treatment 6: resulting from small to 
medium improvements in neurological and functional outcomes).  However, as the findings 
relating to treatments 4 and 6 were found to be at risk of publication bias (see Supplementary 
Appendix F), these findings should be interpreted tentatively. 
In clinical terms, patients who received NSCs via intrathecal injection (treatment 1) 
scored an average of 6.3 points (95% CIs: 5.2–7.5) lower/better on the NIHSS and were 
observed to have mean hematoma volumes 12.8 ml (95% CIs: 9.7–16.0) smaller than the 
standard-care group. Patients treated with combined intravenous BM-MSC and subcutaneous 
G-CSF injections (treatment 2) scored an average of 25.7 points (95% CIs: 21.7–27.2) 
lower/better on the Fugl-Meyer Motor test and 21.7 points (95% CIs: 16.2–27.2) 
higher/better on the Functional Independence Measure (FIM).  Patients who received 
intravenous BM-MSCs (treatment 3) scored an average of 8.9 points (95% CIs: 3.5–14.3) 
higher/better on the FIM and patients treated with intracerebral BM-MNCs (treatment 4) 
scored an average of 4.3 points (95% CIs: 0.5–8.0) lower/better on the NIHSS and 10.5 
points (95% CIs: 1.6–19.4) higher/better than controls on the Barthel Index (note: these data 
were not available for treatments 5 and 6).  No significant improvements were observed 
following intravenous BM-MNCs (treatment 7) or G-CSF (treatment 8) or intra-arterial BM-
MNCs (treatment 9). 
Pre-/post-treatment change 
When the Pre-/post-treatment outcomes of cell therapy recipients were compared for 
treatments 10–16 (Figure 3-3), participants were found to have experienced significantly 
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better overall outcomes after treatment with: (1) intravenous BM-MSCs (treatment 10: 
resulting from very large improvements in neurological and functional outcomes); (2) 
subcutaneous G-CSF (treatment 11: resulting from large to very large improvements in 
neurological and functional outcomes and medium improvements in radiological outcomes); 
(3) intra-arterial BM-CD34+ cells (treatment 13: resulting from large improvements in 
neurological outcomes); (4) intravenous BM-MNCs (treatment 14: resulting from large 
improvements in neurological and functional outcomes); (5) intra-arterial UC-MSCs 
(treatment 15: resulting from large improvements in neurological outcomes); and (6) intra-
arterial BM-MNCs (treatment 16: resulting from medium to large improvements in 
neurological and functional outcomes). Large neurological and functional improvements 
were also observed following intravenous G-CSF injections (treatment 12); however, the 
overall effect was non-significant.  Nfs statistics confirmed a low risk of publication bias for 
each of these results (Nfs > NStudies; see Supplementary Appendix F). 
Lastly, changes in the standard-care control group (see Supplementary Appendix E) 
were assessed in order to evaluate the changes that occur as a result of normal recovery and 
physical rehabilitation. Standard care was associated with large to very large and significant 
improvements in overall (g = 1.44), neurological (g = 1.74) and functional (g = 1.27) 
outcomes.  By contrast, there were only small and non-significant changes in radiological 
measures (g = -0.14).  Notably, however, when the above Pre-/post-treatment findings were 
benchmarked against the changes seen in these standard-care controls in order to control for 
the effects of spontaneous recovery and physical rehabilitation, no cell therapy showed 
significantly better outcomes than standard care (note: the overall effect for standard care is 
shown as a dashed line in Figure 3-3 forest plots for treatments 10–16). However, there was a 
trend toward patients who received subcutaneous G-CSF (treatment 11) or intra-arterial BM-
CD34+ cells (treatment 13) having better radiological outcomes (p = 0.08 and 0.05, 
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respectively) and for patients who received intra-arterial BM-MNCs (treatment 16) to show 
moderate neurological improvements (p = 0.05).  No significant improvements were 
observed following intravenous BM-MSCs, G-CSF or BM-MNCs (treatments 10, 12, 14), 
and the neurological outcomes of patients who received intra-arterial delivery of umbilical 
cord MSCs were not significantly better than those seen in untreated patients (treatment 15).  
Nonetheless, these results should be interpreted cautiously because the standard-care control 
group had significantly more haemorrhagic strokes and/or were significantly older than some 
of the treatment groups (treatments 10, 11, 12, 14, 15). 
Heterogeneity and Subgroup analyses 
Given the small number of studies that examined individual treatments (Nstudies = 1–7), 
it was not possible to perform individual heterogeneity analyses to evaluate the variability in 
the effect sizes from different studies (Higgins et al., 2003). However, significant variability 
was observed when examining the overall treatment effects for the Post-treatment vs Control 
(Q[16] = 214.8; p < 0.001; I2 = 92.6 [95% CI: 89.6–94.7]) and Pre-/post-treatment (Q[18] = 
479.5; p < 0.001; I2 = 96.3 [95% CI: 95.2–97.1]) study designs, possibly due to 
methodological and/or sampling differences between studies.  Subgroup analyses were 
therefore performed to determine whether study blinding, age, dosage, stroke-type or 
treatment timing contributed to this heterogeneity (see Table 3-2). As seen in Table 3-2, none 
of the subgroups differed significantly after Bonferroni corrections (p > 0.01), possibly due to 
the small number of studies in each analysis. However, a number of the results approached 
significance, suggesting there was a trend toward: (1) blinded studies reporting smaller 
treatment effects than non-blinded studies (p = 0.02); (2) younger patients (< 60 years) 
experiencing better outcomes than older patients (≥ 60 years; p = 0.06); and (3) higher 
dosages (≥ 108 cells) being more effective than lower doses (< 108 cells; see Supplementary 
Appendix F for study doses; p = 0.09).
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Table 3-2. Subgroup and Heterogeneity Analyses 
 
Note:  ** p < .001, * p < .05. 




The present study evaluated the reporting quality and findings of 25 studies that used cell 
therapies within 90 days of stroke onset. Based on the CONSORT (Moher et al., 2010) and 
STROBE (Von Elm et al., 2008) reporting guidelines, the quality of reporting was generally very 
good.  Similar strengths were observed across all study designs, with the research objectives, 
eligibility criteria, baseline demographics and key results all consistently provided.  However, 
statistical power, methods of randomisation and study limitations/biases were provided less 
consistently, highlighting potential areas for improvement.  Given that these were Phase I and II 
trials, which focus on safety, statistical power may be a lower priority; but this also impacts on any 
evaluation of efficacy (Von Elm et al., 2008).  Randomisation details, on the other hand, are needed 
to identify potential sources of bias in participant selection and group allocation (Moher et al., 
2010).   
When the studies were evaluated against STEPS (Reynolds, 2009; Savitz et al., 2011; Savitz 
et al., 2014) and RIGOR (Lapchak et al., 2013) recommendations for cell therapy research, 
compliance was found to be quite low. Most notably, few studies labeled and tracked the cells. 
Although aspirational, given currently available technologies, cell labeling and tracking is an 
important to our understanding of the mechanisms that underpin treatment effects (Savitz et al., 
2014).  Indeed, preliminary research suggests that cell uptake in the brain may be minimal, 
compared with other major organs (liver, lungs, spleen, kidneys), especially when delivered via 
intravascular routes (Boltze et al., 2015), highlighting the importance of labeling/tracking cells.  As 
more cost-effective tracking techniques (e.g., optical imaging) are refined for use in clinical studies 
(Gavins & Smith, 2015), in vivo migration, localisation and differentiation of cells will increasingly 
be monitored, thereby enabling a more comprehensive examination of different cell types, delivery 
routes and dosages. 
Similarly, few studies used placebo/sham controls.  Although not surprising, given ethical 
constraints, such controls are needed to definitively rule out placebo effects (Savitz et al., 2014). 
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Controls are particularly important in the current context because treatment effects may be mediated 
by patient expectations and/or the research/hospital setting (Wager & Atlas, 2015), with invasive 
surgical procedures (e.g., intracerebral injections) potentially being more prone to placebo effects 
than other treatments (Diederich & Goetz, 2008). Sham stereotactic procedures, involving the 
injection of saline solutions, have been used previously (Li et al., 2013; Zhu et al., 2013), but are 
controversial and may also not meet ethics regulations.  At a minimum, an untreated stroke group 
would control for improvements attributable to standard care, normal recovery and any practice 
effects that may arise from the repeated administration of an outcome measure (Savitz et al., 2014). 
Lastly, contrary to STEPS and RIGOR recommendations, few studies considered 
psychological and/or cognitive co-morbidities as part of their inclusion/exclusion criteria.  Given 
that patients with depression or dementia commonly experience poorer outcomes after stroke 
(Cramer, 2008), the failure to screen for these conditions may undermine the study findings (Savitz 
et al., 2014).  Similarly, changes to psychological and cognitive outcomes were rarely evaluated; 
consequently the broader impact of cell therapies on patients’ functioning and wellbeing remains to 
be determined.  Anti-depressant medications and cognitive rehabilitation both improve stroke 
outcomes (Langhorne, Bernhardt, & Kwakkel, 2011; Mead et al., 2013), raising the possibility of 
combined treatment approaches. 
When evaluating the safety and efficacy of the cell therapies, treatment-related SAEs were 
observed after five of the eleven treatments and six were associated with significantly better 
outcomes than standard care alone.  For haemorrhagic stroke, the most effective therapy involved 
the intrathecal delivery (lumbar puncture) of NSCs (two injections of 4.0 × 108 cells for 2 weeks) 
(Xue et al., 2014), with significant improvements evident in motor/sensory/speech functions and a 
reduction in lesion size. However, given outcomes were assessed after only 28 days, it is unlikely 
that neural regeneration would explain these improvements (Janowski, Wagner, & Boltze, 2015).  
Instead, preclinical research suggests that the transplanted cells may have prevented further damage 
by secreting a range of growth (VEGF, NGF and neurotrophic [e.g., BDNF]) factors (Horie et al., 
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2011; Ramos, Cabrer, Justicia, Widermann, & Hoehn, 2010).  Although no SAEs were observed, an 
accurate determination of the risks was not possible using the available data and, as such, the long-
term safety has yet to be determined. 
For ischaemic stroke, the data indicated that combined subcutaneous G-CSF (Filgrastim; 
one injection of 150 μg/kg) and intravenous BM-MSCs (one injection of 2.97 × 109 cells [mean 
dosage]) are most effective (Meng et al., 2009), with recipients experiencing better motor/sensory 
functioning and greater physical independence at 6 months. Preclinical research suggests that G-
CSF promotes neuroprotection by activating anti-apoptotic and anti-inflammatory signaling 
pathways (Solaroglu, Digicaylioglu, Keles, & Zhang, 2015) and, when combined with BM-MSCs, 
mobilises cells to the lesion where they stimulate endogenous repair (angio/neurogenesis) (dela-
Peña & Borlongan, 2015).  Interestingly, recipients of the combined BM-MSC/G-CSF therapy were 
also found to have experienced significantly better outcomes than patients receiving BM-MSCs or 
G-CSF treatments, challenging the findings of recent preclinical research (Balseanu et al., 2014).  
Determining the optimal dosages (Wagner et al., 2014) and timing of the combined treatments 
(Pösel et al., 2014) will further clarify the extent of any benefits.  Preliminary findings also suggest 
that the treatment is relatively safe (based on the available 6-month data) and, given autologous 
BM-MSCs are typically used, may be preferable to allogeneic alternatives (requiring 
immunosuppression) in older patients. 
Smaller treatment effects were also observed for persons with a haemorrhagic stroke who 
received an intracerebral injection of BM-MNCs (one injection of 3.79 × 109 cells [mean dosage]) 
or combined intracerebral and intrathecal injections of BM-MSCs (one injection per route of 8.47 × 
107 cells [mean dosage]) (Li et al., 2013; Zhu et al., 2010).  Despite the risks often associated with 
these procedures, no complications were observed.  Importantly, experimental research indicates 
BMMNCs are smaller than NSCs and MSCs, which may lower the risk of further blockages to the 
cerebral arteries or ventricles (Fischer et al., 2009).  More research is needed to assess the efficacy 
of the remaining five cell therapies (Valentine et al., 2010), with treatments involving the intra-
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arterial delivery of BM-CD34+ cells warranting particular attention, given the observed reduction in 
lesion size.  In addition, the long-term risks of all cell therapies require monitoring as few studies 
reported SAEs beyond 1 year.  Although initial findings suggest intravenous delivery of BM-MNCs 
and BM-MSCs may pose the greatest risk, more data are needed. 
The subgroup analyses yielded some additional interesting information.  First, there was a 
trend toward non-blinded research yielding larger treatment effects, highlighting the need for 
double-blind, randomised, placebo-controlled trials, wherever possible.  Second, there was also a 
trend toward younger patients (< 60 years) having better outcomes, possibly due to their better 
general health and/or greater engagement in rehabilitation (Kitago & Marshall, 2015), or because 
these therapies augment the greater neuroplasticity seen in younger patients (Cramer, 2008).  
Additional research is therefore needed to determine whether there is an optimum age for cell 
therapies or an age beyond which efficacy is reduced.  Third, there was a trend toward higher doses 
(≥ 108 cells) being more effective, although this may impact on the safety and tolerability of these 
therapies. By contrast, it was unclear whether cell therapies were more effective following 
haemorrhagic or ischaemic strokes, or when administered in the hyper/acute (< 1 month) or sub-
acute phases (1–3 months), largely due to the small number of studies that could be compared in 
these analyses. 
The aforementioned findings must be tempered by a number of limitations. First, the 
treatment effects calculated by the current meta-analysis were largely based on the short-term 
findings (< 365 days) of small treatment groups (individual studies: Nparticipants = 4–252; individual 
treatments: Nparticipants = 4–211), making it difficult to accurately evaluate their safety and efficacy.  
A conservative random-effects model was used to account for the anticipated heterogeneity in 
treatment effects (DerSimonian & Laird, 1986); however, a high level of variability remained, 
highlighting the need for research that is based on more homogenous samples (e.g., same stroke 
type/region, narrow age range) and assessment points (Higgins et al., 2003; Xu et al., 2008).  
Second, the controls that were used to evaluate the Pre-/post-treatment effects of cell therapy 
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recipients were not matched with the treatment groups in these analyses and, consequently, 
sometimes differed in terms of age and stroke type. Matched control groups (sham or non-
treatment/standard-care controls) provide a more reliable assessment of treatment efficacy but were 
not always available. Although not ideal, this solution was adopted to reduce the likelihood that 
treatment effects would be overestimated. Finally, potentially relevant studies were excluded 
because the information they provided was insufficient for current purposes: ten authors were 
contacted, but only one responded (Moniche et al. 2014). 
Conclusion 
The current findings suggest that a range of mono/combined cell therapies significantly 
improve acute stroke outcomes; however, a number resulted in treatment-related SAEs. Most 
notably, the data suggest that the intrathecal delivery of NSCs and combined subcutaneous G-CSF 
and intravenous BM-MSCs appear very promising for the treatment of acute haemorrhagic and 
ischaemic stroke, respectively.  However, additional adequately powered double-blinded placebo-
/sham-/non-treatment-controlled research that screens for psychological/cognitive co-morbidities, 
assesses a broader range of outcomes (neurological, functional, radiological, cognitive, 
psychological) and tracks cell migration in vivo, is now needed to provide a more definitive 
evaluation of these emerging treatments. In terms of safety, the data suggest intravascular 
approaches are riskier than standard care, although the long-term risks of all treatments require 
continued monitoring. The origin of the cells, the cell sorting process and the standards for cell 
transplantation safety should all be reported in future trials, given the risks associated with 
uncontrolled transplantation procedures (Amaraglio et al., 2009; Berkowitz et al., 2016; Hurst et al., 
2013). Some patients may also benefit more than others, depending on their age, and alternative 
dosages or combined approaches may also prove effective, but need further investigation. 
As the safety and efficacy of cell therapies for acute/sub-acute stroke becomes clearer, the 
next challenge will be to integrate these treatments into existing paradigms of care (e.g., 
intravenous/chemical thrombolysis, mechanical thrombectomy, decompressive surgery).  Although 
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the current findings suggest that cell therapies administered in the hyper-acute phase may reduce 
secondary damage and that cells administered in the acute/sub-acute stages may improve 
neurological, functional and radiological outcomes, some treatments resulted in seizures, tumors 
and further strokes. While it is likely that treatments administering non-immunogenic (autologous) 
cells via intravenous, intra-arterial and subcutaneous routes will be the easiest to implement within 
clinical settings, the current findings suggest non-invasive procedures still involve significant risks 
and, as such, ongoing caution should be exercised. 
Future Perspective 
Given the ever-increasing medical and economic burden associated with stroke, continued 
research into emerging treatments is needed.  In excess of 50 clinical trials are currently underway 
(as registered on clinicaltrials.gov) and, as the safety of individual treatments are more definitively 
established, larger-scale Phase III trials will occur. The refinement of cell labeling and tracking 
techniques should improve the in vivo monitoring of cells, elucidating the mechanisms of action. 
Alternate pluripotent cell sources (e.g., CTX0E03 cells; induced pluripotent SCs) will help to 
overcome the ethical and practical concerns regarding embryonic/fetal NSCs, and the modification 
of BM-MSCs (Steinberg et al., 2016) may provide a more accessible source of multipotent cells for 
use in the hyper-acute/acute phases of stroke. Less invasive delivery methods also need to be 
investigated (e.g., intranasal) to mitigate the risks associated with acute/sub-acute stroke. Cell 
therapies may also be augmented through the harnessing of glial cells, blood–brain barrier 
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Search Terms used to create Database Specific Logic Grids (Study 1 & 2) 
 
          AND                                AND                     AND 
 
 Stroke Stem cell therapy Delivery method 
 Stroke* Stem cell Stereotaxic 
OR Cerebrovascular accident* Autologous Stereotactic 
 Cerebral vascular accident* Allogenic Neurotransplant 
 
Ischem* Mesenchymal Transplant* 
 Ischaem*  Neurosurg* 
 Infarct   
    
 
Note: Truncating terms with an asterisk results in variations of the term (including the plural forms) being included  
in the search.    
 
PubMed Logic Grid 
Stroke Stem cell therapy Delivery method 
stroke[mh] or stroke[tw] or 
cerebrovascular accident*[tw] or 
cerebro-vascular accident*[tw] or 
cerebral-vascular accident*[tw] 
or cva[tw] or brain ischaemia[tw] 
or brain ischemia[tw] or 
infarct*[tw] 
stem cell transplantation[mh] 
or stem cell*[tw] or bone 
marrow transplantation[mh] or 










Cochrane Library Logic Grid 
Stroke Stem cell therapy Delivery method 





Embase Logic Grid 
Stroke Stem cell therapy Delivery method 
‘stroke’:de,ti,ab or ‘brain 
ischemia’/syn or ‘cerebrovascular 
accident’/syn or ‘cerebro vascular 
accident’:de,ti,ab or ‘cerebro vascular 
accidents’:de,ti,ab or ‘cerebrovascular 
accident’:de,ti,ab or ‘cerebrovascular 
















Web of Science Core Collection Logic Grid 
Stroke Stem cell therapy Delivery method 
TS=(stroke* OR cerebrovascular accident 
OR cerebro-vascular accident* OR cerebro 
vascular accident* OR cerebral-vascular 
accident* OR cerebral vascular accident OR 
cva OR infarct* OR ischem* OR ischaem*) 
TS=(stem cell* OR 
autologous OR allogenic 
OR mesenchymal) 
TS=(neurosurg* 




PsycINFO Logic Grid 
Stroke Stem cell therapy Delivery method 
stroke.TW OR exp cerebral ischemia OR 
exp cerebrovascular accident OR 
cerebrovascular accident*.TW OR 
cerebro vascular accident*.TW OR 
cerebralvascular accident*.TW OR 
cerebral vascular accident*.TW OR 
cva.TW OR exp cerebral ischemia OR 
infarct*.TW 

























Publication Details of the Studies used in the Meta-Analysis for Study 1 
Study 
reference 
   First Author    Last Author Publication 
Year 
  Country of  
     Origin 
   Study Type Publication Source 
1     Prasad, K.    Nityanand, S. 2014    India    RCT – Phase II      Stroke 
2     Ringelstein, E.B.    Berrouschot, J. 2013    Europe    RCT – Phase IIb      Stroke 
3 
 
   Moriya, Y.    Takizawa, S. 2013    Japan    Non-RCT – Phase I 
     Journal of Cerebrovascular             
  Diseases 
4 
 
   Prasad, K.    Mishra, N.K. 2012 I   India    Non-RCT – Phase I       Indian Journal of Medical Research 
5 
 
   Savitz, S.I.    Grotta, J.C. 2011    U.S.A. Observational -Prospective 
Cohort 
       Annals of Neurology 
6 
 
   Honmou, O.    Kocsis, J.D. 2011    Japan    Observational - 
   Prospective Cohort 
       Brain 




   Lee, J.S.    Bang, O.Y. 2010    South Korea    RCT – Phase I / II        Stem Cells 
   Bang, O.Y.    Lee, G. 2005    South Korea    RCT – Phase I / II         Annals of Neurology 
9 
 
   Meng, X.G.   Li, D. 2009    China    Non-RCT–Phase n.s. 
        Journal of Clinical Rehabilitative  
     Tissue Engineering Research 
10 
 
   Banerjee, S.   Chataway, J. 2014    U.K. Non-RCT – Phase I     Stem Cells Translational Medicine 
11 
 
   Jiang, Y.    Liu, X. 2013    China    Observational -    
   Prospective Cohort 
        Cell Transplantation 
12       
   Rosado-de-Castro, P.H.   Barbosa da Fonseca, L.M. 2013    Brazil    Non-RCT – Phase I         Regenerative Medicine 
   Battistella, V.    Andre, C. 2011    Brazil    Non-RCT – Phase I         Regenerative Medicine 
   Barbosa da Fonseca, L.M.    Freitas, G. R. 2010    Brazil    Non-RCT – Phase I         Experimental Neurology 
13 [ 
   Moniche, F.    Gil-Peralta, A. 2014    Spain    Non-RCT – Phase I/II         Stroke 
   Moniche, F.    Gonzalez, A. 2012    Spain    Non-RCT – Phase I/II         Cell Transplantation 
14     Friedrich, M.A.G.    De Freitas, G.R. 2012    Brazil    Observational -    
   Prospective Cohort 
        Cell Transplantation 
15 [ 
   Li, Z.M.    Wang, L.X. 2013    China    Non-RCT– Phase n.s.         Clinical Neurology and Neurosurgery 
   Zhu, J.X.    Guo, C.J. 2010    China    Non-RCT– Phase n.s.          Journal of Clinical Rehabilitative      
      Tissue Engineering Research 
16     Xue, Y.Z.    Hao, P.L. 2014    China    RCT – Phase n.s.          Genetics and Molecular Research 
17     Zhu, J.X.    Geng, F. 2015    China    Non-RCT – Phase n.s           Stem Cells International 
18     England, T.J.    Bath, P.M.W. 2012    U.K.    RCT – Phase IIb           Stroke 
19     Prasad, K.    Mishra, N.K. 2011    India    RCT – Phase n.s.           Stroke Research and Treatment 
20     Chen, Y.H.    Liu, X.L. 2011    China    RCT – Phase n.s. 
          Journal of Clinical Rehabilitative       
       Tissue Engineering Research 
21     Boy, S.    Bogdahn, U. 2011    Germany    Non-RCT– Phase I/II            PLoS ONE 
22     Alasheev, A.M. I  Isakova, T.M. 2011    Russia    RCT – Phase II           Translational Stroke Research 
23     Sprigg, N.    Russell, N. 2006    U.K.    RCT – Phase IIa            Stroke 
24     Shyu, W.C.    Li, H. 2006    Taiwan    RCT – Phase n.s. 
           Canadian Medical Association     
        Journal 
25     Taguchi, A.    Nagatsuka, K. 2015    Japan    Non-RCT–Phase I/IIa            Stem Cells and Development 
Note: Brackets indicate where pairs of studies reporting on the same patient group were combined for parts of the analysis. 




Stem Cell Therapy Research Guidelines (STEPS I-III, RIGOR) Assessment Checklist 
1.  Placebo / sham treatment employed 
2.   Cell therapy (cell type, delivery method and dosage) justified by previous research  
3.  Medical comorbidities considered prior to inclusion 
4.   Psychological comorbidities considered prior to inclusion 
5.  Cognitive comorbidities considered prior to inclusion 
6. Stable baseline established based on 2 or more examinations 
7. Imaging employed to assess lesion/infarct size 
8. Cell tracking / labelling undertaken to observe mechanisms of action 
9. Concomitant physical rehabilitation undertaken by participants 
10.  Domain-specific modalities (e.g., sensory, motor, visual, cognitive functions) assessed with 
validated measures 
11. Serious adverse events (SAEs) reported ≥ 1 year 
12. All statistical data reported (including non-significant findings) 





Study 1: Baseline Characteristics of the Control Group for Treatment vs Control:  






Stroke Type  
 
 Isch     Haem 
 Stroke Area Onset to 
randomisation 






(%)   
65.9 (9.17) 58 173          23 MCA =  156 2.3 (3.86) 13.4 (4.5) 13 
   ICH =     20    
   Anterior = 12    





         
Haem = haemorrhagic; ICH = Intracerebral Haemorrhage; Isch = ischaemic; MCA = Middle Cerebral Artery; M = mean; SD = standard  
deviation. 
 
Study 1: Publication Details of the Studies used for the Control Group for Treatment  
vs Control: Pre-/Post-Analysis 
Study 
reference 
  First Author   Last Author Publication 
Year 
  Country of     
     Origin 
     Study Type     Publication Source 
2   Ringelstein, E.B.   Berrouschot, J. 2013      Europe      RCT – Phase IIb     Stroke 
16   Xue, Y.Z.   Hao, P.L. 2014      China      RCT – Phase n.s.     Genetics and Molecular Research 
18   England, T.J.   Bath, P.M.W. 2012      U.K.      RCT – Phase IIb     Stroke 
19   Prasad, K.   Mishra, N.K. 2011      India      RCT – Phase n.s.     Stroke Research and Treatment 
20   Chen, Y.H.   Liu, X.L. 2011      China      RCT – Phase n.s. 
    Journal of Clinical Rehabilitative   
    Tissue Engineering Research 
24   Shyu, W.C.   Li, H. 2006  Taiwan      RCT – Phase n.s. 
Canadian Medical Association 
Journal 





Treatment Dosages per Cell Therapy and Notes relating to Figure 3-1 
 
Note:  **p < .001, *p < .05. 
BM-CD34+ = bone marrow CD34+ cells; BM-MNC = bone marrow mononuclear cells; BM –MSC = bone marrow 
mesenchymal stem cells; CI = confidence interval; Func = Functional; G-CSF = granulocyte -colony-stimulating factor; IA = 
Intra-arterial; IC = Intracerebral; IT = Intrathecal; IV = Intravenous; kg = kilogram; Neuro = Neurological; Nparticipants = 
number of participants assessed; NSC = neural stem cells; Nstudies = Number of studies; Radio = Radiological; Ref = 






Chapter 4.  Study 2 
Cell therapies administered in the chronic phase after stroke:  
A meta-analysis examining safety and efficacy. 
 
This chapter presents a published paper, however copyright restrictions prevent the 
reproduction of this paper in its published form. The details of this publication are:   
 
Unsworth, D. J., Mathias, J. L., & Dorstyn, D. S. (2017). Cell therapies administered in the 
chronic phase after stroke: A meta-analysis examining safety and efficacy. 
Regenerative Medicine, 12, 91-108. doi: 10.2217/rme-2016-0082 
 
Please note:   
- Tables and Figures are formatted in line with the Journal’s requirements. 
- Australian/British English spelling was used.   
- The term ‘cell therapies’ is used in place of ‘SC therapies’, in line with the accepted 
vernacular, to describe treatments involving SCs, SC by-products, and related 
materials.    
- The lack of knowledge and research about the psychological variables had to be 




This study extends on Study 1 (Chapter 3), using meta-analytic techniques to evaluate 
the safety and efficacy of SC therapies administered in the chronic phase of stroke. The need 
to examine beyond the acute and sub-acute phases was deemed important due to differences 
in the way that SC therapies are thought to work once the blood-brain-barrier is no longer 
permeable (Savitz, 2018).  That is, given that SCs administered intravenously or intra-
arterially are no longer thought to reach the stroke-affected regions of the brain during the 
chronic phase of stroke, the emphasis is on intracranial and intrathecal delivery methods 
(Marei et al., 2018).  Key outcomes explored in the current study included the safety and 
neurological and functional efficacy of SC therapies, stratified by SC type and administration 
route.  Notably, data for radiological outcomes was not routinely reported, hence not explored 
in this review.  As with Study 1 (Chapter 3), this review considers the degree to which 
psychological comorbidities were screened for and/or psychological or cognitive outcomes 
were measured.  Indeed, given that mood symptoms often worsen during the chronic phase of 
stroke (Chun et al., 2018; Mitchell et al., 2017), identifying research gaps in these areas was 











Aims: To assess the safety and efficacy of cell therapies for chronic stroke.  Methods: Five 
databases were searched for treatments administered > 90 days post-stroke.  Reporting 
quality, adherence to research guidelines, treatment safety (risk ratios/pooled incidence rates), 
and neurological/functional efficacy (Hedges’ g) were all evaluated.  Results: Twenty-three 
studies examined 17 treatments.  Reporting quality scores were medium-high, but adherence 
to recommended guidelines was lower.  Three treatments resulted in serious adverse events; 
four improved outcomes more than standard care.  However, many studies were under-
powered and individual patients varied in their response to some treatments.  Conclusions: 
Preliminary findings suggest that some cell therapies may be relatively safe and effective, but 






Stroke is the third most common cause of disability (Feigin et al., 2014; Murray et al., 
2012).  Globally, an estimated 33 million stroke survivors currently have ongoing disabilities 
(Corbyn, 2014), and a further five million are permanently disabled each year (Mozaffarian et 
al., 2015).  Following acute medical care, rehabilitation – involving physiotherapy, repetitive 
task training, speech therapy, and psychotherapy – is commonly initiated in order to prevent 
further physical and cognitive deterioration, improve functional independence, and reduce 
psychological distress (Clarke & Forster, 2015; Wade, 2016).  However, patients vary in their 
response to rehabilitation (Langhorne, Bernhardt, & Kwakkel, 2011; Pinter & Brainin, 2012) 
and recovery often plateaus during the chronic phase (> 90 days) (Richards, Malounin, & 
Nadeau, 2015), leaving a significant number of people with residual disabilities (Richards et 
al., 2015; Teasell, 2013).  Beyond rehabilitation, there are currently no approved treatments 
that improve the long-term neurological (motor, speech, vision) and functional (mobility, 
bathing, grooming) outcomes of stroke patients, highlighting the need for safe and effective 
alternatives (Azad, Veeravagu, & Steinberg, 2016). 
A variety of pharmacological (e.g., selective-serotonin re-uptake inhibitors [SSRIs]), 
neuromodulatory (e.g., cortical/cerebellar stimulation) and neuroprotective (e.g., mild 
hypothermia, postsynaptic density-95 protein) interventions are being tested (see Azad et al., 
2016 for a review); as are a range of cell therapies, which involve the transplantation of 
neural stem cells (NSCs), mesodermal-derived SCs (e.g., bone marrow mesenchymal SCs 
[BM-MSCs]), hematopoietic/endothelial cells (e.g., umbilical cord MSCs [UC-MSCs], 
peripheral-blood SCs [PBSCs]), and/or cell-related products (e.g. bone marrow mononuclear 
cells [BM-MNCs]), and growth factors (e.g., granulocyte-colony stimulating factor [G-CSF]).  
Preliminary research suggests that cells obtained from either the patient (autologous) or from 
foreign sources (non-autologous/allogeneic: human or animal) may offer significant 
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neurorestorative benefits (Borlongan, Jolkkonen, & Detante, 2015; Savitz, 2015), although 
the latter source may require immunosuppression to prevent rejection (Boltze et al., 2015).   
To date, trials undertaken throughout the chronic phase of stroke have largely focused 
on the intracerebral (stereotactic) delivery of cells (commonly NSCs) because it is thought to 
provide a greater chance of cellular regeneration (neuro- or glio-genesis) due to the higher 
concentration of cells in and around the infarct (Reyes, Tajiri, & Borlongan, 2015; Tang et 
al., 2015).  Intracerebral injections circumvent the blood-brain-barrier, permitting cells to 
penetrate the lesion and penumbra, where they are thought to repair and restore stroke-related 
damage through the formation of new neurons, astrocytes and oligodendrocytes (Azad et al., 
2016).  However, these benefits need to be balanced against the complex and invasive nature 
of intracerebral transplantation (Reyes et al., 2015), and an increased risk of complications 
(e.g., haemorrhages, seizures, infections) and tumors/graft overgrowth due to the strong 
proliferative capacity of NSCs (Boltze et al., 2015).   
A range of less invasive approaches are also being investigated.  Intrathecal delivery 
involves the injection of cells – commonly NSCs – into the subarachnoid space via lumbar 
puncture, which results in a diffuse spread of cells throughout the central nervous system 
(including the lesion site), purportedly resulting in angiogenesis, neovascularisation and 
increased synaptic plasticity (Boltze et al., 2015; Sharma et al., 2014).  This method may 
therefore provide a safer and more accessible form of cell transplantation (Sharma et al., 
2014), although lumbar-sacral damage can occur (Hurst et al., 2013) and, in the case of 
NSCs, spinal tumors may develop (Amariglio et al., 2009; Saad et al., 2016).     
Intravenous and subcutaneous injections of BM-MSCs, UC-MSCs, PBSCs, BM-
MNCs and G-CSF have also been examined; with these cell types and delivery methods 
considered to be safer, more readily available, and less likely to raise ethical concerns than 
human embryonic/fetal NSCs (Janowski, Wagner, & Boltze, 2015).  However, cell survival 
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and migration may be compromised when these approaches are used in the chronic phase of 
stroke, due to diminished inflammatory signaling (Tang et al., 2015) and decreased blood-
brain-barrier permeability (Tajiri et al., 2016).  Instead, neurorestoration is thought to occur 
as a consequence of ‘bystander’ effects, resulting from the release of growth factors (dela 
Peña, & Borlongan, 2015; Liu et al., 2014).   
To date, research examining cell therapies in the chronic phase of stroke has largely 
consisted of early-phase clinical trials and observational studies.  A few meta-analyses have 
compared efficacy, based on randomised control trials (RCTs) (Boncoraglio et al., 2010; 
Yuan, Zeng, & Wu, 2007) or single-arm studies (Jeong et al., 2014), but they did not examine 
acute/sub-acute and chronic treatments separately, despite pathophysiological differences 
(e.g., blood-brain-barrier permeability) that may impact upon efficacy.  Moreover, in the 
absence of a control group, it was not possible to determine whether the changes observed in 
single-arm studies were due to the cell therapy, spontaneous recovery and/or placebo effects 
(Jeong et al., 2014).  Other meta-analyses have examined MSCs (Cao & Li, 2015; Lalu et al., 
2012; Wang et al., 2016) and G-CSF (Fan et al., 2015) in isolation, but were not able to 
compare the safety and efficacy of these treatments with other cell therapies.  Moreover, the 
impact of various clinical (e.g., patient age, treatment timing, cell source/dosage) and 
methodological (e.g., study blinding) variables on efficacy, and the reporting quality and 
adherence to cell-therapy guidelines, have yet to be evaluated.     
The current study therefore meta-analysed the data from all studies – RCTs, non-
RCTs, case-control and cohort designs – that have treated patients with cell therapies in the 
chronic phase after stroke (> 90 days) in order to evaluate their relative safety and efficacy.  It 
extends on the findings of a recent study, which examined cell therapies administered in the 
acute and sub-acute phase (Unsworth, Mathias, & Dorstyn, 2016).  Reporting quality was 
assessed using the Consolidated Standards of Reporting Trials (CONSORT) (Moher et al., 
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2010) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines (Von Elm et al., 2008), and adherence to current cell-therapy research 
recommendations was evaluated using the Stem Cells as an Emerging Paradigm in Stroke 
(STEPS I-III) and RIGOR guidelines (Lapchak, Zhang, & Noble-Haeusslein, 2013; 
Reynolds, 2009; Savitz et al., 2011; Savitz et al., 2014).  Treatments were stratified by 
delivery route and cell type, with safety being evaluated in terms of the number of treatment-
related serious adverse events (SAEs), and efficacy measured in terms of improvements to 
neurological, functional and ‘overall’ (combined) outcomes.  Subgroup analyses were 
additionally performed to determine whether efficacy differed according to patient age (</≥ 
60 years), cell source (autologous vs allogeneic), dosage (</≥ 108 cells), treatment timing 
(</≥ 1 year), reporting quality score (low vs medium/high), and study blinding (none vs 
single/double). 
4.5 Methodology 
This study adhered to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (Moher, Liberati, Tetzlaff, & Altmann, 2009). 
Search Strategy and Inclusion Criteria 
A comprehensive search of the PubMed, Embase, Web of Science, Cochrane, and 
PsycINFO databases was conducted (January 1960–June 2016) to locate published research 
that administered cell therapies > 90 days after ischaemic/haemorrhagic stroke onset (see 
Supplemental Appendix A for searches).  To be included, studies had to have assessed the 
safety (SAEs), neurological (e.g., National Institutes of Health Scale [NIHSS], modified 
Rankin Scale [mRS]) and/or functional outcomes (e.g., Barthel Index [BI]) of adult (≥ 18 
years) stroke survivors, and provided data that permitted the calculation of standardised mean 
differences (Hedges’ g) (e.g., means and SDs, t-statistics, exact p-values).  Experimental 
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(RCTs, non-RCTs) and observational (case-control, cohort) study designs were included, but 
case studies were excluded.  The search was not restricted to English publications.  Study 
eligibility was determined by the 1st author (DJ Unsworth) in consultation with the 2nd author 
(JL Mathias).  Scopus citation searches were performed for the included studies in order to 
find any additional relevant research.  
The literature search identified 3,941 articles (see flowchart, Supplemental Appendix 
G for details).  Initial screening of titles and abstracts reduced the number to 86, after which 
full-text versions were reviewed: five required information/data to be extracted by a fluent 
Mandarin Chinese speaker to enable inclusion (Huang et al., 2009; Li et al., 2007; Wang et 
al., 2007; Yang et al., 2007; Zhang et al., 2006).  Twenty-five articles met the inclusion 
criteria, however closer examination of the participant data revealed that eight used 
overlapping samples, reducing the number to 21 independent studies (Supplemental 
Appendix H).  Of these, two examined multiple treatments in separate samples (Bhasin et al., 
2013; Chen et al., 2013), which were therefore treated as two additional independent studies.  
Effectively, data from 23 independent studies were included in the meta-analysis (refer to 
Supplemental Appendix H), including one for which graphical data was converted to 
numerical data (Qiao et al., 2014) using GetData Digitizer software, Version 2 (Federov, 
2013). 
Data Extraction 
Key background (sample size, age, gender, country), stroke (type, region), treatment 
(delivery route; cell type, source and dosage; time post-stroke; assessment point/s) and 
outcome (neurological and/or functional) data were extracted from each study by the first 
author (DJ Unsworth).  All analyses were conducted using the Comprehensive Meta-Analysis 
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Software, Version 3 (CMA; 2014, Biostat, Inc., Englewood, NJ, USA) and forest plots were 
generated using Meta Data Viewer (National Institutes of Health, 2015).   
Assessment of Reporting Quality and Adherence to Research Guidelines  
 The CONSORT (Moher et al., 2010) and STROBE (Von Elm et al., 2008) guidelines 
were used to assess the reporting quality of the RCTs and non-RCTs/case-control/cohort 
studies, respectively.  A 13-item checklist (Supplemental Appendix D) was also formulated 
from the STEPS I-III (Reynolds, 2009; Savitz et al., 2011; Savitz et al., 2014) and RIGOR 
(Lapchak et al., 2013) cell-therapy research guidelines to evaluate adherence to current 
recommendations (e.g., placebo/sham treatments, cell labeling/tracking, reporting conflicts of 
interest).  For both the CONSORT/STROBE and STEPS/RIGOR evaluations, information 
relating to each item was judged to be: ‘Present’ (2 points), ‘Present with Limitations’ (1 
point), ‘Not Present’ (0 points), or ‘Not Applicable’ (n/a).  Two percentage scores were then 
calculated: (1) one measuring the overall reporting quality of each study ([study score  no. 
of applicable items] x 100), with scores < 50%/50%-75%/> 75% reflecting low/medium/high 
quality (Viswanathan et al., 2012); and (2) one measuring the quality of reporting for 
individual checklist items (i.e. % studies that reported, reported with limitations, or did not 
report each item).  
Hedges’ g, Heterogeneity and Publication Bias analyses 
Hedges’ g was calculated using the inverse variance method (Hedges, 1982) to 
measure the standardised mean difference in: (1) the post-treatment outcomes of cell therapy 
and standard-care stroke groups (‘Post-treatment vs Control’) using data obtained from the 
RCTs, non-RCTs and case-control studies; and (2) the pre- and post-treatment outcomes of a 
single treatment group (‘Pre-/post-treatment’) using data extracted from all four study designs 
(RCT, non-RCT, case-control & cohort studies) (note: not all RCTs/non-RCTs provided pre- 
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and post-treatment data).  In addition, the latter pre-post differences were also compared to 
those seen in a standard-care stroke group over an equivalent interval (‘Pre-/post-treatment vs 
Control’) in order to determine whether they exceeded what would be expected to occur as a 
result of spontaneous/normal recovery, practice and/or placebo effects.  Data for the standard-
care stroke group were sourced from four of the eligible RCTs/non-RCTs (Ncontrols = 53; see 
Supplemental Appendix I for further details) because these were thought to provide the most 
reliable source of control data (Moher et al., 2010; Von Elm et al., 2008). 
Cell therapies were stratified by delivery route and cell type to allow for comparisons 
between treatments.  Risk ratios (RR) and pooled incidence rates (%) were calculated to 
assess the safety/risks associated with each therapy.  The definition of a SAE varied between 
studies, consequently it was restricted to: death, cancer/tumor, stroke, seizure, and major 
cardiac/renal disorders.  SAEs were only included if they were deemed to be 
possibly/probably/definitely related to the treatment.  Hedges’ g statistics were computed to 
determine the neurological, functional and ‘overall’ (all outcomes combined) efficacy of each 
cell therapy.  Ninety-five percent confidence intervals (95% CIs) indicate the upper/lower 
bounds of g and forest plots were used to assess statistical power (Boyles, Harris, Rooney, & 
Thayer, 2011; Valentine, Pigott, & Rothstein, 2010).  A significant (p < .05) positive g 
indicates that cell-therapy recipients experienced better outcomes than controls (Post-
treatment vs Control and Pre-/post-treatment vs Control analyses) or improved pre- to post-
treatment (Pre-/post-treatment analyses), with g = .2, .5, .8 and 2.0 equating to small, 
medium, large and very-large standardised mean differences, respectively (Cohen, 1988; 
Hopkins, Marshall, Batterham, & Hanin, 2009).  Fail-safe N statistics (Nfs) assessed the risk 
of publication bias by estimating the number of unpublished studies with non-significant 
effects that would be required to reduce a finding from the current study to a small 
standardised mean difference (g = .2) (Lipsey & Wilson, 2001).  Where Nfs exceeded the 
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number of studies examining a particular treatment (Nstudies), publication bias was considered 
unlikely to pose a serious threat to the findings.   
As an emerging area of research, the total number of studies was small, preventing us 
from performing heterogeneity analyses to determine whether the data from studies that 
examined the same treatment could be validly combined (Higgins, Thompson, Deeks, & 
Altman, 2003).  Instead, a random-effects model was used to calculate Hedges’ g in order to 
take into account clinical and methodological variability between the studies (DerSimonian & 
Laird, 1986).  As an additional step, Q-statistics and the I2 index were used to provide an 
overall indication of the heterogeneity in treatment effects reported by the studies in both the 
Post-treatment vs Control and the Pre-/post-treatment analyses.  A significant Q indicates that 
effects differed between studies and I2 index values < 50%, 50-75%, and > 75% suggest low, 
medium, and high levels of heterogeneity, respectively (Higgins et al., 2003).  Following on 
from this, subgroup analyses (with Bonferroni corrections [p < .008]) examined potential 
source/s of heterogeneity (Xu, Platt, Luo, Wei, & Fraser, 2008) in order to determine whether 
the reported effects for individual studies differed according to: age (</≥ 60 years); cell 
source (autologous [incl. G-CSF] vs allogeneic); dosage (</≥ 108 cells); treatment timing (</≥ 
1 year); reporting quality score (low vs medium/high); and study blinding (none vs 
single/double).  
4.6 Results 
Study Characteristics  
Details of the participants (e.g., age, stroke type/region), cell therapies, outcomes 
assessed, study designs (e.g., RCT, non-RCT) and countries of origin are summarised in 
Table 4-1.  The Post-treatment vs Control analyses were based on eight studies of 206 
participants (Ntreatment = 98, Ncontrols = 108) who had a mean age of 52.3 years.  Most (74%) 
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were male and had ischaemic strokes (88%) affecting mixed/non-specified regions.  On 
average, cell therapies were administered 1.5 years post-stroke: six therapies were examined, 
with intravenous injections of BM-MNCs being the most common (Nparticipants = 26).  All 
studies assessed safety, six examined neurological outcomes and seven assessed functional 




Table 4-1. Descriptive and Categorical Data for the Study Participants 
  
ACA = anterior circulation artery; BGS = basal ganglia stroke; BM-CD34+ = bone marrow CD34+ cells; BM-MNC = bone 
marrow mononuclear cells; BM-MSC = bone marrow mesenchymal stem cells; Cl = control group; G-CSF = granulocyte-
colony stimulating factor; IC = intracerebral; IT = intrathecal; IV = intravenous; LGE = porcine fetal cells; M = mean; MCA 
= middle cerebral artery; NSC = neural stem cells; Nparticipants = number of participants assessed; NPC = neural progenitor 
cells; n.s. = not specified; Nstudies = number of studies; NT2-D1 = Ntera 2.cl.D1; PBSC = peripheral blood stem cells; RCT 
= randomised controlled trial; SB623 = modified BM-MSCs; SD = standard deviation; SubCut = subcutaneous; Tmt = 
treatment group; UC-MSC = umbilical cord mesenchymal stem cells. 
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The Pre-/post-treatment analysis was based on data from 17 studies of 279 
participants (including 2 studies/24 participants [Kondziolka et al., 2005; Rabinovich et al., 
2005] from the previous analysis) (see Table 1).  The average age was 54.6 years, 65% were 
male and 75% had ischaemic strokes.  On average, cell therapies were administered 3.6 years 
post-stroke and, of the 13 treatments examined, intrathecal NSCs were most common.  Safety 
was again examined by all studies; 13 and 15 of which examined neurological and functional 
outcomes, respectively.  The majority used prospective cohort designs and were undertaken 
in China.   
As noted, we additionally extracted standard-care control data (Nparticipants = 53; see 
Supplemental Appendix I) from four RCTs/non-RCTs to supplement the Pre-/post-treatment 
vs Control analyses; enabling us to evaluate whether improvements in the Pre-/post treatment 
outcomes of cell-therapy recipients exceeded the changes seen as a consequence of 
spontaneous/normal recovery, test practice and/or placebo effects.  The average age of the 
standard-care control group was 47.4 years (SD = 11.5), 79% were male, and 96% had 
ischaemic strokes.  Standard care – which included physical rehabilitation – commenced, on 
average, 1.2 years post-stroke.   
Reporting Quality 
 The reporting quality of all 21 studies was assessed.  The three RCTs were evaluated 
against the CONSORT reporting guidelines (Moher et al., 2010), with a mean score of 76% 
(range: 68%-82%).  Two studies had scores indicating high reporting quality (scored > 75%) 
and one was of medium quality (68%).  Individual item data are summarised in Figure 4-1a, 
where it can be seen that the title (i.e. included RCT), rationale, objectives, study design and 
eligibility criteria (Items 1a, 2a, 2b, 3a, 4a) were consistently provided (100%), as were 
details of the interventions, outcome measures, blinding, statistics, losses, harms, 
113 
 
generalisability, interpretation, and funding sources (Items 5, 6a, 11a, 12a, 13b, 19, 21, 22, 
25).  Details regarding the settings/locations (Item 4b: 33%), randomisation methods (Items 
8-10: 0%-33%), recruitment/follow up (Item 14a: 33%) and protocol access (Item 24: 33%) 
were all reported less frequently.   
The remaining 4 non-RCTs, 1 case-control and 13 cohort studies were evaluated 
using the STROBE guidelines (Von Elm et al., 2008): the mean reporting quality score for 
these studies was 71% (range: 46% - 90%); six studies (33%) were assessed as high-quality, 
11 studies (61%) were medium-quality and 1 study (6%) was rated in the low-quality 
category.  As Figure 4-1(b) shows, all studies provided details of the research objectives 
(Item 3: 100%), number of participants at each stage of analysis (Item 13a: 100%), amount of 
missing data (Item 14b: 100%), outcome events (Item 15: 100%), unadjusted results (Item 
16a: 100%), and key results (Item 18: 100%), and most confirmed the study design (Item 4: 
94%), quantitative analyses (Item 11: 88%), and generalisability of the findings (Item 21: 
83%).  However, details regarding the methods of assessment (Item 8a: 11%), potential 
biases (Item 9: 11%), sample size calculations (Item 10: 0%), sensitivity analyses (Item 12e: 





               Figure 4-1(a)          Figure 4-1(b) 
Figure 4-1.    Reporting quality assessment: (a) CONSORT evaluation of RCT study designs (Nstudies = 3) and (b) STROBE evaluation of non-RCTs and cohort study  
designs (Nstudies = 18). 
   
Nstudies = number of studies; RCT = randomised controlled trial.   
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Adherence to Research Guidelines 
All 21 studies were additionally evaluated against the 13 cell-therapy research 
recommendations provided in the STEPS I-III (Reynolds, 2009; Savitz et al., 2011; Savitz et 
al., 2014) and RIGOR (Lapchak et al., 2013) guidelines (see Figure 4-2).  The average score 
for all studies was 45% (range: 15%-73%), indicating relatively low adherence to these 
guidelines.  Notably, very few studies used placebo/sham treatments (Item 1: 5%), assessed 
psychological (Item 4: 19%) or cognitive (Item 5: 24%) comorbidities prior to inclusion, 
established stable neurological baselines (Item 6: 10%), labeled and tracked the cells (Item 8: 
5%), or assessed domain-specific outcomes (e.g., sensory, motor, visual, cognitive; Item 10: 
33%).  More justified the cell type/method/dosage (Item 2: 43%), used neuroimaging to 
detect changes in the lesion/infarct size (Item 7: 42%), confirmed the use of concomitant 
physical rehabilitation (Item 9: 48%), reported SAEs ≥ 1 year (Item 11: 57%), and 
acknowledged conflicts of interest (Item 13: 52%).  Most assessed medical comorbidities 





Figure 4-2.     Percentage of studies (Nstudies = 21) meeting the STEPS (I-III) and   




Safety and Efficacy of Cell Therapies  
 The safety and efficacy data for cell therapies administered in the chronic stages of 
stroke are summarised in Figure 4-3, where treatment data are grouped according to study 
design (Post-treatment vs Control or Pre-/post-treatment) and cell therapies ordered according 
to the associated Hedges’ g (highest to lowest: 1 to 19).  Summary study and participant 
details (mean age, stroke type/region, time from stroke-onset to therapy, timing of 
assessment) are provided, in addition to the safety (risk ratios, pooled incidence), efficacy 
(neurological, functional, overall) and publication bias (Nfs) data.  Forest plots display the 
overall Hedges’ g statistic and 95% CIs for each therapy.  The comparable Hedges’ g statistic 
for the control group (Pre-/post-treatment vs Control analysis) is shown as a dashed line on 
the forest plots for treatments 7-19.  Additional study information (e.g., dosages) is provided 





Notes:  ** p < .001, * p < .05.      The overall effect for standard care is shown by a dashed line on the forest plots for Treatments 7-19. 
†: Nstudies and Nparticipants differs, refer Appendix J for further detail.        
BGS = basal ganglia stroke; BM-MNC = bone marrow mononuclear cells; BM –MSC = bone marrow mesenchymal stem cells; CI = confidence interval; Func = functional outcomes ;  
G-CSF = granulocyte-colony stimulating factor; Hem = haemorrhagic; IC = intracerebral; Isch = ischaemic; IT = intrathecal; IV = intravenous; LGE = lateral ganglionic eminence cells;  
M = mean; MCA = middle cerebral artery; Neuro = neurological outcomes; Nfs = Fail-safe N; Nparticipants = number of participants; NPC = neural progenitor cells; n.s. = not specified;  
NSC = neural stem cells; Nstudies = number of studies; NT2/D1 = Ntera 2/cl.D1; OEC = olfactory ensheathing cell; PBSC = peripheral blood stem cells; SB623 = modified BM-MSCs;  
SubCut = subcutaneous; T/ment = treatment; UC-MSC = umbilical cord mesenchymal stem cells; yrs = years.   
Figure 4-3.    Safety and efficacy of cell therapy for chronic stroke, separated by delivery route and cell type for studies 





As seen in Figure 4-3, the risk of experiencing a SAE (death, tumor, stroke, seizure), varied 
considerably between the treatment and control groups (Treatments 1-6).  No statistically-
significant increases in risk were observed for any of the six treatments; however, most data were 
based upon small samples and/or short follow-up periods, which limits the reliability of these 
findings.  The pooled incidence rates (Figure 4-3: Treatments 7-19) indicate that 40% (n = 2 out of 
5: 4 year follow-up) of patients who received intracerebral porcine fetal cells (Treatment 14), 17% 
(n = 3 out of 18: 1 year follow-up) of patients who received intracerebral SB623 (modified BM-
MSCs) cells, and 8% (n = 2 out of 26: 6 month follow-up) of patients who received intracerebral 
NT2/D1 (human embryonic carcino-derived) cells (Treatment 18), suffered SAEs.  No SAEs were 
reported for the other 10 cell therapies (Treatments 7-13, 15-17), although – with few exceptions 
(e.g., Treatments 10, 11, 15, 18) – the small sample sizes and short follow-up periods again limit the 
reliability of these findings. 
Post-treatment vs Control Group comparisons  
When the (post-treatment) outcomes of the treatment and control groups were compared 
(Figure 4-3: Treatments 1-6), cell-therapy recipients were found to have significantly better overall 
outcomes after treatment with: (1) intrathecal NSCs (Treatment 1: very large difference in 
functional outcomes); (2) combined subcutaneous G-CSF and intracerebral PBSCs (Treatment 2: 
large difference in neurological outcomes); (3) intracerebral NT2/D1 cells (Treatment 3: large 
overall difference); and (4) intravenous BM-MNCs (Treatment 5: large difference in functional 
outcomes).  Treatments 1 to 3, but not 5, were additionally found to be at low risk of publication 
bias (see Figure 4-3). 
Further analyses revealed the extent of these improvements.  Specifically, patients receiving 
NSCs via intrathecal injection (Treatment 1) scored an average of 30.3 points (95% CIs: 20.9 to 
39.7) higher/better on the Karnovskii Functional Activity Score than controls; patients receiving 
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combined subcutaneous G-CSF/intracerebral PBSC injections (Treatment 2) had lower/better scores 
than controls on the NIHSS (mean = -3.2 points, 95% CIs: -1.8 to -4.6), European Stroke Scale 
(ESS; mean = 9.0 points, 95% CIs: -3.1 to -14.9), European Motor Scale (EMS; mean = 8.8 points, 
95% CIs: -2.6 to -15.0), and mRS (mean = -0.6 points, 95% CIs: -0.3 to -0.9); and patients receiving 
intravenous BM-MNCs (Treatment 5) scored higher/better than controls on the modified BI (mean 
= 8.2 points higher, 95% CIs: 2.7 to 13.7), although – as noted – this finding should be interpreted 
cautiously because it is vulnerable to publication bias.  These same analyses were not performed for 
intracerebral NT2/D1 recipients (Treatment 3) because significant differences were only observed 
for the overall/combined data, not for individual measures.  No significant differences were 
observed following treatment with intravenous BM-MSCs (Treatment 4) or subcutaneous G-CSF 
(Treatment 6). 
Pre-/post-treatment changes  
When differences in the pre- and post-treatment outcomes of cell-therapy recipients were 
compared (Figure 4-3, Treatments 7 to 19), significant overall improvements were observed after 
treatment with: (1) intravenous UC-MSCs (Treatment 7: very large differences in neurological and 
functional outcomes); (2) intracerebral BM-MSCs (Treatment 8: very large differences in 
neurological and functional outcomes); (3) combined intravenous NPCs and intrathecal BM-MSCs 
(Treatment 9: large differences in neurological and functional outcomes); (4) intracerebral SB623 
cells (Treatment 10: large difference in neurological outcomes); (5) intracerebral NSCs (Treatment 
11: large difference in functional outcomes); (6) combined subcutaneous G-CSF and intrathecal 
BM-MNCs (Treatment 12: medium difference in functional outcomes); (7) combined subcutaneous 
G-CSF and intrathecal BM-CD34+ cells (Treatment 13: medium difference in functional outcomes); 
(8) combined intracerebral OECs/NPC injections (Treatment 14: medium difference in overall 
outcomes); and (9) intrathecal NSCs (Treatment 16: medium difference in functional outcomes).  
Treatments 7 to 13 were all at low risk of publication bias, but the findings for Treatments 14 and 
16 should be interpreted cautiously (see Figure 4-3).   
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Lastly, differences in the Pre-/post-treatment outcomes of the standard-care control group 
(see Appendix I) were assessed, with large to very large improvements observed in neurological (g 
= 0.95), functional (g = 2.09), and overall (g = 1.54) outcomes.  The overall Hedges’ g statistics for 
the Pre-/post-treatment and control groups were then compared, which indicated that no cell therapy 
led to significantly better outcomes than standard care (see Figure 4-3, forest plots for Treatments 7-
19: overall Hedges’ g for standard care shown as dashed line); although the improvement in 
neurological outcomes following intravenous UC-MSCs (Treatment 7) approached statistical 
significance (p = .06).  However, caution should again be exercised when interpreting these results 
because the standard-care control group proved to be significantly younger, had fewer 
haemorrhagic strokes and was assessed earlier (p < .05). 
Heterogeneity and Subgroup analyses  
Although the heterogeneity of individual therapies could not be assessed due to the small 
number of studies examining each treatment (range: 1 to 4 studies) (Higgins et al., 2003), medium 
to large and significant variability was observed when all of the Post-treatment vs Control (Q[7] = 
23.1, p < .001, I2 = 70.3 [95% CI: 38.5 to 85.7]) and Pre-/post-treatment (Q[16] = 107.58, p < .001, 
I2 = 85.13 [95% CI: 77.6 to 90.1]) studies were analysed together.  Subgroup analyses therefore 
explored whether patient age, cell source, dosage, treatment timing, reporting quality score and 
study blinding contributed to this heterogeneity.  As seen in Table 4-2, treatment effects were 
significantly larger for studies with low reporting quality scores (i.e. studies that provided 
information for < 50% of assessable items) and higher dosages (≥ 108 cells) (see Appendix J for 
study dosages).  Non-significant differences were observed for the remaining subgroup analyses 
(possibly due to the small Nstudies); however, there was a trend toward allogeneic cells being more 
effective than autologous cells (Post-treatment vs Control: p = .01), blinded studies (single/double) 
reporting smaller treatment effects than non-blinded studies, and younger patients (< 60 years) 
experiencing better outcomes than older patients (≥ 60 years).  Whether therapies administered 
within 1 year after a stroke were more effective than later treatments remained unclear. 
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Table 4-2. Subgroup and Heterogeneity Analyses 
 
Note:  ** p < .001, * p < .05. 





The present study evaluated the reporting quality of 21 studies – 3 RCTs, 4 non-RCTs, 1 
case-control and 13 prospective cohort designs – that administered cell therapies in the chronic 
phase (> 90 days) after stroke.  Based on the CONSORT (Moher et al., 2010) guidelines, the 
reporting quality of the three RCTs was found to be medium to high, with details regarding the 
study objectives, participants, interventions, key results and funding sources frequently provided.  
However, important information relating to the treatment setting (e.g., hospital, clinic), 
randomisation procedures (e.g., randomisation implementation, sequence) and trial protocols were 
frequently omitted, making it difficult to evaluate the generalisability of the findings, the potential 
for selection bias, and whether the analyses and findings were reported accurately and completely 
(Moher et al., 2010). 
Although a number of similar strengths were observed when evaluating the reporting quality 
of the 18 non-RCT/case-control/cohort studies using the STROBE (Von Elm et al., 2008) 
guidelines, the quality of reporting was found to be lower for these studies; largely due to the fact 
that a number of important limitations were frequently overlooked when interpreting the data.  Most 
notably, observer bias was rarely acknowledged throughout the non-/single-blinded studies, which 
may have led to the overestimation of treatment effects by clinicians (Hróbjartsson et al., 2014); and 
sample-size calculations were seldom provided, which meant that some studies may have lacked the 
statistical power to accurately assess the safety and/or efficacy of the treatment (Von Elm et al., 
2008).   
When evaluating all 21 studies against the STEPS I-III (Reynolds, 2009; Savitz et al., 2011; 
Savitz et al., 2014) and RIGOR (Lapchak et al., 2013) research recommendations for cell-therapies, 
adherence was also found to be relatively low.  Most notably, few studies incorporated sham-
treatment groups, which are necessary to rule out placebo effects (Diederich & Goetz, 2008), or 




remains difficult at present (Gavins & Smith, 2015), research that tracks the survival and migration 
of cells is needed in order to better understand the mechanisms of action underpinning different cell 
therapies (Savitz et al., 2014).   
In addition, few studies screened for psychological (e.g., depression, anxiety) and cognitive 
(e.g., dementia) problems at each stage of the treatment process; thus, little is currently known 
about the impact of psychological and cognitive comorbidities on treatment outcomes or patient 
wellbeing following cell therapies.  Greater consideration of psychological/cognitive factors is 
important because depression and anxiety are very common following stroke (Ayerbe et al., 2013; 
Campbell-Burton et al., 2013), and depression and cognitive decline have both been observed in 
stroke patients who have undergone cell therapies (Suárez-Monteagudo et al., 2009). 
In terms of safety, it proved difficult to assess the risks associated with specific cell 
therapies due to the small number of patients who underwent these treatments and the fact that most 
were only followed up within the first year after undergoing treatment.  However, based on the 
available research, intracerebral procedures appeared to involve the most risk, with a seizure and 
cortical vein occlusion observed following the transplantation of porcine fetal cells (Treatment 14 
[Savitz et al., 2005]); a seizure, subdural hematoma and case of pneumonia observed after SB623 
injections (Treatment 10 [Steinberg et al., 2016]); and a seizure and subdural hematoma 
experienced following the delivery of NT2/D1 cells (Treatment 3/18 [Kondziolka et al., 2000; 
Kondziolka et al., 2005]).  Although these results must be treated as preliminary, it is important to 
note that each of these SAEs was attributed to the surgery itself and that no cell-related 
consequences were reported during follow-up (4 years, 1 year and 6 months, respectively).  The 
remaining 14 therapies appeared to be relatively safe; however the long-term risks (> 1 year) have 
yet to be examined in many cases, which is problematic because some SAEs (e.g. teratoma 




The limited amount of data also made it difficult to definitively establish the efficacy of the 
various treatments, although the findings provisionally indicate that a few cell therapies (Treatments 
1-3, 5) may produce significantly better outcomes than standard care.  The largest improvements 
were reported following the intrathecal delivery of human-fetus-derived NSCs (1-2 injections of 2.0 
x 108 cells), with very-large differences observed when comparing the post-treatment functional 
outcomes of cell therapy and control groups following ischaemic and haemorrhagic stroke 
(Rabinovich et al., 2005).  Pre-clinical research suggests that NSCs delivered via lumbar puncture 
migrate to the lesion site via the cerebral ventricles, where they promote endogenous repair and 
angiogenesis through the release of nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), and glial cell line-derived neurotrophic factor (GDNF) (Janowski et al., 2015).  However, 
given the mechanisms of action have yet to be established in a clinical setting, and smaller 
improvements were observed when analysing the Pre-/post-treatment data, further research is 
needed to more accurately determine the benefits of this treatment.   
Promising changes were also seen in recipients of combined subcutaneous G-CSF 
(Filgrastim; 5 injections of 15 μg / kg) and intracerebral PBSCs (1 injection of 3.0-8.0 x 106 cells) 
(Chen et al., 2014), where large neurological differences were observed between treatment and 
control groups following middle cerebral artery (MCA) stroke.  In addition, despite being based on 
a relatively small sample (Ntreatment = 15, Ncontrol = 15), structural improvements were observed 
throughout the stroke-affected areas when brain imaging was performed at 12 months, providing 
additional support for the efficacy of this treatment.  When administered as a combined treatment, 
preclinical research suggests G-CSF may enhance the regenerative benefits of the PBSCs (dela 
Peña, & Borlongan, 2015; Detante et al., 2014; Solaroglu et al., 2015), with the later also supporting 
endogenous repair by allowing host SCs to reach the lesion site through the creation of a ‘biobridge’ 
(Sullivan et al., 2015). 
Large overall differences were also observed between recipients of intracerebral delivery of 




this treatment appears warranted given NT2/D1 cells are derived from an immortalised 
teratocarcinoma cell line, rather than human-embryonic/fetal cells, and the results suggested new 
synapses were formed (Kondziolka et al., 2000; 2005; Takagi, 2016).  Moreover, preclinical 
research suggests efficacy may be further enhanced via extracellular scaffolds (Cohen & Jensen, 
2015) or through the harnessing of glial cells within the microenvironment (Xiao, Saiki, & Ide, 
2014).   
Large functional differences were also observed when comparing the outcomes of 
intravenous BM-MNC recipients (Nparticipants = 26, majority ischaemic strokes) and controls, which 
suggests that this approach may be an effective method of facilitating neural regeneration (Bhasin et 
al., 2013).  Further examination of this treatment also appears warranted, given preclinical research 
suggests intravenous treatments for chronic-phase stroke may be augmented through the use of 
blood-brain-barrier permeabilisers (e.g. mannitol), which may allow more cells to reach the infarct 
(Tajiri et al., 2016).   
Lastly, the Pre-/post-treatment comparisons also indicated that intravenous UC-MSCs may 
improve the neurological and functional outcomes of ischaemic and haemorrhagic stroke patients; 
although, when compared to standard care – in order to control for spontaneous physical recovery, 
rehabilitation, practice and/or placebo effects – the benefits were only borderline (p = .06).  None of 
the remaining cell therapies were found to have produced significantly larger pre/post treatment 
differences when compared with standard care, although the findings are not definitive given the 
control group was younger, had fewer haemorrhagic strokes and were assessed earlier than many of 
the treatment groups.  
The subgroup analyses indicated that studies with low reporting quality scores (i.e. provided 
information for < 50% of assessable items) found significantly larger effects than studies with 
higher reporting quality scores (i.e. provided information for > 50% of assessable items), and that 




These findings highlight the importance of comprehensive reporting by future trials, particularly in 
relation to the number of injections/cell dosages that are administered, given they may impact upon 
the efficacy.  No further significant differences were observed, although there was a trend toward 
allogeneic cells (e.g., NSCs) being more effective than autologous cells (e.g., BM-MSCs), non-
blinded research reporting larger treatment effects than single-/double-blinded research, and 
younger patients (< 60 years of age) having better outcomes. Although non-significant, the later 
findings reinforce the importance of: developing viable and practical sources of pluripotent 
allogeneic cells (e.g., CTX0E03 cells; induced pluripotent SCs [iPSCs]) (Cefalo et al., 2015; 
Kalladka et al., 2013), minimising the impact of observer bias throughout future trials (Hróbjartsson 
et al., 2014), and examining whether younger patients show greater improvements, possibly due to 
differences in the rate of neurological recovery and/or neuroplasticity (Cramer, 2008; Popa-Wagner 
et al., 2015). 
The aforementioned findings should, however, be interpreted in light of the following 
limitations.  First, cell therapies are an emerging field and, as such, many of the current findings are 
based on small samples and short follow-up intervals.  Moreover, despite the broad range of cell 
therapies under investigation, heterogeneity analyses could not be performed for individual 
treatments due to the limited number of studies (Xu et al., 2008).  Although Hedges’ g statistics and 
a random-effects model were used in order to reduce the impact of the small samples and 
methodological variability (Hedges, 1982; DerSimonian & Laird, 1986), the confidence intervals 
were typically wide, suggesting that safety and efficacy was quite variable.  Therefore, rather than 
providing definitive conclusions, the current study standardised and compared preliminary data 
from a broad range of treatments, in order to inform future research.  Second, reporting quality was 
assessed on the basis of the information provided in the study publications.  It is possible that some 
studies may have met additional CONSORT or STROBE criteria, but failed to report this 
information.  Third, cell therapy recipients were, on average, younger than the majority of stroke 




findings (Cramer, 2010).  Fourth, the control group used in the final analysis differed from the 
treatment groups in potentially important ways (e.g., age, stroke type, post-injury interval).  
Although matched controls (sham/placebo or non-treatment controls) would provide a more reliable 
comparison, they were not typically available.  The current comparison was therefore undertaken in 
order to reduce the likelihood that the effects would be overestimated.  Lastly, although the impact 
of dosage was crudely assessed in a subgroup analysis (</> 108 cells) in order to examine potential 
sources of variability in the data, this issue needs to be examined further by comparing the 
outcomes (safety and efficacy) of groups who receive different dosages of the same treatment, 
while also controlling for other confounding variables (e.g., age, stroke type, treatment onset). 
Conclusion 
Serious adverse events were relatively uncommon amongst the cell therapies that were 
examined, and a small number of treatments (intrathecal NSCs, combined subcutaneous G-CSF and 
intracerebral PBSCs, intracerebral NT2D1 cells, and intravenous BM-MNCs) resulted in better 
treatment outcomes than current approaches.  However, given the majority of findings were based 
on small, non-blinded, observational studies, with short assessment periods, these results should be 
considered provisional.  Adequately-powered double-blinded placebo-controlled research that 
screens for psychological and cognitive comorbidities, tracks cell migration in vivo, and evaluates 
treatment outcomes beyond 1 year is now needed to provide a more definitive assessment of these 
emerging treatments.  More comprehensive reporting is also required, guided by the relevant 
reporting guidelines. 
Future Perspectives 
Given the medical and economic burden associated with stroke, and the limited availability 
of long-term treatments, there is a need for safe and effective alternatives.  With increasing 
evidence of safety, larger studies are likely, some of which may examine combined treatments (e.g., 




in conjunction with blood-brain-barrier permeabilisers, biobridges, and extracellular scaffolds.  
Clarifying the role of glial cells may also augment current treatments, and the 
development/refinement of cell labeling and in vivo tracking techniques should lead to an improved 
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Study 2:  Baseline Characteristics of the Control Group for Treatment vs Control:  






    Stroke Type  
 
 Isch           Haem 
         Stroke  
         Region 
Onset to 
randomisation 
M yrs (SD) 
NIHSS 
baseline 
M (SD)  








(%)   
47.4 (11.53) 79 51 (96%)     2 (4%)  Large Artery:    19 1.2 (1.1) 9.6 (1.3) 47.6 (9.7) 100% 
   MCA:                15     
   Small Vessel:     6     
   Cardioembolic:   4     





      
Isch = ischaemic; Haem = haemmorhagic; M = mean; MCA = Middle Cerebral Artery; NIHSS = National Institutes of Health Stroke 
Scale; SD = standard deviation. 
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Treatment Dosages per Cell Therapy and Notes relating to Figure 4-1 
 
Notes:   **p < .001, *p < .05. 
 
BM-MNC = bone marrow mononuclear cells; BM –MSC = bone marrow mesenchymal stem cells; Func = functional 
outcomes; G-CSF = granulocyte -colony-stimulating factor; IC = intracerebral; IT = intrathecal; IV = intravenous; kg = 
kilogram; LGE = lateral ganglionic eminence cells (porcine fetal cells); Neuro = neurological outcomes; n.s. = not specified; 
Nfs = fail safe N statistic; Nparticipants = number of participants; NPC = neural progenitor cells; NSC = neural stem cells; 
Nstudies = number of studies; NT2/D1 = Ntera 2/cl.D1 (human embryonic carcino-derived cell line); OEC = olfactory 
ensheathing cell; PBSC = peripheral blood stem cells; Ref = reference; SB623 = modified BM-MSCs; SubCut = 






Chapter 5.  Study 3 
Stroke Survivor Attitudes Toward, and Motivations for, Considering  
Experimental Stem Cell Treatments 
 
This chapter presents a published paper, however copyright restrictions prevent the 
reproduction of this paper in its published form. The details of this publication are: 
 
Unsworth, D. J., Mathias, J. L., Dorstyn, D. S., & Koblar, S. A. (2019). Stroke survivor 
attitudes toward, and motivations for, considering experimental stem cell treatments. 
Disability and Rehabilitation, 1-9. doi: 10.1080/09638288.2018.1517193 
 
Please note:   
- Tables and figures are formatted in line with the Journal’s requirements.  






Studies 1 (Chapter 3) and 2 (Chapter 4) highlighted a range of concerns regarding the 
safety and efficacy of SC therapies for stroke.  Most notably, there is a lack of large-scale, 
placebo-controlled clinical trial data that confirm the effectiveness and examine the long-term 
treatment-related risks associated with individual SC therapies.  Despite these concerns, 
unregulated, experimental SC treatments are increasingly being sought by patients with a 
variety of neurodegenerative disorders, particularly those who are dissatisfied with 
mainstream treatments and have unrealistic views about the probable treatment outcomes 
(Cohen & Simana, 2018; Petersen, Seear, & Munsie, 2014; Rachul, 2011 Sipp et al., 2017).   
To date, however, little research has been undertaken to assess the general level of 
interest in ‘stem cell tourism’ among stroke survivors, or to examine the reasons why patients 
may consider having risky and experimental SC treatments.  A cross-sectional, nation-wide 
survey of Australian stroke survivors was therefore conducted to address this research gap. 
The number of patients who were considering experimental SC treatments, in addition to 
some of the biopsychosocial (i.e. medical, cognitive, psychological) and demographic (i.e. 
age, sex) factors that may increase the likelihood of a stroke survivor considering 
experimental SC treatments, were considered in order to address objectives 3 and 4.  In 
addition, patients’ attitudes regarding the safety, effectiveness, accessibility, affordability, 
and perceived social norms regarding SC treatment were examined, consistent with the 












Purpose:  Interest in stem cell (SC) treatments is increasing among some patient groups, but 
it is unclear whether this holds true for stroke survivors.  This study examined stroke survivor 
attitudes toward SC treatments and identified a number of variables that may increase the 
likelihood that patients will consider these treatments.  Methods:  Adult stroke survivors (N 
= 183) were recruited (stroke advocacy/support groups, outpatient register) for a cross-
sectional study.  Attitudes to SC treatments were surveyed, guided by the Theory of Planned 
Behaviour.  Demographic information was collected, and a number of self-report medical, 
cognitive and psychological measures completed.  Results:  Twenty-five percent (n = 46) of 
respondents indicated they were considering undergoing SC treatments, although most were 
unsure about the safety/effectiveness and accessibility/affordability.  Stroke survivors with 
positive attitudes toward SC treatments, longer post-stroke intervals, poorer physical 
functioning, younger age, and greater perceived caregiver burden were more likely to be 
considering experimental treatments (odds ratios = 1.22, 1.08, .95, .96, 1.07; respectively).  
Conclusions:  Stroke survivors may consider undergoing experimental SC treatments despite 
uncertainty regarding the risks/benefits.  Clinicians should be mindful of the factors that may 
increase the likelihood of patients considering these treatments, and intervene, where 






Over 15 million people suffer a stroke annually (Thrift et al., 2014) and, despite 
improvements in acute care (Wang & Wang, 2018) and multidisciplinary rehabilitation 
(Anderson et al., 2017), one in three patients experience ongoing physical disabilities, 
cognitive impairments (Mozaffarian et al., 2016), and/or emotional problems (Hackett et al., 
2014).  The extent to which a patient recovers is largely dependent upon the speed with 
which medical treatment is received, but is also contingent upon the type of stroke 
(ischaemic, haemorrhagic), extent of the damage, and severity of the initial impairments; in 
addition to, the patient’s age, premorbid health/functioning, ongoing mental health, and level 
of social support (Richards, Malouin, & Nadeau, 2015).  SC treatments (i.e. intracranial, 
intrathecal, intra-arterial, intravenous, or subcutaneous injections of SCs/cell-related matter), 
are being examined as a potential means of reducing stroke-related disability, and preliminary 
data suggest that some treatments may improve neurological (motor, speech,) and functional 
(mobility, self-care) outcomes, by augmenting endogenous repair processes and restoring 
damaged brain tissue (Nagpal et al., 2017; Unsworth, Mathias, & Dorstyn, 2016; 2017). 
However, the majority of data originate from early-phase clinical trials or 
observational studies, few of which controlled for placebo effects or tracked the injected 
cells.  Moreover, treatment-related adverse events, including brain and spinal tumours, 
seizures, and further strokes have been observed (Nagpal et al., 2017; Unsworth, Mathias, & 
Dorstyn, 2016; 2017).  Phase II/III clinical trials are currently being conducted 
(NCT02448641; NCT02961504; NCT03545607; NCT03004976; NCT01716481 
[clinicaltrials.gov]) but, even if proven to be safe and effective, it will be some time before 
these treatments are approved for clinical use (Jolkkonen & Kwakkel, 2016).  Thus, SC 
treatments are not currently approved for use with stroke patients in the United States, United 




Despite uncertainty regarding their risks and benefits, expensive (≤ US$100,000) 
experimental SC treatments are currently offered for stroke by private clinics throughout 
Asia, Russia and South America (Sipp et al., 2017).  These treatments often involve 
unregulated, non-standardised administration practises, non-disclosure of cell sources and 
manufacturing processes, and a lack of empirically-based treatment data (Srivastava et al., 
2016).  Although research suggests that there is a growing interest in experimental SC 
treatments among people with multiple sclerosis, Parkinson’s disease and amyotrophic lateral 
sclerosis (Mikati et al., 2014), it is not yet known whether stroke survivors show a similar 
interest in, and expectations of, these treatments.  Moreover, little is known regarding why 
patients seek unproven SC treatments, with the limited data suggesting that being male, 
having severe long-term physical disabilities (Kim et al., 2012), and dissatisfaction with 
existing/available treatments (Petersen, Seear, Munsie, & 2014; Rachul, 2011) may increase 
the chance that a person will consider or undergo experimental SC treatments.  
Given that the stroke sequelae differs from that of the neurodegenerative disorders 
that have been studied (e.g., sudden onset of severe, persistent disabilities), a number of 
additional variables may need to be considered when examining which patients are most 
likely to consider SC treatments (Richards et al., 2015).  Indeed, the stroke literature 
identifies multiple factors that contribute to physical disability; including age, time-post 
stroke, health-related quality of life, cognitive functioning, mental health and social support 
(Stucki et al., 2016).  In addition, the attitudes of a stroke survivor and their family/friends 
toward a treatment (i.e. the perceived risks/benefits/accessibility/affordability), may influence 
whether or not they consider it.  This is consistent with the Theory of Planned Behaviour 
model (Ajzen, 1991; Sheeran et al., 2016), an empirically validated socio-cognitive 
framework that has been used to predict treatment-seeking behaviours.  Thus, stroke 




family/friends support them having these treatments, may also be more likely to consider 
having them (Seow et al., 2017). 
The current study therefore surveyed a group of Australian stroke survivors who had 
not previously undergone SC injections in order to: (1) evaluate how many were considering 
having SC treatments; (2) explore their attitudes toward, and expectations of, these 
treatments; (3) identify what demographic, medical, cognitive, psychological and attitudinal 
variables may increase the likelihood of a stroke survivor considering SC treatments; and (4) 
construct an integrated model to help identify which stroke survivors may be most 
likely/unlikely to consider such treatments.  
5.5 Method 
This study adhered to the Strengthening the Reporting of Observational Studies in 
Epidemiology guidelines (Von Elm et al., 2007) (see Supplementary Material for STROBE 
checklist).    
Participant Eligibility and Recruitment 
Participants were eligible if they were adults (≥ 18 years) at the time of their stroke 
(ischaemic or haemorrhagic), had not previously undergone experimental SC treatments, and 
could complete a paper-based, online or telephone survey (with or without assistance).  Eight 
Australian stroke advocacy organisations and stroke support groups (see acknowledgements) 
promoted the survey among their members, which resulted in 114 responses.  The Australian 
Stroke Clinical Registry, an outpatient registry, also mailed 500 paper-based surveys to 
members, from which 69 responses were received (13.8% response rate).  Of the 183 
responses that were received in total, 173 were completed via mail or online, and 10 were 
completed via telephone interview with the first author (DJU).  Informed consent was 
obtained from each participant prior to completion of the survey.  Recruitment occurred from 




SC Treatment Survey 
A 14-question survey (see table 1) was constructed to: (1) assess the number of stroke 
survivors who were considering experimental SC treatments (yes, no, or unsure) (item 1); and 
(2) explore respondents’ familiarity with, and main sources of information about, SC 
treatments (items 2-4), the perceived risks and benefits of SC treatments (items 5, 6), their 
preference for different treatment types (items 7, 8), their desired outcomes (item 9), the 
perceived accessibility and affordability of these treatments (items 10-13), and their main 
concerns (item 14).  SC treatments were defined as those that are unproven and experimental 
in nature, and that involve the injection of SCs/cell-based materials sourced from the patient, 
other people, embryos/foetuses or animals, into the brain, spinal cord, vein, artery or stomach 
by an overseas clinic (Srivastava et al., 2016).  Prior to conducting the survey, the content 
was piloted with a separate group of 10 stroke survivors, who were sourced from Stroke SA, 





Table 5-1. Survey Questions Exploring Attitudes and Expectations of Stroke Survivors 
concerning Experimental Stem Cell Treatments, together with Summary Findings (N=183) 
 
 
Notes: a: Item scores used to calculate stem cell treatment attitude score. b: Multiple responses permitted (percentage totals > 
100%). 





Other Self-Report Measures 
A range of additional self-report measures were included in order to help identify the 
demographic, medical, cognitive and psychological variables that may influence the 
likelihood that a stroke survivor would consider SC treatments.  
Demographic variables  
Respondents’ age, sex and year of stroke were all surveyed, as was information 
pertaining to their type of stroke (ischaemic/haemorrhagic), residential location, relationship 
status (married/partnered/single), work status (employed/unemployed due to health or age), 
years of education, and recruitment source.  
Medical & cognitive variables 
Physical independence was assessed using the Nottingham Extended Activities of 
Daily Living Scale (Nouri & Lincoln, 1987), which measures the level of assistance required 
to perform 22 tasks in the past 2 weeks (4-point Likert scale: lower scores = greater physical 
dependence; range: 0 - 66).  Health-related quality of life was evaluated using the pain, sleep 
and communication items from the Assessment of Quality of Life questionnaire (Version 4-
D) (Hawthorne, Richardson, & Osborne, 1999).  Item scores range from 1 to 4; with lower 
total scores indicating poorer health-related quality of life (range: 3 - 12).  The 
memory/thinking subscale of the Stroke Impact Scale (Duncan et al., 1999) was used to 
evaluate cognitive functioning.  Using a 5-point Likert scale, participants reported how 
difficult it was in the past week to perform seven tasks that required concentration, immediate 
and delayed recall, or executive functioning (lower scores = poorer cognition; range: 7 - 35).  
Psychological Variables 
Treatment satisfaction was assessed using the Patients’ Satisfaction with Stroke 




areas using a 4-point Likert scale (lower scores = less satisfaction; range: 14 - 56).  Social 
support was evaluated using the 12-item Multidimensional Scale of Perceived Social Support 
(7-point Likert scale, lower scores = less social support; range: 12 - 84) (Zimet et al., 1988).  
Anxiety and depression were measured using the Hospital Anxiety and Depression Scale 
(Snaith, 2003), which assesses how frequently (0 to 3) respondents experienced 14 symptoms 
during the past week (higher scores = greater anxiety/depression; range: 0 - 21; scores ≥ 4 = 
clinically-significant levels of symptoms [Sagen et al., 2009]).  Participants who had an 
unpaid/informal caregiver (spouse/family/friend) additionally completed the 10-item Self-
Perceived Burden Scale (Cousineau, McDowell, & Hotz, 2003); reporting how often (scale of 
1 - 5) they felt guilty/worried/concerned about the demands placed on their carer (higher 
scores = greater concern; range: 10 - 50).  
Attitudinal Variables  
Participant attitudes toward experimental SC treatments were measured using a five-
item scale that was designed for this study.  Specifically, respondents were asked to rate (5-
point Likert scale) how safe, effective, accessible and affordable they perceived SC 
treatments to be, and how likely it was that their family/friends would want them to have SC 
injections (see table 1, items 5, 6, 10-12).  Item scores were summed to create a composite 
score, with higher scores indicating more positive attitudes regarding experimental SC 
treatments (range: 5 - 25).  
Data Preparation & Statistical Analysis 
Summary results (means [SDs], frequencies [percentages]) were calculated, both for 
the full sample and for two subgroups (Considering SC treatment: Yes and No/Unsure).  In 
the small number of cases (n = 6) where respondents were ‘unsure’ of the timing of their 
stroke, the mean duration of 5.3 years was imputed (average of observed values) (Horton & 




were performed for each respondent based on their mean item score.  This method was 
selected because the number of respondents with missing data was less than 10% (Eekhout et 
al., 2014).   
A multivariate logistic regression was conducted, using the Purposeful Selection of 
Covariates approach (Hosmer, Lemeshow, & Sturdivant, 2013), to identify which 
demographic, medical, cognitive, psychological and attitudinal variables increased the 
probability that a stroke survivor would consider experimental SC treatments (model 1).  This 
analysis was repeated for respondents who had an unpaid/informal caregiver (n = 106) in 
order to determine whether perceived caregiver burden was an additional predictor (model 2).  
Exploratory univariate analyses were conducted (nominal/categorical data: Pearson χ2 tests; 
continuous and ordinal data: Mann Whitney U-tests) to identify significant differences (p < 
.20) between those who were considering SC treatments and those who were not or were 
unsure.  
Odds ratios (ORs) and confidence intervals (95% CIs) were calculated for each of the 
predictors that were included in the final models (p < .05).  An OR > 1 represented the 
increased odds of a patient considering SC treatment per unit increase in score on the 
corresponding measure (higher scores = higher odds) and an OR < 1 represented the 
decreased odds of a patient considering SC treatment per one unit increase in score (lower 
scores = higher odds) (Hosmer et al., 2013).  Bootstrapped beta-coefficient standard errors 
(SEs) and p values were used when assessing the statistical significance of the predictors 
(based on 1,000 samples) to establish the internal validity of the respective models 
(Steyerberg & Harrell, 2016).  Likelihood ratio and Hosmer and Lemeshow tests assessed the 
quality and ‘fit’ of the final models; respectively (Hosmer et al., 2013).  
As an additional step, the ORs were also converted to predicted probabilities using the 




average), so that the cumulative probability of an individual considering experimental SC 
treatments could be estimated based on their scores across multiple variables (Muller & 
MacLehose, 2014).  Probabilities ≥ 80%, ≥ 60% and < 60% were categorised as likely, 
possible and unlikely to consider experimental SC treatments, respectively (Zipkin et al., 
2014); consistent with guidelines for the identification of ‘at risk’ patients in clinical practice 
(Muller & MacLehose, 2014).  Statistical power was evaluated when the final N was known, 
based on a minimum event-to-predictor ratio of 5:1 (Vittinghoff & McCulloch, 2007).  All 
analyses were performed using IBM SPSS Statistics for Windows (version 24.0) (IBM Corp, 
2012). 
5.6 Results 
Demographic and Clinical Details  
A total of 183 stroke survivors, aged between 26 and 96, completed the survey (see 
table 2 for summary details).  The post-stroke interval ranged from 1 to 36 years.  Similar 
numbers of women and men responded, the majority of whom were married/partnered, had 
completed high school, and were unemployed/retired due to age or health.  Ischaemic strokes 
were more common than haemorrhagic strokes.  Most respondents had received medical 
treatment and rehabilitation after their stroke, although only around one in three had also 




Table 5-2.  Demographic and Clinical Characteristics of the Full Sample and Stem Cell 
Treatment Subgroups 
 
Notes:  a: variables included in multivariate logistic regression analyses. Tests performed to compare Considering Stem Cell 
Treatment: Yes and No/Unsure groups. b: Mann–Whitney U-test. c: Pearson χ2. d: Subgroup of respondents with caregiver 
(n = 106): Considering Stem Cell Treatment: Yes: n=35, No/Unsure: n = 71) 
 




On average, scores on the measures of physical independence (Nottingham Extended 
Activities of Daily Living Scale), health-related quality of life (Assessment of Quality of Life 
Scale) and cognition (Stroke Impact Scale) fell within the moderate-to-good range, as did the 
treatment satisfaction (Patient Satisfaction with Stroke Services Questionnaire) and social 
support (Multidimensional Scale of Perceived Social Support) scores.  Conversely, 70% and 
66% of the sample reported levels of anxiety and depression; respectively, that exceeded 
stroke guidelines (Hospital Anxiety and Depression subscale scores ≥ 4 [Sagen et al., 2009]).  
Self-Perceived Burden Scale scores fell in the moderate range for those with a carer (n = 
106).  
SC Treatment Survey Responses 
Summary findings from the SC treatment survey are provided in table 1.  In total, 46 
respondents (25.1%) indicated that they were considering experimental SC treatments, the 
remainder were not (n = 97, 53.0%) or were unsure (n = 40, 21.9%).  Most respondents 
(57.4%) indicated that they knew nothing about such treatments.  The media was the main 
source of people’s information (48.1%); far less had discussed SC treatments with 
doctors/nurses (3.8%) or read empirical research (3.8%), and only 18 respondents had 
previously accessed a patient information booklet.  Most respondents were unsure about the 
risks (62.3%) and benefits (67.2%) associated with experimental SC treatments.  
A large proportion said they would not consider treatments that used SCs from 
animals (64.9%) and human embryos/foetuses (49.2%), or involved injections to the spinal 
cord (46.1%) and brain (40.1%).  In terms of preferred treatment outcomes, the majority 
wanted physical (64.5%), rather than cognitive (24.6%) or psychological (10.9%), 
improvements.  Most indicated that it would be difficult/very difficult to locate/attend a SC 
clinic (55.2%) or to afford treatment (42.6%), and few indicated that their family and friends 




would consider SC treatments if they were available domestically.  Respondents were mainly 
concerned about treatment-related side-effects (48.2%) and treatment costs (25.1%).  The 
mean score for SC treatment attitude fell in the mid-range (see table 2), suggesting a high 
level of uncertainty and ambivalence about the safety, effectiveness, accessibility and 
affordability of these experimental stroke treatments. 
Characteristics of those Considering Experimental SC Treatments 
The sample of 183 respondents was divided into two groups to enable a comparison 
of those who were considering experimental SC treatments (Yes: n = 46) with those who 
were not or were unsure (No/Unsure: n = 137).  Descriptive statistics and the results of the 
univariate analyses are provided in table 2.  The multivariate regression models are provided 
in table 3.  Model 1 (full sample) indicates that stroke survivors who had positive attitudes 
towards SC treatments (OR: 1.22, p = .008), longer post-stroke intervals (OR: 1.08, p = .024), 
lower levels of physical independence (OR: 0.95, p = .001) and younger ages (OR: 0.96, p = 
.003) were more likely to be considering experimental SC treatments.  In model 2 
(respondents with carers; n = 106), stroke survivors with positive attitudes towards SC 
treatments (OR: 1.30, p=.004), longer post-stroke intervals (OR: 1.10, p = .010) and greater 
self-perceived caregiver burden (OR: 1.07, p = .029) were more likely to be considering 
experimental SC treatments.  Likelihood ratio tests confirmed that the final models were 
better than intercept-only/null models at predicting which respondents were at risk of 
considering experimental SC treatments.  Hosmer and Lemeshow tests indicated the 
‘goodness-of-fit’ for each model was fair (see table 3).  Each model predicted 70% to 80% of 
overall cases correctly; although both models identified those who were not considering 
experimental SC treatments with greater accuracy (see table 3).  Residual plots were 
inspected for potential outliers and influential cases, but all data were retained (Sarkar, Midi, 




Table 5-3.  Multivariate Logistic Regression Analysis Identifying Potential Predictors for 
Stroke Survivors considering Experimental Stem Cell Treatments 
 
Note:  a: Values based on 1000 bootstrapped samples. 
CI: confidence interval; df: degrees of freedom; N: number; OR: odds ratio; p: p values; SE: standard error. Predicted 






The probability that a stroke survivor would be likely, possibly, or unlikely (≥ 80%, ≥ 
60%, < 60%; respectively) to consider experimental SC treatments was calculated, based on 
the variables identified by models 1 and 2.  As shown in Figure 5-1, the cumulative 
probability estimates for model 1 indicate that stroke survivors who: had high scores (i.e. 
positive responses) on the questions relating to SC treatment attitudes, were ≥ 10 years post-
stroke, had low levels of physical independence (e.g., were unable to walk around outside, 
feed themselves, socialise without assistance; Nottingham Extended Activities of Daily 
Living Scale scores ≤ 10), and were aged ≤ 40 years, were more likely to consider 
experimental SC treatments.  If they had a carer, model 2 indicates that stroke survivors who: 
had high scores (i.e. positive responses) on the questions relating to SC treatment attitudes, 
were ≥ 10 years post-stroke, and had strong concerns regarding their burden on caregivers 
(Self-Perceived Burden Scale scores ≥ 50) were more likely to consider experimental SC 






Figure 5-1.  Cumulative predicted probabilities of stroke survivors considering 
experimental stem cell treatments (model 1, N = 183). 
 
 
Figure 5-2.  Cumulative predicted probabilities of stroke survivors with caregivers 







This study surveyed Australian stroke survivors to examine their level of interest in, 
and attitudes toward, experimental SC treatments.  Overall, one in four (25%) respondents 
reported that they were considering experimental SC treatments, which is lower than a 
previous South Korean study (46%) (Kim et al., 2012), possibly reflecting cultural 
differences in attitudes and/or knowledge relating to experimental medical treatments (Yu & 
Ko, 2012).  Consistent with studies conducted in Asia (Kim et al., 2012) and Europe (Aked et 
al., 207), this study found that the majority of respondents knew very little about the risks and 
benefits of SC treatments, with most relying on the media (e.g. radio, newspapers, internet) 
for health information.  This is concerning, given that media reports – particularly those 
found online – tend to exaggerate the positive aspects of experimental SC treatments, without 
disclosing financial interests (Petersen et al., 2017).   
Most respondents also indicated that they would not consider treatments that involve 
injections into the spine (intrathecal) or brain (intracranial), but would consider having SC 
injections into a vein (intravenous) or the abdomen (subcutaneous).  These findings are 
noteworthy because the only large-scale clinical trial currently being conducted for patients in 
the chronic phase of stroke involves intracranial injections (NCT02448641), which suggests 
that stroke survivors may be reluctant to have this form of treatment even if it were to 
become publically available.  Moreover, the findings also suggest that stroke survivors may 
be more likely to seek out SC treatments that they perceive to be safer (i.e. intravenous, 
subcutaneous injections), despite evidence suggesting that the cells do not reach damaged 
brain tissue and are, therefore, less effective (Nagpal et al., 2017; Unsworth et al., 2017).  In 
addition, approximately one third of respondents reported that, if they were to have SC 
injections, they would prefer improvements in their cognitive (i.e. executive functioning, 




physical capabilities; however, neither of these areas have been routinely examined by 
current SC research (Unsworth et al., 2016; 2017).  
Lastly, although most respondents thought it would be difficult to locate or attend a 
private clinic and to afford SC treatments, approximately half indicated that they would 
consider having them if they were available domestically.  This is concerning because private 
clinics that offer adipose (stomach fat, bone marrow) SC injections, primarily for chronic 
pain conditions (i.e. osteo/rheumatoid arthritis), have begun operating throughout the United 
States, United Kingdom and Australia, without the need for regulatory approval (Knoepfler, 
2018; Tanner, Petersen, & Munsie, 2017).  Given chronic pain is also common after a stroke, 
the findings from this study suggest patients may seek treatment from these clinics, despite 
only two Phase I clinical trials currently being conducted to establish the safety and 
tolerability of adipose SC injections for stroke (NCT03570450; NCT02813512 
[clinicaltrials.gov]).     
The present study also highlighted a number of potential factors that may influence 
whether a stroke survivor considers experimental SC treatments.  In each of the groups that 
were examined (i.e. full sample and respondents with carers), positive attitudes regarding the 
safety, effectiveness, accessibility and affordability of SC treatments appeared to be the most 
important factors.  These findings are consistent with the Theory of Planned Behaviour 
(Ajzen, 1991) and suggest that educational interventions – which are designed to improve 
stroke survivors and their family/friends’ understanding of the risks and benefits associated 
with experimental SC treatments – may assist in reducing the likelihood that patients will 
consider having these treatments.  However, given that only 10% of respondents indicated 
that they had previously read an online patient-information booklet, more appealing and 
interactive methods of communicating this information (e.g. telephone advice lines, stroke 
community events) may prove to be more effective (Tanner et al., 2017).   Moreover, the 




private clinics (i.e. via increased local and international regulation), fewer stroke survivors 
may consider undergoing experimental treatments.  However, it is also important to note, 
that, despite ongoing attempts to regulate and/or close SC clinics that offer non-evidence 
based treatments, progress has been slow, particularly in non-Westernised countries (Sipp et 
al., 2017; Tanner et al., 2017).      
The findings from this study also suggest that the longer an individual continues to 
live with stroke-related disabilities, the more likely they may be to consider SC treatment.  
This result was particularly evident amongst respondents who were also physically dependent 
on others; a source of frustration for many patients (Kim et al., 2012; Petersen et al., 2014).  
Younger stroke survivors may also be more likely to consider experimental SC treatments, 
possibly reflecting lower risk aversion and a greater focus on treatment benefits, rather than 
risks (Sparrow & Spaniol, 2016).  Lastly, stroke survivors who are concerned about the 
burden they place on their caregivers (i.e. a spouse or family member) may be more likely to 
consider experimental SC treatments.  Rehabilitation interventions to help patients and their 
caregivers prepare for, and adjust to, the physical, cognitive, and emotional difficulties that 
commonly arise after a stroke are important in this respect (Kneebone, 2016; Winson, 
Wilson, & Bateman, 2016).  Lastly, the cumulative probability estimates provide valuable 
information for treatment planning, by highlighting the importance of inter-disciplinary 
interventions that aim to maximise physical functionality, in addition to supporting patient 
mental wellbeing, and patient-caregiver communication. 
Study Limitations 
There are a number of limitations that should be taken into account when considering 
these results.  First, the current study was underpowered, having a 4:1 event-to-variable ratio 
(i.e. 46 ‘Considering SC treatment: Yes’ cases; 12 predictors) (Vittinghoff & McCulloch, 




of the main aims of the study was to identify a list of potentially useful predictors.  Therefore, 
all variables were examined using conservative statistical techniques (e.g., 95% CIs, 
bootstrapped beta-weight SEs and p values).  Second, the generalisability of these findings to 
other countries remains to be determined, due to demographic, clinical, treatment (Thrift et 
al., 2014) and attitudinal differences (Yu & Ko, 2012).  Third, stroke survivors who were 
considering SC treatments may have been more likely to participate in the online survey (i.e. 
selection bias) and, those who were not, may have been less likely to have responded to the 
mailed surveys (i.e. non-response bias).  Consequently, stroke survivors who were 
considering SC treatments may be over-represented in the current sample.  Fourth, some of 
the variables that were identified (physical dependence, age) only marginally increased the 
odds of considering SC treatment, therefore predictions based upon multiple variables were 
provided.  Lastly, the current study did not collect specific information about the 
respondents’ strokes (e.g. size and location of the infarct), premorbid health/functioning, or 
current health (e.g. blood pressure, blood gas levels), nor did it examine a number of 
potentially important variables (e.g. history of overseas travel, prior experimental treatments 
for other conditions).  Future research should examine these additional variables, preferably 
within the context of a large international study, in order to extend the current findings. 
Conclusions 
The current survey suggests that some stroke survivors may consider having 
experimental SC treatments, despite the significant costs and ongoing uncertainty regarding 
the medical risks and benefits.  Having to travel overseas for treatment may have previously 
acted as a deterrent; however, clinics offering adipose SC treatments for related conditions 
(e.g. chronic pain) are now operating in the United States, United Kingdom, and Australia, 
which may result in more patients undergoing these experimental treatments for their ongoing 
stroke-related symptoms.  Consequently; health professionals working with stroke survivors 




considering these risky, experimental and unproven treatments.  By clarifying misconceptions 
regarding the safety and effectiveness of experimental SC treatments, and educating families 
to help them prepare for, and adjust to the difficulties arising after a stroke, treating clinicians 
may help stroke survivors and their caregivers to make more informed decisions regarding 
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Chapter 6.  Study 4 
Are Patient Educational Resources Effective at Deterring Stroke Survivors 
from Considering Experimental Stem Cell Treatments? A Randomised 
Controlled Trial 
 
This chapter presents a paper currently under peer review, the details of which are:  
Unsworth, D. J., Mathias, J. L., Dorstyn, D. S., & Koblar, S. A. Are patient educational 
resources effective at deterring stroke survivors from considering experimental stem 
cell treatments? A randomised controlled trial. Patient Education and Counselling, 103, 
1373-1381. doi: 10.1016/j.pec.2020.02.012 
 
Please note:   
- Tables and figures are formatted in line with the Journal’s requirements.  






In response to the concerning level of interest in ‘stem cell tourism’ that was 
identified in Study 3 (Chapter 5), a prospective parallel-group RCT (Study 4) was conducted 
to evaluate whether two existing online resources influenced stroke survivors’ attitudes about 
the safety and effectiveness of experimental SC treatments (objective 5).  Patient education is 
part of a widespread effort by SC research and patient advocacy groups to decrease growing 
participating in these risky, unproven treatments (Weiss, Turner, Levine, & Ikonomou, 2018).  
Although a wide range of educational resources are currently available, it is unclear whether 
existing online resources, which were primarily developed for patients with 
neurodegenerative disorders, can effectively dissuade stoke survivors from undergoing 
experimental SC treatments.  
To evaluate the effectiveness of the pre-existing patient education resources, 112 
stroke survivors, recruited from international support groups, were randomly allocated to one 
of three groups: 37 received a downloaded version of an online resource (‘booklet’) 
developed by the International Society for Stem Cell Research (2015), 38 accessed a brief 
video provided by the Stem Cell Network (2014), and 37 were assigned to a waitlist control 
group.  The SC treatment attitudes of each group were evaluated before, immediately after 
and 30-days post-intervention, using a purposely designed measure based on the Theory of 
Planned Behaviour (Ajzen, 1991).  The SC resources were additionally examined in terms of 
how interesting, informative, intelligible and comprehensive they were in order to determine 












Objective:  To evaluate whether online resources developed to educate people about the risks 
associated with experimental stem cell (SC) treatments influence stroke survivors’ attitudes 
about the safety and effectiveness of these treatments.  Methods:  Adult stroke survivors who 
had not previously received SC treatments (N= 112) were recruited from international stroke 
advocacy/support groups for a prospective, parallel-group randomised controlled trial.  
Participants indicated whether they were considering SC treatments (yes/no) prior to, 
immediately following, and 30-days after reading/viewing the International Society for Stem 
Cell Research booklet or Stem Cell Network video.  Participant attitudes regarding the safety, 
effectiveness, accessibility and affordability of SC treatments were examined on each 
occasion, and compared to those of a waitlist control group.  Results:  Significantly fewer 
participants were considering SC treatments immediately after reading the SC research 
booklet (p = .031), although neither intervention had any impact after 30-days (p > .05).  
Waitlist and intervention groups reported positive attitudes toward SC treatments at each 
assessment.  Conclusions:  Stroke survivor attitudes toward SC treatments were initially 
influenced by the patient booklet, however these changes were not maintained.  Practical 
Implications: Clinicians are encouraged to initiate discussions about experimental SC 








Globally, an estimated 33 million people live with stroke-related disabilities (Thrift et 
al., 2014).  Although recent advances in emergency treatments (Nogueira et al., 2018) and 
rehabilitation (Bernhardt et al., 2017) have improved the prognosis for many patients, only 
10% fully recover (Mozaffarian et al., 2016).  Preliminary research suggests that certain 
intracranial and intrathecal stem cell (SC) injections may improve functional recovery 
following a stroke (Boltze et al., 2015; Nagpal et al., 2017; Unsworth, Mathias, & Dorstyn, 
2016; 2017; Xue, Wang, & Yan, 2018).  To date, however, few large-scale placebo-controlled 
clinical trials have been conducted (Sarmah et al., 2018).  Therefore, despite some promising 
initial results (Savitz et al., 2019; Steinberg et al., 2018; Wang & Wang 2017), the risks and 
benefits associated with these SC treatments remain poorly understood (Boltze et al., 2015; 
Nagpal et al., 2017; Unsworth et al., 2016; 2017; Xue, Wang, & Yan, 2018).   
Undeterred by this, private clinics throughout Asia, Russia and South America offer 
non-evidence based, experimental SC treatments for a range of neurological conditions, 
including stroke (Weiss, Turner, Levine, & Ikonomou, 2018), some of which have resulted in 
patients developing brain tumours and spinal lesions (Amariglio et al., 2009; Berkowitz et al., 
2016; Hurst et al., 2013).  Although the number of patients who are undergoing experimental 
SC treatments is unclear, a recent study found that up to 25% of stroke survivors were 
considering them after seeing media reports and online advertisements promoting the benefits 
of SC injections (Unsworth, Mathias, Dorstyn, & Koblar, 2019).     
Recognising the significant medical and financial risks associated with experimental 
SC treatments, government bodies have sought to restrict the availability of these treatments 
by tightening international regulatory guidelines (Sipp, 2018; Sipp & Okano, 2018).  SC 
research and advocacy organisations have additionally developed a range of patient resources 




al., 2017; Weiss et al., 2018).  However, whether these educational resources effectively deter 
stroke patients from considering risky SC treatments is unknown.  Indeed, previous research 
conducted with patients diagnosed with either multiple sclerosis or Parkinson’s disease 
suggest that they may not (Rachul, 2011; Seear, Petersen, Munsie, & Skinner, 2010; Tanner, 
Petersen, & Munsie, 2017).  Given that the available resources were designed for use with 
patients who have a range of medical conditions, it is possible that the content, level of detail, 
and design of the materials may not be optimal for stroke survivors who frequently 
experience cognitive, language, communication and/or visual problems (Du, Ma, & Li, 2016; 
Hackett, Köhler, & O'Brien, 2014).   
This study examined whether two online patient educational resources, one in a 
booklet and the other in a video format: (1) deterred stroke survivors from considering 
experimental SC treatments, and (2) influenced stroke survivors’ attitudes regarding the 
safety, effectiveness, accessibility and affordability of these treatments, relative to a waitlist 
control group.  Participants indicated whether they were considering SC treatments prior to 
(pre-intervention), immediately after (post-intervention), and 30-days (follow-up) after 
reading or viewing their allocated resource.  The booklet and video resources were 
additionally examined in terms of how interesting, informative, intelligible and 
comprehensive they were in order to determine their suitability for use in a stroke setting.     
6.5 Methodology 
This prospective, parallel group, randomised controlled trial was approved by the 
University of Adelaide Human Research Ethics Committee (Approval Number: H-2018-128) 
and was registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN12618001094268).  This project adhered to the Consolidated Standards of Reporting 





Resource Evaluation and Selection, Participant Recruitment, and Trial Design 
An online search, using the Google search engine, was undertaken to identify patient 
education resources that were produced by key SC research and advocacy organisations (i.e. 
International Society for Stem Cell Research, Stem Cell Network, Stem Cells Australia, Euro 
Stem Cell, International Society of Cell and Gene Therapy).  For the purposes of the current 
study, preference was given to resources with an explicit focus on providing evidence-based 
patient information regarding experimental SC treatments, as opposed to SC fact sheets, 
presentation slides, or cartoons/comics.  Resources that required participants to access large 
amounts of information from external links were excluded so as to standardize the patient 
education interventions.  Four booklets and two videos were located that met these broad 
criteria (refer to Appendix L for details).  These resources were independently evaluated by 
the first author (DJU) and a clinical psychologist specializing in stroke rehabilitation using 
the Patient Education Materials Assessment Tool (PEMAT; Shoemaker, Wolf, & Brach, 
2014) for printed materials (26-items, score range: 0-26) or audio-visual materials (25-items, 
score range: 0-25).   
Two of the six resources received the highest PEMAT score from both raters and 
were subsequently selected for this study (refer to Appendix L for summary scores). The 
“Nine Things to know about Stem Cell Treatments” booklet (International Society for Stem 
Cell Research, 2015) outlines the different SC types, associated medical (short/long-term 
effects, potential ineligibility for future evidence-based SC treatments) and financial risks, 
distinguishes between treatments provided by private clinics and those offered by clinical 
trials, and flags the potential misleading nature of online marketing and patient testimonials.  
The “What Is Stem Cell Tourism?” video (Stem Cell Network, 2014) identifies the promise 
associated with SC treatments, summarizes the lengthy bench-to-bedside translational 




(medical and financial). Written permission was subsequently obtained from the relevant 
organisations to use both educational materials in this study. 
English-speaking adult (≥18 years) stroke survivors were recruited from two 
international stroke advocacy organisations and 18 online brain injury support groups 
between June and December 2018.  Participants were screened to ensure that they had not 
previously received SC treatments for their stroke, stroke-related symptoms (e.g. chronic 
pain), or any other medical or neurological disorder. Eligible participants were randomised 
(1:1:1) to a booklet intervention (Group 1), video intervention (Group 2), or waitlist control 
(Group 3) group by the first author (DJU) using computer-generated number sets (Urbaniak 
& Plous, 2013).  Those who reported having visual and/or hearing difficulties upon screening 
were allocated to either the waitlist control group or most appropriate intervention group 
(Group 1 booklet: if hearing difficulties; Group 2 video: if visual difficulties).  Participants in 
the waitlist control group received both educational resources at the conclusion of the study.  
Informed consent was obtained prior to participation. 
Patient Education Intervention  
Demographic (age, sex, relationship status, country of residence), stroke (type, year) 
and outcome data were collected from each participant upon study enrolment.  Specifically, 
physical independence was assessed using the Nottingham Extended Activities of Daily 
Living Scale (NEADL; Nouri & Lincoln, 1987), which measures the level of assistance 
required to perform 22 tasks in the preceding 2 weeks (4-point Likert scale: lower scores = 
greater physical dependence; range: 0-66).  Health-related quality of life was evaluated using 
the pain, sleep and communication items from the Assessment of Quality of Life 
questionnaire (AQoL; Version 4-D; Hawthorne, Richardson, & Osborne, 1999), with lower 
total scores indicating poorer quality of life (individual item scores: 1-4, total score range: 3-




participants reported how difficult it was in the past week to perform seven memory, 
concentration and/or executive functioning tasks using a 5-point Likert scale, (lower scores = 
poorer cognition; range: 7-35).  Depression and anxiety symptomatology were measured 
using the Hospital Anxiety and Depression Scales (HADS; Snaith, 2003), which assessed 
how frequently (0 to 3) participants experienced 14 symptoms (e.g. anhedonia, excessive 
worry) during the past week (higher scores = greater anxiety/depression; range: 0-21; scores 
≥ 8 indicate clinically-significant levels of symptoms). 
Participants from Groups 1 (booklet intervention), 2 (video intervention) and 3 
(waitlist control), were then asked to rate their knowledge of SC treatments (1 item: nothing, 
a little, quite a bit, a lot) and to identify their main source of information about SC treatments 
(e.g. media, doctor/nurse, friends/family) - for descriptive purposes and to identify group 
differences that could confound intervention effects (see Table 1 for individual items).  
Attitudes toward SC treatments were also measured at that time (see Table 1), using four 
items from a previously trialled survey (Unsworth et al., 2019).  Specifically, participants 
were asked to rate using how safe, effective, accessible and affordable they thought SC 
treatments were on a 5-point Likert scale (see Table 1 for individual items); item scores were 
summed to create a composite score (range: 4-20; negative attitude: scores 4-8, neutral 
attitude: scores 9-10; positive attitude: scores > 10-20).  The Cronbach’s alpha of the 
composite score indicated acceptable internal consistency (α > 0.70) (Tabachnick & Fidell, 






Table 6-1.   Pre-intervention Stem Cell (SC) Treatment Survey and the Proportion of 
Participants who were considering SC Treatments at Different Time Intervals  
   Group 1 Group 2 Group 3  
  Booklet Video Waitlist Control  
  (n = 37) (n = 38) (n = 37)  
      
Pre-intervention knowledge 
about SC treatments 
      
 (1)  How much do you know about SC therapies for stroke?   
  n     % n     % n     % p  
Nothing                                       
                                         
 10    27.0 15    39.5 15     40.5 .699 † 
A little  23    62.2 16    42.1 15     40.5  
 Quite a bit                                   
 
 4      10.8  6     15.8 6      16.2  
 A lot                                              0       0  1      2.6 1       2.7  
       
 (2)  From what source have you heard about them most?  
 
  n       % n       % n      % p 
Media  29     78.4 27     71.2 19     51.4 .347 † 
 No source  5       13.5 7       18.4 14     37.8  
 Empirical research  1        2.7 1        2.6 2        5.4  
 Family / Friends  2        5.4 1        2.6 1        2.7  
 Doctors/Nurses  0        0.0 2        5.2 1        2.7  
       
SC treatment attitude scores per 
item at each time interval # 
 
  
(3)  How safe do you think experimental SC treatments are?   
 
  M      SD M      SD M      SD p 
Pre-intervention:       3.3    0.8 3.5     0.9 3.4     0.8 .456 ϶ 
Post-intervention:       3.3    0.9 2.9     1.0 -         - .117 ϶ 
30-day follow up  3.4    0.8 3.2     0.8 3.4     0.8 .529 ϶ 
      
  (4)  How effective do you think experimental SC treatments are?    
      
Pre-intervention:       3.5    1.0      3.0     0.9 3.1     0.7 .071
 ϶ 
Post-intervention:       3.2    1.3 2.7     1.0 -         - .094 
϶ 
30-day follow up  3.5    1.1 3.3     0.9 3.3     0.9 .300 
϶ 
  (5)  If you wanted SC treatments now, how difficult do you think it would be to locate and attend an overseas clinic?  
       
 Pre-intervention:       2.1    1.1 2.2     1.2 2.4     1.2 .576 ϶ 
 Post-intervention:       2.5    1.2 2.7     1.4 -         - .636 ϶ 
 30-day follow up  2.3    1.2 2.4     1.2 2.4     1.2 .738 ϶ 
 




 Pre-intervention:       1.9    0.9 1.7     0.8 2.0     1.1 .719 ϶ 
 Post-intervention:       1.9    0.8 1.4     0.7 -         - .004 ϶ 
 30-day follow up  1.8    0.9 1.6     0.8 1.8     0.9 .014 ϶ 
       
Proportion of respondents who 
were considering SC treatments 
at each time interval 
(7)  Are you considering SC treatments?   
 
  n       % n       %  p 
Pre-intervention:     Yes  18     48.6 17     44.7  .728 π 
Pre-intervention:     No  19     51.4 21     55.3   
      
Post-intervention:    Yes  12    32.4 15     39.5   
Post-intervention:    No  25    67.6 23     60.5   
                  p    .031  ¥   .500  ¥   
 
      
30-day follow up:    Yes  17     45.9 17     44.7   
30-day follow up:    No  20     54.1 21     55.3   
 
                  p   .076  €     .717  €   
 
       
Notes: † = Pearson’s χ2 test; # = Score range per item: 1 – 5; higher scores = more safe, effective, accessible and affordable.  
϶ = Kruskal-Wallis test; π = proportion difference test, ¥ = McNemar test comparing proportion of participants considering 
SC treatments from each intervention group pre-intervention and post-intervention; € = Cochran’s-Q test proportion of 
participants considering SC treatments from each intervention group at each of the three assessed time intervals.  




Participants in Groups 1 and 2 were asked to read/watch their allocated resource.  
Groups 1 and 2 indicated whether they were considering having SC treatments (yes/no) prior 
to (i.e. the pre-intervention time interval), and immediately after reading/watching their 
allocated resource (i.e. the post-intervention time interval), as well as re-doing the SC attitude 
survey following the educational intervention.  In addition, participants in both groups were 
asked to rate whether the booklet or video resource: was interesting (yes, no), informative 
(yes, no), easily understood (5-point Likert scale: very easy-very difficult), and answered any 
questions they had about SC treatments (yes, no; see Table 2 for individual items).  Finally, 
participants in Groups 1, 2 and 3 were contacted after 30-days and, once again, asked whether 
or not they were considering SC treatments at that time, and how safe, effective, accessible 





Table 6-2. Intervention Group Ratings of the Stem Cell Treatment Educational Resources  
 
Notes: † = Pearson’s χ2 test used to compare groups.  







Summary demographic, stroke and outcome data (means [SDs], frequencies) were 
calculated for the three groups.  Non-parametric tests were used to compare the clinical 
characteristics (e.g. stroke type, year of stroke, stroke outcomes) of the three groups due to 
skewed data (nominal data: Pearson χ2 tests; continuous/ordinal data: Mann Whitney U-tests; 
p < .05).  Summary data regarding participants’ knowledge about SC treatments and their 
main sources of information were calculated (%) and then compared using Pearson’s χ2 tests 
(Table 1: items 1-2; p < .05).  Kruskal-Wallis tests were used to compare group responses to 
individual SC treatment attitude items (Table 1: items 3-6; p < .05).  McNemar and 
Cochran’s Q tests were used to determine whether the education resources deterred 
participants from seeking out experimental SC treatments by comparing the proportion of 
people in Groups 1 (booklet intervention) and 2 (video intervention) who were considering 
having them at the three time intervals (pre- and post-intervention, 30-day follow-up, see 
Table 1: item 7; p < .05).   
A 3 (group: booklet, video, waitlist control) x 3 (time: pre-intervention, post-
intervention, 30-day follow-up) mixed Analysis of Variance (ANOVA) was conducted to 
compare the average SC treatment attitude composite scores (dependent variable) for each 
group at each time interval (Group 3: waitlist controls were not assessed post-intervention, 
pre-intervention scores were instead used).  Normality (histogram), homogeneity of variance 
(Box’s M: p > .001) and sphericity (Mauchley’s test: p > .05) assumptions were assessed.  
Between-group, within-group and interaction effects were examined using F ratios (p < .05), 
and partial-eta squared (ηp
2) effect sizes were calculated to determine the magnitude of the 
effects (≤ 0.05 = small effect; 0.06 to 0.13 = medium effect; ≥ 0.14 = large effect) 




A power analysis indicated that a minimum of 108 participants (36 per group) would 
be required to detect moderate differences in SC attitude scores between the three groups 
across the three time intervals (F ≥ 0.25) with 80% chance and at an alpha level of .05 
(Tabachnick & Fidell, 2019).  Those who were lost to follow-up at any point during the study 
were excluded from the final analysis (as per the study analysis protocol) because adequate 
statistical power was dependent on data from all three assessments (Ranganathan, Pramesh, 
& Aggarwal, 2016).  The ratings obtained from Groups 1 and 2 were compared using Pearson 
χ2 tests to identify any perceived strengths or weaknesses in the resources.  All analyses were 
performed using SPSS version 24.0 (IBM Corp, 2016).  
6.6 Results 
Participant Recruitment  
 Of the 225 prospective participants initially screened for eligibility, three had 
previously had SC injections and were therefore ineligible (see Figure 6.1).  The remaining 
222 participants were randomly assigned to the booklet, video or waitlist control group.  
Between 50% and 60% of the participants who were allocated to each group provided pre-
intervention data, most of whom completed the post-intervention (Groups 1 & 2 only: 100%) 














Summary Demographic and Clinical Details  
Table 6.3 provides summary data for the three groups.  Participants in Group 1 
(booklet) were significantly younger than those in Group 3 (waitlist control), but not Group 2 
(video).  The length of time-post stroke was similar across the three groups.  There were more 
females than males in each group, and the majority were married/partnered.  Ischaemic 
strokes were more common than haemorrhagic strokes.  Most of the participants lived in the 
United States and Australia, with the remaining from the United Kingdom, Canada, Europe, 
Africa, and New Zealand or Tonga (‘Other’).  There were no significant group differences in 
physical independence (NEADL), health-related quality of life (AQoL) or cognition (SIS).  
Group depression (HADS-D) and anxiety (HADS-A) scores were also similar, as was the 
number of participants who screened positive for clinically-significant levels of depression 










Note:  * = Mean age of Group 1 significantly lower than Group 3 (p < .05); participants with visual or hearing difficulties 
were not allocated to Group 1 or Group 2, due to the reading and listening required to participate in the respective 
interventions. Tests performed to compare groups: † = Mann Whitney U-test; π = Pearson’s χ2 test. 
AQoL = Assessment of Quality of Life questionnaire; HADS-A = Hospital Anxiety & Depression Scale – anxiety subscale; 
HADS-D = Hospital Anxiety & Depression Scale – depression subscale M = mean; n = number of participants; NEADL = 
Nottingham Extended Activities of Daily Living Scale; SIS = Stroke Impact Scale; SD = standard deviation; U.K. = United 




Effectiveness of the Intervention 
The results of the patient educational interventions are displayed in Table 6-1.  On 
enrolment, most of the participants in each of the three groups indicated that they knew either 
‘a little’ or ‘nothing’ about SC treatments (item 1), and confirmed that the media (internet, 
newspapers, radio) was their main source of information (item 2).  No significant between-
group differences in perceived safety, effectiveness, and accessibility of SC treatments were 
noted at any time interval (items 2-5).  However, Group 2 (video) reported significantly lower 
mean scores in relation to perceived affordability (item 6; i.e. SC treatments less affordable) 
compared to Group 1 (booklet) at post-intervention and 30-day follow up, and to Group 3 
(waitlist control) at 30-day follow up.  Comparable numbers of participants from Groups 1 
(booklet) and 2 (video) were considering having SC treatments at the pre-intervention time 
interval (p = .728).  Post-intervention, there was a significant reduction in the number of 
participants who were considering SC treatments in Group 1 (booklet) (p = .031), but not in 
Group 2 (video) (p = .500).  However, 30-days later, the number of participants in Groups 1 
and 2 who were considering SC treatments was similar to that seen pre-intervention (Group 
1: Q[2] = 5.17, p = .076; Group 2: Q[2] = .67, p = .717).  Thus, although the booklet resource 
initially acted as a deterrent, this effect was not maintained (see item 7).   
The results of the 3 (group) x 3 (time interval) mixed ANOVA, which compared the 
SC attitude scores of each group during the study, are displayed in Figure 2 (scores > 10 = 
positive attitude range).  Normality, homogeneity of variance (p > .001) and sphericity (p > 
.05) assumptions were met.  No significant main effect was observed between the groups’ SC 
attitude scores (F [2, 109] = 1.56, p = .214, ηp
2= .028), which were all in the positive range 
(Group 1: M = 10.88, SE = .35; Group 2: M = 10.19, SE = .34; Group 3: M = 10.98, SE = 
.35).  A significant main effect was observed for time (F [2, 218] = 3.15, p = .045, ηp
2= .028), 




educational intervention (M = 10.46, SD = 2.59) than they were 30-days later (M = 11.32, SD 
= 2.19, p = .011).  Despite this, no significant interaction was observed when comparing the 
mean attitude scores of the groups at any of the assessed time intervals (F [4, 218] = 1.20, p = 
.313, ηp
2= .021).  Further analysis revealed that the mean scores for Group 2 were lower than 
Group 1 (Mean difference range: -0.58 to -1.18) and Group 3 (Mean difference range: -0.87 








Figure 6-2.    Mean differences in stem cell treatment attitude scores for the intervention  













































When asked to rate the educational materials, participants in Groups 1 (booklet) and 2 
(video) mostly reported that they found the resources interesting and informative (Table 2, 
items 1 & 2).  A significantly larger proportion of participants in the video intervention group 
indicated that their resource was ‘very easy’ to understand (p = .002), although more in the 
booklet group reported that the resource adequately addressed their questions (p = .011) 
(items 3 & 4). 
6.7 Discussion 
This prospective parallel-group randomised controlled trial examined whether two 
online patient education resources (booklet, video) deterred stroke survivors from considering 
experimental SC treatments and influenced their attitudes regarding the safety, effectiveness, 
accessibility and affordability of these treatments.  At the commencement of the study, a 
large proportion (45% to 49%) of the stroke survivors indicated that they were considering 
SC treatment, despite most reporting that they knew ‘little’ or ‘nothing’ about these 
treatments.  Although more specific details were not sought from participants regarding what 
they knew about SCs, the majority listed their primary source of information to be the media 
(internet, radio, newspapers); a source known to preference public opinion over empirical 
data (Du, Rachul, Guo, & Caulfield, 2016; Kamenova, Reshef, & Caulfield, 2014).  These 
findings are consistent with other stroke studies (Aked et al., 2017; Kim et al., 2012; 
Unsworth et al., 2019) and highlight the need to for up-to-date evidence-based educational 
resources that are both patient- and media-friendly in order to provide accurate and balanced 
information about SC treatments to the general public (Benjaminy & Illes, 2016; Kamenova 
et al., 2014; Tanner et al., 2017).   
The number of stroke survivors who were considering experimental SC treatments 
was found to initially decrease after reading the International Society for Stem Cell Research 




content and level of detail provided by each of the resources may account for these findings 
(Du et al., 2016).  Although participants from both groups found the resources interesting, 
informative and easy to understand, nearly 40% indicated that the video did not answer all of 
their questions: a significantly higher number than for the booklet (14%).  Unlike the video, 
the booklet contained additional information regarding the potential for biased patient 
testimonials and the fact that recipients of experimental treatments may be ineligible for 
future proven SC treatments; information which may have influenced their subsequent 
ratings.  However, given that both groups maintained a broadly positive attitude after reading 
or viewing their respective resources, it appears that SC safety and efficacy need to be better 
communicated in order to safe-guard this group.   
Although the booklet intervention was initially effective at reducing the number of 
people who were considering experimental SC treatments, this figure returned to pre-
intervention levels 30 days after reading the educational materials.  Poorer memory, 
concentration and executive functioning may have contributed to this finding (Du et al., 
2016), with the cognition scores being lowest for the booklet group.  It was not possible to 
determine the features and characteristics of those who were most likely to change their mind 
at each assessment, due to sample size limitations.  However, previous research suggests that 
stroke patients who are physically dependent and/or feel like they are ‘burdening’ family 
members and friends may be more likely to consider experimental treatments, despite 
knowing the risks (Unsworth et al., 2019).   
The results also suggest that treating clinicians may need to be proactive in promoting 
these resources in order to raise awareness about the risks associated with experimental SC 
treatments.  Indeed, the provision of more balanced, evidence-based information regarding 
the multifaceted risks associated with experimental SC treatments may be one of the most 
effective means of counteracting the highly persuasive effect that online patient testimonials 




about the growing number of ‘patient-funded’ SC trials listed on clinicaltrials.gov, which 
effectively require patients to pay for the opportunity to receive experimental SC treatments 
for research purposes (Turner, 2017; Wagner et al., 2018).      
Patient and caregiver education on these matters may need to occur during 
rehabilitation (Faux et al., 2018; Forster et al., 2012), given that community-based stroke 
survivors have been shown to have less contact with health-professionals (Pindus et al., 2018) 
and are, therefore, more reliant on informal sources of information (e.g. the media) about SC 
treatments (Unsworth et al., 2019).  Stroke advocacy organisations and support groups may 
also want to consider providing regular information sessions to ensure that the effectiveness 
of their educational materials does not diminish over time (Forster et al., 2012).  In addition, 
it has been suggested that dedicated SC information centres be established to allow patients 
and caregivers to seek advice via telephone, email or video conferencing at times convenient 
to them (Tanner et al., 2017).   
Limitations 
The following limitations should be considered when interpreting these findings.  
First, the current study measured SC treatment attitudes in terms of the perceived risks, 
benefits, accessibility and affordability.  However, the results suggest that additional factors – 
such as the potentially misleading nature of online patient testimonials and the fact that 
recipients may be ineligible for future evidence-based SC treatments – may also influence 
patient attitudes.  Second, the effects of the selected educational interventions may be 
overestimated given that approximately 50% of participants did not complete all of the 
assessments and were, therefore, excluded from the final results (per-protocol analysis).  An 
intention-to-treat analysis that included data from all of the enrolled participants was 
considered but not undertaken because statistical power was estimated assuming participant 




were, inadvertently, not asked about considerations of stem cell treatments upon study 
enrolment; information that would be valuable in future research.  Fourth, detailed 
information regarding the stroke type and location, and the nature and severity of the visual, 
hearing, or any additional communication difficulties (i.e. aphasia) was not obtained, hence 
the potential impact of these variables on the interventions could not be assessed.  Fifth, the 
brief cognitive screening tool was based on self-report (Duncan et al., 1999) and may, as 
such, have lacked the sensitivity needed to accurately identify any cognitive or 
communication deficits that could influence the long-term effectiveness of the resources 
(Lonie, Tierney, & Ebmeier, 2009; Tsoi et al., 2015).  Lastly, future research might consider 
a longer-term (i.e. 6-12 month) follow-up interval with additional questions about whether 
experimental SC treatments were accessed, in order to determine the overall effectiveness of 
the educational interventions in this regard.      
Conclusions 
The patient education resources employed in the current study did not deter stroke survivors 
from considering experimental SC treatments.  Thus, the findings highlight the need for 
stroke-specific, SC educational resources to be created for use by patients, preferably in both 
written and audio-visual formats due to the visual and auditory problems experienced by 
many stroke survivors (Du et al., 2016).  These resources should highlight the significant 
medical and financial risks, the potential to be misled by biased testimonials, and the 
likelihood of being deemed ineligible for future approved SC trials and treatments, should 
they become available.  In addition, educational materials could be improved by including 
patient and media-friendly summaries of current research findings, and by updating the stroke 
community about emerging SC treatments and when they may become available through 
government regulated health services.  Having done this, the resources will need to be 




order to challenge the claims that are made by less credible sources (Datta, 2018; Du et al., 
2016; Kamenova et al., 2014). 
Practical Implications 
Clinicians should consider initiating discussions about experimental SC treatments 
with stroke survivors and their significant others early during inpatient rehabilitation (Faux et 
al., 2018; Forster et al., 2012).  Stroke advocacy organisations should also consider providing 
regular SC information sessions, particularly given that community-dwelling stroke survivors 
may have limited ongoing contact with health professionals (Pindus et al., 2018) and, as such, 
may be more reliant on the media for information about SC treatments (Unsworth et al., 
2019).  Lastly, dedicated SC centres which provide information via telephone, email or video 
conferencing may prove useful to patients and their families (Tanner et al., 2017) to address 
their specific questions, and to ensure that the deterrent effects from previous educational 
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Study 4: Consolidated Standards of Reporting Trials (CONSORT) guidelines checklist 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 167 




2a Scientific background and explanation of rationale 171 
2b Specific objectives or hypotheses 172 
Methods 
Trial design 3a Description of trial design including allocation ratio 172-4 
3b Important changes to methods after trial commencement, with reasons Not 
applicable 
Participants 4a Eligibility criteria for participants 174 
4b Settings and locations where the data were collected 174 
Interventions 5 The interventions for each group with sufficient details to allow replication, 
including how and when they were actually administered 
175-8 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed 
179 
6b Any changes to trial outcomes after the trial commenced, with reasons Not 
applicable 
Sample size 7a How sample size was determined 180 
7b When applicable, explanation of any interim analyses Not 
applicable 
Randomisation:    
  Sequence 
generation 
8a Method used to generate the random allocation sequence 174 




9 Mechanism used to implement the random allocation sequence, describing  
any steps taken to conceal the sequence until interventions were assigned 
174 
Implementation 10 Who generated the random allocation sequence, who enrolled participants,  
and who assigned participants to interventions 
174 
Blinding 11a If done, who was blinded after assignment to interventions and how Not 
applicable 




12a Statistical methods used to compare groups for primary and secondary 
outcomes 
180 
12b Methods for additional analyses 180 
Results 
Participant flow 13a For each group, the numbers of participants who were randomly assigned, 






13b For each group, losses and exclusions after randomisation 182 
Recruitment 14a Dates defining the periods of recruitment and follow-up 182 
14b Why the trial ended or was stopped n/a 
Baseline data 15 A table showing baseline demographic and clinical characteristics  
for each group 
Table 6-3 
Numbers analysed 16 For each group, number of participants (denominator) included in each  
analysis and whether the analysis was by original assigned groups 
  Figure 6-1 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and  
the estimated effect size and its precision (such as 95% confidence interval) 
184-7 
17b For binary outcomes, presentation of both absolute and relative effect  
sizes is recommended 
Not 
applicable 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses  
and adjusted analyses, distinguishing pre-specified from exploratory 
184-5 
Harms 19 All important harms or unintended effects in each group Not 
applicable 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, and imprecision 189-91 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 189-91 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms,  




Registration 23 Registration number and name of trial registry 172 
Protocol 24 Where the full trial protocol can be accessed, if available Not 
applicable 








Study 4: Summary Results for Assessment and Selection of Patient Education Materials  
 
                         Booklet: PEMAT-P Score Video: PEMAT-AV Score 
 Resource 1 Resource 2 Resource 3 Resource 4 Resource 5 Resource 6 
Understandability (%) 12 / 17 (71%) 16 / 17 (94%) 10 / 13 (77%) 12 / 13 (92%) 9 / 12 (75%) 8 / 10 (80%) 
Actionability (%) 5 / 6 (83%) 3 / 6 (50%) 4 / 6 (67%) 3 / 5 (60%) 2 / 3 (67%) 0 / 3 (0%) 
Total Score (%) 17 / 23 (74%) 19 / 23 (82%) 14 / 19 (74%) 15 / 18 (83%) 11 / 15 (73%) 8 / 13 (62%) 
Notes:  Resource 1:  National Stem Cell Foundation of Australia. What you should know about stem cell therapies: Now and 
in the future 2015.  Accessed from: http://www.stemcellsaustralia.edu.au/AboutUs/GetFile.axd?oid=B832BE26-D103-
418D-98B4-DEAAA1049172 on 1st February 2018. Resource 2:  Stem Cell Network. What you need to know about stem 
cell therapies 2015. Accessed from: https://oirm.ca/wp-content/uploads/2018/07/sc_patient_booklet_feb_2014.pdf on 1st 
February 2018. Resource 3:  International Society for Stem Cell Research. Patient handbook on stem cell therapies 2008. 
Accessed from: http://www.isscr.org/docs/default-source/patient-handbook/isscrpatienthandbook.pdf on 1st February 2018. 
Resource 4:  International Society for Stem Cell Research. Nine things to know about stem cells 2015. Accessed from: 
https://www.closerlookatstemcells.org/stem-cells-medicine/nine-things-to-know-about-stem-cell-treatments/ on 1st February 
2018. Resource 5:  Stem Cell Network. What is stem cell tourism? 2014. Accessed from: https://www.youtube. 
com/watch?v=WZ4KETVYYX8 on 1st February 2018. Resource 6: National Stem Cell Foundation of Australia. Stem cell 
tourism. Accessed from: https://www.youtube.com/watch?v=ZjYfQUm1_6g on 1st February 2018.   
PEMAT-AV: Patient Education Materials Assessment Tool for Audio-visual Materials; PEMAT-P: Assessment Tool for 





Chapter 7: Discussion 
7.1 Thesis Overview 
This thesis outlined the findings of four studies that were designed to examine the 
safety and efficacy of SC therapies, and investigate stroke survivors’ level of interest in ‘stem 
cell tourism’.  The main objectives were to: (1) review and evaluate clinical research 
examining the safety and efficacy of SC therapy for stroke; (2) identify the extent to which 
psychological factors have been considered by existing SC researchers, (3) provide an 
estimate of the number of stroke survivors who are considering having experimental SC 
treatments; (4) clarify some of the biopsychosocial and attitudinal factors that increase the 
likelihood that stroke survivors will consider having experimental SC treatments; and (5) 
examine whether existing patient education resources deter stroke survivors from ‘stem cell 
tourism’. 
Two meta-analyses were conducted to evaluate the potential risks and benefits 
associated with SC therapies administered in the hyper-acute, acute or sub-acute (Study 1) 
and chronic (Study 2) phases of stroke (objective 1).  As part of these analyses, the number of 
studies that screened for psychological disorders pre-treatment or evaluated psychological 
wellbeing pre-/post treatment were also identified (objective 2). Next, a cross-sectional 
survey of Australian stroke survivors was conducted (Study 3) to ascertain the number of 
patients who were considering undergoing experimental SC treatments (objective 3), and to 
identify some of the biopsychosocial, attitudinal and demographic factors that increased the 
likelihood of them doing so (objective 4).  Lastly, a RCT trial (Study 4) was conducted to 
evaluate whether an online educational booklet and video altered stroke survivor attitudes 




This chapter summarises the key findings from these four studies, discusses the 
clinical implications, and outlines the methodological strengths and limitations.  The chapter 
concludes with a statement outlining how the findings fulfilled the overall aims of the thesis.  
7.2 Summary of Findings  
Safety and Efficacy of SC Therapies administered in the Hyper-Acute, Acute, Sub-Acute 
and Chronic stages after Stroke. 
The first meta-analysis (Study 1, Chapter 3) reviewed and summarised existing data 
relating to the safety and/or efficacy of SC therapy throughout the hyper-acute, acute and 
sub-acute stages of stroke.  Extending on earlier meta-analyses (Boncoraglio et al., 2010; Cao 
& Li, 2015; Fan et al., 2015; Jeong et al., 2014; Lalu et al., 2012; Wang et al., 2016), this 
study included data from RCTs and non-RCT/observational studies.  SC therapies were also 
stratified based upon the delivery route and cell type, due to proposed differences in the 
mechanisms of action (Rodríguez-Frutos et al., 2016).  Eleven different SC therapies were 
evaluated based on data from 1,485 stroke survivors.  When evaluating the safety of these 
therapies, considerable variability was observed in the types and frequency of treatment-
related serious adverse effects.  Five therapies resulted in serious complications, such as 
death, tumours, strokes and seizures, while the remaining six therapies reported no adverse 
effects.  However, many of the studies that reported no safety concerns had small participant 
numbers and generally only monitored patients for a period of six months.  This suggests 
further research and longer-follow up is required to more adequately establish the risks. 
Moreover, when assessing efficacy, most of the hyper-acute, acute and sub-acute SC 
therapies failed to produce neurological, functional and/or radiological improvements that 
exceeded standard care.  This is likely due to the fact that most studies were designed to test 
the safety of specific dosages among small groups of stroke survivors, rather than to assess 




more than one occasion to establish stable neurological baselines, or incorporated 
placebo/sham treatment conditions into the trials, both of which are of critical importance 
when evaluating the effectiveness of SC therapy, relative to standard care (Savitz, 2014).   
Of the six SC therapies that resulted in better outcomes than standard care, neural SC 
injections delivered via lumbar puncture into the spinal canal (intrathecal injections) were 
most effective for haemorrhagic stroke, and a combination of subcutaneous G-CSF and 
intravenous bone-marrow mesenchymal SC injections were most effective for ischaemic 
stroke.  Although the specific mechanisms underpinning the improvements were not 
identified, neural SCs delivered via lumbar puncture are thought to migrate to the lesion site 
via the cerebral ventricles, where they secrete protective growth factors, thereby reducing the 
amount of damage caused by a stroke (Janowski et al., 2015).  G-CSF is also understood to 
migrate to the stroke site where it protects against further damage, and bone-marrow 
mesenchymal SCs are thought to travel through the permeable blood-brain-barrier to the 
lesion where they stimulate and support natural repair processes (dela-Peña & Borlongan, 
2015).  
Overall, the reporting quality of the included studies was found to be high, with 
information regarding the research objectives, baseline demographics and key results 
consistently provided.  However, contrary to research guidelines, no studies screened for 
psychological comorbidities (e.g. depression) as part of their inclusion/exclusion criteria.  It 
should be acknowledged that it is difficult to assess mood symptoms throughout the hyper-
acute and acute stages of stroke due to the cognitive and communication difficulties 
experienced by many patients (Hankey, 2017).  However, a failure to screen for mood 
symptoms in the sub-acute studies may have impacted on the results because of the 
established link between depression and poorer stroke outcomes (Dar et al., 2017; Savitz et 
al., 2014).  Similarly, changes in psychological outcomes pre-/post treatment were not 




or negative) throughout the early stages of stroke remains to be determined.  Whether 
psychological support was routinely provided as part of the standard care rehabilitation 
process was also unclear; a concerning finding given the prevalence of post-stroke depression 
(Dar et al., 2017).  Taken together, these results suggest that little is currently known about 
the potential impact of psychological symptoms, including depression and anxiety, on hyper-
acute, acute or sub-acute SC therapy outcomes, and the impact of these treatments on the 
psychological wellbeing of patients’ remains poorly understood.  
The second meta-analysis (Study 2, Chapter 4) extended on these findings, by 
reviewing data pertaining to the safety and efficacy of SC therapy throughout the chronic 
phase (> 90 days) of stroke.  For this study, 17 different SC therapies (stratified by 
administration route and SC type) were analysed, based upon data from 23 independent 
studies (RCT’s and non-RCTs/observational) and 461 stroke survivors.  The safety risks were 
again found to vary considerably.  For instance, whilst 14 therapies reported nil adverse 
effects, the remaining three, all of which involved SC injections into the brain (intracerebral 
administration), reported a mix of deaths, tumours, strokes and seizures.  Although these 
results appear to suggest that the alternate administration routes (i.e. intrathecal, intravenous, 
subcutaneous) are relatively safe, it was not possible to determine this with any certainty due 
to the small number of patients who received these treatments and the short-follow up periods 
that were utilised.   
In terms of efficacy, only four of the 17 SC therapies administered in the chronic 
phase of stroke improved neurological or functional outcomes more than standard care.  Of 
these, neural SC injections into the spinal canal (intrathecal) were again found to be most 
efficacious - for both ischaemic and haemorrhagic strokes - followed by combined 
subcutaneous G-CSF and intracerebral peripheral blood SC injections (ischaemic stroke 
only).  As the blood-brain-barrier is no longer permeable during the chronic phase of stroke, 




the brain are thought to be preferable (Savitz, 2018).  Once present, neural SCs have the 
potential to regenerate damaged brain tissue (Janowski et al., 2015), while G-CSF, in 
combination with peripheral blood SCs, promotes and supports the brain’s naturally 
occurring (endogenous) repair processes (dela Peña & Borlongan, 2015; Solaroglu et al., 
2015). 
As with Study 1, the reporting quality of the studies that were examined in Study 2 
was high, with details regarding the study objectives, participants, interventions, key results 
and funding sources frequently provided.  However, once again, few studies were found to 
have incorporated placebo/sham-treatment conditions.  Utilising sham treatment conditions 
may be particularly important when evaluating SC therapies that involve injections into the 
brain or spine, as invasive medical procedures more broadly are thought to produce larger 
placebo effects (Schedlowski, Enck, Rief, & Bingel, 2015).  To this end, one of the included 
studies, a Phase 2 clinical trial, was found to have gained regulatory approval for the 
inclusion of a sham-treatment condition for intracerebral SC injections (Steinberg et al., 
2018).  In the absence of a placebo/sham-treatment group, which may be controversial from 
an ethical standpoint, the inclusion of a waitlist control group that receives standard care may 
provide a secondary option (Savitz, 2014).   
In addition, only a small number of studies labelled and tracked the implanted cells to 
identify the mechanisms of action.  This remains a challenging process throughout each phase 
of stroke (Gavins & Smith, 2015) and it is likely that most researchers were unable to access 
reliable and affordable means of doing so.  In light of this, the routine labelling and tracking 
of implanted SCs remains an aspirational goal for many SC researchers.  This is expected to 
change in the coming years as a range of safe and cost-effective ways of performing these 
tasks are currently being developed, which will further aid our understanding of how 
individual SCs improve stroke outcomes (Jasmin, Louzada, Rosado-de-Castro, Mendez-




More encouragingly, around one quarter of the studies in Study 2 screened for the 
presence of serious psychological disorders prior to SC treatment, including major 
depression, anxiety, psychosis, and schizophrenia.  Although, this step was necessary to 
ensure patient safety and to control for the confounding effects of these conditions, future SC 
therapy trials may need to incorporate patients with depression and/or anxiety to determine 
the safety and efficacy of the treatment among more representative stroke samples (Savitz, 
2014).  That said, the inclusion of patients with psychosis or schizophrenia remains a far 
more difficult proposition, given the potential severity of the symptoms and the level of 
consent required to participate in clinical trials (Weissinger & Ulrich, 2019).  
Two studies also measured the severity of depression and/or anxiety symptoms before 
and after treatment.  Depression increased 12 months after intracranial bone-marrow 
mesenchymal SC injections (Suarez-Monteagudo et al., 2009), while depression and anxiety 
symptoms were stable 6 months after intracerebral NT2/D1 cell injections (Kondziolka et al., 
2005).  Interestingly, when comparing the results of the studies, it was found that the stroke 
survivors with higher levels of depression post-treatment (Suarez-Monteagudo et al., 2009) 
had experienced less neurological and functional benefits compared to those who experienced 
stable mood (Kondziolka et al., 2005).  Overall, these findings provide important preliminary 
data regarding the potential psychological impact of receiving SC therapies with unknown 
long-term benefits.  More specifically, they suggest that patients may be at risk of 
experiencing depression following ineffective treatments (Mancuso et al., 2018), particularly 
those that involve invasive medical procedures (Ghoneheim & O'Hara, 2016).   
Stroke Survivor Attitudes Toward, and Motivations for, Considering Experimental SC 
Treatments 
The findings from Studies 1 and 2 highlighted ongoing uncertainty in relation to the 




identified growing interest in the experimental SC treatments offered by private clinics 
among patients with neurological conditions, such as multiple sclerosis and Parkinson’s 
disease (Rachul, 2011; Rai et al., 2019; Tanner et al., 2017).  However, far less is currently 
known about the level of interest among stroke survivors.  The survey described in Chapter 5 
(Study 3) was designed to provide these much needed data (objective 3), in addition to 
identifying possible biopsychosocial, attitudinal and demographic factors that may increase 
the likelihood of a stroke survivor seeking out experimental SC treatments (objective 4).   
One-hundred and eighty three Australian stroke survivors were surveyed, of which 
25% indicated that they were considering undergoing experimental SC treatments.  Those 
with positive attitudes toward SC treatments were found to be more likely to be considering 
having them. This observation is consistent with the Theory of Planned Behaviour (Ajzen, 
1991) and supports previous data concerning the important role that patient attitudes toward 
the perceived safety, efficacy, accessibility, and affordability of an intervention play when 
weighing up ‘medical tourism’ options (Seow et al., 2017).  Although the contribution of 
specific attitudes to this result were not evaluated, around one third of those surveyed 
indicated that they thought SC therapies were safe and effective to some degree, which is at 
odds with the risks that were identified in Studies 1 and 2.  Moreover, participants also 
identified the media (i.e. television, radio, newspapers, internet) as their main source of SC 
information.  Similar findings have been reported from SC studies in Asia (Kim et al., 2012) 
and Europe (Aked et al., 207), which further highlights the need for clinicians to initiate 
discussions about SC treatments with patients in order to clarify any misconceptions.  
From a biopsychosocial standpoint, stroke survivors who viewed themselves as being 
a burden on family and friends were also more likely to be considering undergoing 
experimental SC treatments.  This is noteworthy given the high level of caregiver burnout 
among this cohort (Oliva-Moreno et al., 2018) and the possibility that stroke survivors may 




were more physically dependent on others were also identified as being at an increased risk 
of considering experimental SC treatments, as were individuals who had longer post-stroke 
intervals, and who were younger in age.  While each of these medical and demographic 
variables have been flagged previously as potential risk factors (Kim et al., 2013), the 
cumulative effect of multiple biopsychosocial and attitudinal factors presented by Study 3 
appears to present a more comprehensive explination as to why stroke survivors may 
consider ‘stem cell tourism’.  Moreover, based on the identified factors, a role for 
psychologists has emerged to help mitigate some of the risks.  One such example would be 
by working with stroke suvivors to reduce their level of perceived burden and to assist 
caregivers to improve self-care.         
Participants were also asked to nominate a range of SC treatment preferences.  
Interestingly, the majority of stroke survivors indicated that they would not consider 
undergoing treatments that involved injections into the spinal cord (intrathecal) or brain 
(intracranial), despite these methods being the focus of most chronic-phase SC therapy 
research trials (Marei et al., 2018; Wechsler et al., 2018).  Approximately half of those 
surveyed also indicated that they would not consider treatments that used SCs derived from 
human embryos/foetuses.  This highlights strong ethical concerns regarding particular types 
of SCs, even those that have the greatest potential to regenerate stroke-damaged brain tissue 
(Janowski et al., 2015).  Lastly, around one in three respondents indicated that, if they were to 
have SC injections, they would prefer to experience improved psychological or cognitive, 
rather than physical functioning. This finding is, perhaps, not surprising given the extent of 
cognitive and psychological problems following a stroke, although the fact that neither area 
are currently being routinely investigated by SC researchers is significant (see Study 1 & 2; 




Effectiveness of Online Patient Educational Resources at deterring Stroke Survivors from 
considering Experimental SC Treatments  
The findings from Study 3 identified a concerning level of interest among stroke 
survivors in experimental SC treatments, and also highlighted the need for evidence-based 
patient resources that clarify potential misperceptions about the efficacy and safety of such 
treatments (Petersen et al., 2017).  Study 4 therefore evaluated the effectiveness of two pre-
existing online resources designed to inform and deter patients with a range of neurological 
disorders from undergoing experimental SC treatments (objective 5).  One hundred and 
twelve stroke survivors were recruited, primarily from online stroke support groups, to 
participate in a RCT.  Participants were allocated to one of two intervention groups (booklet, 
video) or a wait-list control group.  
At the commencement of the study, 45% of the full sample indicated that they were 
considering undergoing experimental SC treatments.  This number was significantly higher 
than that reported by the previous Australian sample (25%; Study 3), but is equal to that 
observed in an earlier South Korean study (45%) (Kim et al., 2012).  The reason for the 
difference is unclear, but may reflect variability in the quality or accessibility of stroke 
treatments between countries (Thrift et al., 2017), a growing awareness of SC treatments 
throughout the global stroke comunity, and/or broader cultural differences in attitudes toward 
experimental medical treatments (Yu & Ko, 2012).  A large number of the Study 4 
participants were also located in closer proximity to countries more renowned for ‘stem cell 
tourism’ (i.e. South America, Russia), thereby making accessibility easier, which Study 3 
identified as an important attitudinal factor (refer Chapter 5).  
Following the educational interventions, the number of stroke survivors who were 
considering SC treatments decreased among the group that read the booklet, but not among 




detail and type of content provided by each of the resources (Du et al., 2016).  For instance, 
the booklet was more comprehensive (six pages of online written content vs 1.18 minute 
video) and, unlike the video, warned readers about the potential for biased patient 
testimonials.  Furthermore, the booklet highlighted the fact that patients who receive 
experimental SC treatments may be ineligible for future proven SC treatments, which may 
have also served as a strong initial deterrant.   
Despite the promising initial results, the intervention effects observed within the 
booklet group were not maintained at the 30-day assessment point.  Although, a clear reason 
for the increasing interest in ‘stem cell tourism’ was not identified, written information is 
thought to be more difficult for stroke survivors to recall than information provided in a video 
format, due to the level of detail incorporated in some texts, and the involvement of 
additional neural pathways when information is received using multimedia formats (Denny, 
Vahidy, Vu, Sharrief, & Savitz, 2017).  Educational interventions are also based on the 
assumption that patients rationally weigh up information regarding the associated risks and 
benefits, however research suggests that frustration with existing treatment approaches, in 
addition to hope, also factor into decision-making regarding SC treatments (Master et al., 
2014).  Furthermore, the attitudes of both intervention groups toward experimental SC 
treatments remained positive during the course of this study.  This is again consistent with the 
findings of Study 3, which also found that personal attitudes toward SC treatments were the 
strongest single predictor of whether a stroke survivor would consider such treatments.  
Lastly, the majority of respondents once again confirmed that the media (television, internet, 
radio) was their main source of information about SC treatments, reinforcing the need for 






7.3 Clinical Implications and Opportunities for Future Research  
 
 The results of the four studies have a number of important clinical implications.  The 
combined findings of Studies 1 and 2 suggested that some SC therapies may improve the 
neurological, functional and/or radiological outcomes of stroke survivors beyond that of 
current treatments.  Preliminary results, such as these, are highly encouraging and, as a result 
are often promoted throughout the media (Petersen et al., 2017).  However, by emphasising 
the positive results, other important aspects, such as the need for further research to establish 
the associated risks, tends to be overlooked.  Experimental SC clinics have also been 
criticised for their misleading use of observational research data, which typically emphasise 
the benefits without acknowledging the potential role of natural recovery, standard care, 
and/or placebo effects (Petersen et al., 2017).  The ongoing proliferation of inaccurate 
information about SC treatments remains a significant challenge for SC researchers, media 
outlets, patients and caregivers.  However, it also presents an opportunity for doctors, 
psychologists and other allied-health staff, who could potentially reduce the future risk of 
stroke survivors undergoing experimental treatments by educating them about the risks 
throughout the various phases of care. 
Incorporating psychological assessments within future clinical trials will also be 
important given that undetected symptomology may impact upon the overall safety and 
efficacy of the SC therapies being investigated (Dar et al., 2017; Savitz, 2014).  Routine 
screening of this kind may be achieved using a range of tools validated for stroke survivors 
(e.g. Hospital Anxiety and Depression Scale [Snaith, 2003]), including patients with aphasia 
(e.g. Depression Intensity Scale Circles [Turner-Stokes, Kalmus, Hirani, & Clegg, 2005]), 
followed by a more comprehensive diagnostic interview, where indicated (e.g. Structured 
Clinical Interview for DSM-5; First, 2014).  As an extension to routine screening, reserchers 




future trials, rather than excluding them, in order to investigate the risks and benefits of the 
therapy among more representative stroke samples.   
Similar routine screening practices should also be considered to monitor the 
psychological wellbeing of participants throughout clinical trials and beyond.  Indeed, 
performing routine psychological screening arguably forms part of the researchers’ duty of 
care, given that participants enter into SC trials with little certainty regarding the potential 
risks and benefits which places them at an increased risk of future depression and anxiety 
(Ghoneheim & O'Hara, 2016; Mancuso et al., 2018).  The timeframe for mood symptoms to 
develop may also vary given that they may result from treatment-related complications 
during the acute, sub-acute or chronic phase of recovery, and/or due to a lack of treatment 
efficacy over the longer term.  In light of this, regular psychological follow-up throughout the 
months and years following treatment appears to be the most appropriate strategy for future 
trials.         
Concerningly, Studies 3 and 4 suggest that between one quarter and one half of stroke 
survivors may be considering ‘stem cell tourism’ options.  Given that published case studies 
have documented brain and spinal tumours as a result of SC treatments, these findings 
highlight an ongoing need for governments, regulatory bodies, advocacy organisations, and 
clinicians to deter stroke survivors from doing so (Amariglio et al., 2009; Berkowitz et al., 
2016; Nakamura et al., 2016).  Educational interventions targeting higher-risk groups, namely 
patients with positive attitudes toward SC treatments, longer post-stroke intervals, poorer 
physical functioning, younger age, and greater perceived caregiver burden may be an 
important first step toward this goal (Study 3).  Psychological support may also need to be 
extended to the caregivers of stroke survivors, in order to help counteract perceived caregiver 
burden. This might include CBT for depression and anxiety, or problem-solving therapy 




Further confirmation of the factors identified in Study 3 using an international sample 
would help to confirm the current findings.  Additionally, identifiying whether the likelihood 
of considering experimental SC treatments is higher among patients who have travelled 
overseas previously, have had prior experimental treatments for other conditions, or who live 
in close proximity to countries where ‘stem cell tourism’ is more common, would also be of 
interest.  Following this, longitudinal research to confirm the number of stroke survivors who 
were not only considering undergoing experimental SC treatments, but actually proceeded to 
do so would provide important insight into the differences between those patients who did 
and did not follow through with treatment.   
The findings from Study 3 also suggest that the current focus of SC therapy research, 
which is designed to improve patients’ physical and functional outcomes primarily via 
intracerebral transplantation, may in fact differ from patient treatment preferences.  Indeed, a 
large proportion of stroke survivors indicated that they would prefer less invasive approaches 
that improve psychological and cognitive outcomes.  Therefore, whether SC therapy may 
reduce the severity of stroke-related mood disorders (Aizenstein et al., 2016) and cognitive 
problems may be an avenue for future research.  However, for this to occur, it is likely that 
methods of SC labelling and tracking will have to improve, in order to enable a clearer 
understanding of whether the changes are the result of structural brain changes or are 
secondary to improved physical or functional outcomes (Gavins & Smith, 2015).  
The results of Study 4 provide further insight into the issue of ‘stem cell tourism’, 
indicating that existing online educational resources, may not be an effective means of 
deterring stroke survivors from considering experimental SC treatments.  Rather, the findings 
suggest that stroke-specific SC resources that individually cater for the broad the range of 
physical (i.e. vision, hearing), functional (i.e. difficulties accessing materials), cognitive (i.e. 
attention, executive functioning, memory) and psychological (depression, anxiety) problems 




that information presented in an audio-visual format has been found to be easier for stroke 
survivors to recall (Denny et al., 2017).  Moreover, psychological research in the field of 
decision making suggests that patients who are interested in an area and are motivated to 
make a decision are more likely to be influenced by text/audio-based information (i.e. direct 
marketing), whereas those who are not are more likely to be influenced by non-
verbal/imagery-based information (indirect marketing) (Boudewyns & Williams, 2016).   
New methods of disseminating information about the risks associated with 
experimental SC treatments may also be required.  Methods that allow for updated 
information to be provided should be considered given that the effectiveness of the 
educational booklet was found to have diminished over time.  Previous studies have 
promoted telephone advice lines as one means of achieving this (Tanner et al., 2017). Regular 
community events run by stroke-advocacy groups may be another means.  In addition, more 
aggressive promotion of evidence-based SC information via the media and internet, may be 
warranted given that both mediums were consistently found to be the main source of 
information regarding SC therapies (Studies 3 and 4).  As younger stroke survivors were 
found to be more likely to consider having experimental SC treatments, increased promotion 
via social media – a platform used to great effect by private SC clinics – may be a priority 
(Kamenova, Reshef, & Caulfield, 2014).   
Lastly, the combined results of Study 3 and 4 strongly suggest that clinicians, such as 
doctors and psychologists, may need to be more proactive in initiating discussions about SC 
treatments when consulting with patients, particularly where frustration with current 
treatment approaches is detected.  Warning patients about the risks associated with 
experimental SC treatments during the sub-acute rehabilitation program may be one way of 
achieving this (Faux et al., 2018; Forster et al., 2012).  However, given that a longer length of 




treatments, ongoing discussions with patients throughout the chronic phase of stroke also 
appear to be required.   
7.4 Methodological Strengths and Limitations 
 
The four studies in this thesis endeavoured to address some of the research and 
knowledge gaps identified in Chapters 1 and 2 by incorporating a number of novel 
methodological and theoretical approaches.  The meta-analyses outlined in Studies 1 and 2 
included non-English publications and extracted data from charts/plots, thereby resulting in 
more data than previous meta-analyses (Boncoraglio et al., 2010; Cao & Li, 2015; Fan et al., 
2015; Jeong et al., 2014; Lalu et al., 2012; Wang et al., 2016).  The safety and effectiveness 
of individual SC therapies that were stratified by SC type and delivery route were also 
provided to help identify the optimal approaches for the different phases of stroke.  
Moreover, safety and efficacy estimates were provided for single and combined SC therapies, 
which highlighted the potential benefits associated with G-CSF and SC injections.   
In addition, acute/sub-acute and chronic data were analysed separately, which had not 
been done previously, despite differences in the medical stability of patients and differences 
in blood-brain-barrier permeability.  By doing so, progress was made toward understanding 
the optimal cell types and administration routes for each phase of stroke.  RCT and non-
RCT/observational data were also included, with the latter compared to control group data 
pooled from the RCTs.  As a result of these comparisons, the benefits suggested by some 
observational data were no longer statistically significant, relative to standard care/normal 
recovery.  Lastly, a checklist was created based upon recommended SC research guidelines, 
which was used to identify a number of important gaps in the literature, some of which were 
highly pertinent from a psychological perspective. 
The logistic regression models created for Study 3 were constructed using the 




which is considered to be more accurate than standard logistic regression techniques (Zhang, 
2016).  The predictors identified by the final logistic regression models were also combined 
to create cumulative predictive probabilities based on multiple, rather than single, variables 
(Hosmer et al., 2013).  A further strength relates to the theoretical framework used in Study 3.  
This included a biopsychosocial model, which focused on the dynamic interaction between 
biological (e.g. level of physical functioning), psychological and social factors (e.g. health-
related quality of life, depression, anxiety, cognitive functioning, social support, perceived 
caregiver burden) - many of which have not been investigated in SC research (Wade & 
Halligan, 2017).  Moreover, stroke survivor attitudes were assessed using the Theory of 
Planned Behaviour (Ajzen, 1991); a framework which correctly predicted that patients who 
perceive SC injections to be safe, effective, accessible, affordable, and who felt that their 
family/friends also want them to have them, were more likely to be considering undergoing 
them (Sheeran et al., 2016).   
In Study 4, a mixed-ANOVA was used to compare the effectiveness of the two 
educational interventions with a wait-list control group across three assessment time intervals 
(Tabachnick & Fidell, 2019).  This was achieved by comparing the attitudes of participants 
regarding experimental SC treatments before, immediately following and 30-days after the 
interventions, in addition to comparing the proportion of stroke survivors who responded 
‘yes’ or ‘no’ when asked if they were considering these treatments at those time points.  
Study 4 also used an international sample, thereby expanding on the Australian findings in 
Study 3, and providing greater insight into global ‘stem cell tourism’ trends.  
Nonetheless, there were also a number of study design and data quality limitations 
that could not be overcome and, should therefore be acknowledged.  First, despite the 
comprehensive literature search undertaken in Studies 1 and 2, much of the safety and 
efficacy data for the meta-analyses were based on small samples and short-term (< 1 year) 




individual therapies, the current thesis summarised and evaluated the preliminary data from a 
broad range of treatments.  Second, stroke survivors with an interest in experimental SC 
treatments may have been more likely to respond to the mailed survey in Study 3 (response 
bias) or the online survey in Study 4 (selection bias), which may have lead to an 
overestimation in the the number of stroke survivors who were reportedly considering SC  
treatments.  Third, Studies 3 and 4 were predominantly conducted via mail and online, which 
necessitated the use of self-report data when assessing a range of key areas (e.g. functional 
independence, depression, anxiety).  Although, valid measures were selected, the reliance on 
self-report data may have impacted on the reliability of some results, due to memory errors 
(recall bias) or a desire to represent themselves in a certain manner (social desirability bias; 
Althubaiti, 2016).  Fourth, brief measures were used to minimise the time commitment for 
respondents and increase the likelihood of their participation.  Although, a more 
comprehensive measure of cognition may have been more appropriate for Study 4, given that 
unidentified attention, memory or executive functioning deficits may have influenced the 
long-term effectiveness of the educational resources (Stolwyk, 2016; Stolwyk, O’Neill, 
McKay, & Wong, 2014; Tsoi et al., 2015).  Fifth, although the tool used to select the patient 
education resources (Shoemaker, Wolf, & Brach, 2014) in Study 4 had been previously used 
to evaluate stroke-related materials (Du, Ma, & Li, 2016), other studies have incorporated 
more specific questions about the SC information provided, rather than focussing on the 
‘understandability’ and ‘actionability’ of the resource, which allowed for more in-depth 
comparisons of the tools (Master et al., 2014).  Sixth, the online patient education resources 
that were evaluated in Study 4 contained addresses and links for patients to obtain further 
information about experimental SC treatments, which suggests they may not have been 
intended for use as stand-alone resources.  Whether participants accessed this additional 
information was not recorded, therefore the level of standardisation that was achieved 




potentially useful medical information was not requested and could not be accessed directly 
via medical records, including specific stroke details (e.g., size and location of the infarct), 
premorbid health and functioning, and current health (e.g., blood pressure).  Lastly, around 
half of the participants in Study 4 failed to complete all of the assessments and were, 
therefore, excluded from the final results.  While adequate statistical power was still 
achieved, excluding data in this manner can impact on the reliability of the intervention 
effects (Ranganathan, Pramesh, & Aggarwal, 2016).    
7.5 Conclusion 
The four studies detailed in this thesis highlight the promise and risks associated with 
both regulated (i.e. clinical trials) and unregulated (‘stem cell tourism’) forms of treatment.  
The results of Studies 1 and 2 suggest that a small number of different SC therapies may be 
safe and effective for use throughout the various phases of stroke, but also highlight the need 
for further testing of these therapies via large-scale, placebo-controlled RCTs.  Both studies 
also identified a distinct lack of research concerning a range of potentially significant 
psychological factors.  Most importantly, major depression was not routinely screened for 
prior to participating in SC therapy trials, which may have confounded the results due to the 
established link between depression and poorer stroke outcomes (Dar et al., 2017; Savitz et 
al., 2014).  There was also preliminary evidence to suggest that participants in SC therapy 
trials may be at increased risk of developing long-term depression due to the uncertain 
treatment outcomes.  
The findings from Studies 3 and 4 suggest that a significant proportion of stroke 
survivors may be considering experimental SC treatments and that a range of biopsychosocial 
(e.g. poorer physical functioning, younger age, greater perceived caregiver burden) and 
attitudinal characteristics increase the likelihood of patients considering experimental SC 




resources, particularly when delivered in booklet form, may help deter stroke survivors from 
considering experimental SC treatments in the short-term. However, they also suggest that 
regular updates by clinicians and stroke-advocacy organisations via the media and internet 
are necessary to maintain the change in attitudes over the longer term.  
From a clinical perspective, the findings highlight the promise associated with SC 
therapies for stroke, but also the need for further research to improve our understanding of the 
medical and psychological risks and benefits.  Given the strong level of interest in ‘stem cell 
tourism’ that was reported by both Australian and international stroke survivors, there is a 
need for clinicians to work with patients and their caregivers to reduce the likelihood that 
they will undergo these risky treatments.  One way to achieve this goal may be for clinicians 
to work with SC advocacy groups to develop stroke-specific educational resources that are 
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